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1 Summary  
Poly-ADP-ribose (PAR) is a post-translational modification (PTM), with widely 
recognized importance in regulating physiological homeostasis. Perturbed PAR signaling was 
linked to numerous human patho-physiologies like diabetes, neurodegeneration, cancer or 
ischemia. In a cell, PAR chains are synthesized in majority thanks to the enzymatic activity of 
poly-ADP-ribose polymerase 1 (PARP1). PARP1 is known as a “guardian of genome integrity” 
due to its involvement in regulation of multiple DNA repair mechanisms. More recently, PARP1 
has been shown to function in DNA replication and transcription.     
 Key to PARP1 functions and activation is PARP1's interaction with DNA. Various 
distorted DNA structures activate PARP1 and it is known that PARP1 binds to DNA via its DNA 
binding domain (DBD). The functional importance of two zinc fingers within the DBD is 
however not clear and has been heavily disputed over the last 30 years. The molecular 
mechanism of PARP1's DNA target site selection and its ability to distinguish between DNA 
lesion and transcription sites has been never evaluated in vivo. In addition, PARP1 achieves 
majority of its nuclear functions via regulation of chromatin structure. For example, via PAR 
binding dependent recruitment of the ATP-utilizing chromatin remodeler called amplified in 
liver cancer (ALC1). The in vivo functions of ALC1 are not known.    
 In my Ph.D., I therefore aimed to evaluate the molecular mechanism of PARP1's DNA 
target site selection and activation, but also to study the in vivo role of ALC1 in transcription. 
 I tested PARP1's interactions with chromatin and analyzed in detail the roles of the DBD 
in binding to DNA in vivo. To do that, I used kinetic modelling of fluorescence microscopy data. 
I found that PARP1 recognizes target sites through free diffusion. PARP1 is highly mobile and 
constantly exchanges between genome sites with weak DNA binding. My data suggests that 
DNA breaks are key to PARP1`s immobilization in vivo. I found that both zinc fingers are 
essential and sufficient to promote PARP1 binding to DNA.    
 I also demonstrate that ALC1's role in transcription recapitulates PARP1 functions. My 
results suggest that ALC1 can both co-activate and co-repress transcription in a PAR-dependent 
manner. Nonetheless, the molecular details leading to this interesting double function await 
further experiments. My data also suggest that PARP1 and ALC1 are not essential for nuclear 
receptor-mediated transcription activation.         
 The novel insight into the mechanism of PARP1 binding DNA, which is the prerequisite 
to its activation, sheds new light on PARP1's roles in all DNA-related processes. My observation 
that ALC1 is involved in regulation of transcription is an important step forward in 
understanding the cancer origins that involve ALC1. 
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Poly-ADP-ribose (PAR) ist eine posttranslationale Modifikationen, die eine anerkannte 
große Bedeutung bei der Regulation der physiologischen Homöostase hat. Störungen im PAR 
Signalweg wurden mit zahlreichen menschlichen Pathophysiologien wie Diabetes, 
Neurodegeneration, Krebs oder Ischämie in Verbindung gebracht. In der eukaryotischen Zelle, 
die PAR Modifikation wird mehrheitlich durch das Enzym poly-ADP-ribose polymerase 1 
(PARP1) katalysiert und aktiviert. Auf Grund der wichtigen Beteiligung von PARP1 bei DNA 
Reparaturmechanismen wird PARP1 klassischerweise betrachtet als ein “Hüter der Genom 
Integrität”. In letzter Zeit, erlangte PARP1 auch wichtige Funktionen bei der DNA-Replikation 
und der Transkription. Der Schlüssel zu den Funktionen und der Aktivierung von PARP1 sind 
die Wechselwirkungen mit DNA. Verschiedene verzerrte DNA-Strukturen aktivieren PARP1 
und es ist bekannt, dass PARP1 über dessen DNA-bindende Domäne (DBD) an DNA bindet. Die 
Bedeutung der beiden Zink-Finger innerhalb der DBD ist jedoch nicht klar und wurde in den 
vergangenen 30 Jahren intensiv diskutiert. Auch sind die molekularen Mechanismen der PARP1 
Erkennung bestimmter der DNA-Zielsequenzen nicht bekannt. Sowohl die Auswahl, als auch die 
Spezifität der Erkennung von DNA-Läsionen wurde nie in vivo bisher noch nicht untersucht. 
Zum Beispiel, rekrutiert PARP1 über einen PAR-abhängigen Mechanismus den ATP-
abhängigen „Chromatin Remodeler“ amplified in liver cancer 1 (ALC1). Darüber hinaus sind die 
in vivo Funktionen von ALC1 nicht bekannt.       
 In meiner Doktorarbeit, habe ich somit gezielt die molekularen Mechanismen untersucht, 
die hinter der Auswahl und Erkennung von DNA-Zielseiten stehen. Auch habe ich die Funktion 
von PARP1 und ALC1 in Regulation der Transkription analysiert. Mittels kinetischer 
Modellierung von Fluoreszenz-Mikroskopie Daten habe ich in vivo die PARP1 
Wechselwirkungen mit Chromatin, sowie die genaue Rolle der DBD getestet. Meine Daten 
zeigen, dass PARP1 Zielseiten durch freie Diffusion erkannt werden. PARP1 ist ein sehr mobiles 
Enzym das ständig im Austausch zwischen bestimmten Genom-Orten steht. Meine Daten lassen 
vermuten, dass in vivo DNA-Brüche der Schlüssel für die PARP1 Immobilisierung sind. Ich 
konnte auch zeigen, dass beide Zink-Finger notwendig und ausreichend für die PARP1 Bindung 
an DNA sind.           
 Meine Ergebnisse deuten auch darauf hin, dass ALC1 sowohl eine co-aktivierende, als 
auch co-reprimierende PAR-abhängige Rolle bei der Transkription ausüben kann. Es sind jedoch 
weitere Experimente nötig, um die molekularen Details dieser Doppelfunktion genau 
aufzuklären. Die neu gewonnenen Einblicke in den Mechanismus der PARP1 DNA-Bindung, 
eine Voraussetzung für Aktivierung von PARP1, werfen ein neues Licht auf PARP1's 
Beteiligung bei allen DNA-abhängigen Prozessen. Die Beobachtung, dass ALC1 direkt die 
Transkription regulieren könnte, ist ein wichtiger Schritt für das Verständnis über die 
Beteiligung von ALC1 bei der Entstehung bestimmter Tumore. 
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2 Introduction 
The genome and epigenome integrity is critical to human health  
Ongoing genome wide association studies (GWAS), epigenome wide association studies 
(EWAS) and epidemiologic studies constantly update our understanding on determinants of 
human health, aging and disease. Especially valuable is the progress concerning the 
identification of the genome alterations (e.g. Single Nucleotide Variation, Copy Number 
Variation), aberrant epigenomes (e.g. deregulated DNA methylation) and environmental risk 
factors (e.g. chemical hazards) causative to human disorders. The early detection of these 
pathological changes allow us to fulfill the promise of disease prevention and pave the way for 
the delivery of personalized medicine, accessible on the broad scale (Witte, 2010, Rakyan et al., 
2011, Bakulski and Fallin, 2014). However, despite of the knowledge of frequently studied 
alterations within genomes and epigenomes of for example, one of the most frequently 
researched tumors, limitations still prevail. Specifically an identification of the exact molecular 
mechanisms that drive these alterations remains a challenge. Consequently, these unknown 
mechanisms prevent the development of the next generation therapies, urgently looked for in 
cancer treatment but also other human disorders. Importantly, the packaging of DNA into higher 
order chromatin structure is critical for genome and epigenome integrity. Aberrant chromatin 
structure (e.g. abnormal nucleosome positioning) could lead to regional increase of mutation 
rates, chromosomal translocations and aberrant gene expressions (Schuster-Böckler and Lehner, 
2012, Roukos and Misteli, 2014). Thus, obtaining a complete understanding of unknown 
molecular mechanisms behind chromatin structure regulation by various nuclear proteins is of 
great significance. Poly-ADP-ribose polymerase 1 (PARP1) exemplifies this situation.  
PARP1 is an abundant protein within the nucleus that directly and indirectly reorganizes 
chromatin structure, important in DNA repair, transcription and replication (Kraus and Hottiger 
et al., 2013). The focus of my Ph.D. was first, to investigate the details of the molecular 
mechanism of DNA-coupled PARP1 activation, which leads to synthesis of poly-ADP-ribose 
(PAR), a post-translational modification (PTM). The acceptor proteins of this PTM are in 
consequence regulated in their interactions with various proteins and functions on chromatin. For 
example, the PAR dependent chromatin remodeler called amplified in liver cancer (ALC1), 
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which in vivo functions are not known. My Ph.D. focued on evaluation of the basis of ALC1 
functions in transcription, as well.  
2.1 The PARP1 family regulates human physiology   
2.1.1 Poly-ADP-ribose (PAR) originates from PARP activity 
Poly-ADP-ribose (PAR) is an abundant post-translational modification. The beginning of studies 
over PAR took place already 51 years ago. All started with the report of the presence of an acid-
insoluble fraction of poly(A)-containing products when liver nuclear extracts were incubated 
with nicotinamide adenine dinucleotide (NAD+). The nuclear enzyme synthetizing PAR 
products, was named poly-ADP-ribose polymerase (PARP; Chambon et al., 1963). Soon after, 
the structure of PAR was reported	  and PARP was purified (Doly et al., 1967, Nishizuka et al., 
1967, Reeder et al., 1967, Sugimura et al., 1967). Eventually the PARP gene (later named 
PARP1) was cloned and additional PARP genes were identified (Alkhatib et al., 1987, Kurosaki 
et al., 1987, Uchida et al., 1987). The PARP enzymes are conserved from prokaryotes to 
eukaryotes, with human orthologs identified e.g. in Herpetosiphon aurantiacus, Neurosporra 
crassa, Aspergillus nidulans, Caenorhabditis elegans, Dictyostelium discoideum, Arabidopsis 
thaliana, Zea mays, Drosophila melanogaster, Danio rerio, Xenopus laevis, Gallus gallus, Canis 
familiaris and others, except yeast (Hottiger et al., 2010). 
The human PARP family consists of 17 members. Based on the presence of functionally 
characterized domains the human PARP proteins can be classified into: (i) DNA-binding PARPs, 
(ii) tankyrases with protein binding ankyrin repeats, (iii) PARPs that contain CCCH zinc finger 
domains shown to bind viral RNA, (iv) PARPs with macrodomains that bind PAR and ADP-
ribose (see also 2.3.2), and (v) the remaining unclassified PARPs (Figure 2.1). Alternatively, the 
PARPs can be also classified into two groups: active and inactive enzymes. Active PARPs are 
further divided into PARPs synthesising PAR (PARP1-5), and PARPs catalyzing the mono-
ADP-ribosylation of proteins (PARP6-8, 10-12, 14-16). Inactive enzymes, unable to bind NAD+, 
are PARP9 and PARP13 (Kleine et al., 2008). Most human PARPs are present throughout the 
cell cycle in the cytoplasm with additional punctate or diffused enrichment at specific cellular 
sites for specific PARPs (centrosome, membranous organelles, nuclear envelope, Golgi, plasma 
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membrane, endoplasmic reticulum, mitotic spindle and spindle poles; Table 2.1; Vyas et al., 
2013). 
      
Figure 2.1 Human PARP proteins and their classification (from Vyas et al., 2013). Functional 
domains are indicated in colors, the green dashes within the catalytic domain indicate H-Y-E 
amino acids thought to be required for PAR synthesis activity. Dashes with different colors 
indicate the replacement of these amino acids with the following residues: I (red), Y (blue), V 
(purple), Q (yellow), T (pink) and L (orange) in PARP functional studies. Antigen – corresponds 
to the domain region, which served as antigen to generate antibodies specific to individual PARP, 
NLS - nuclear localization signal, NES - nuclear export signal. PARP13.1 and PARP13.2 are two 
isoforms originating from the same gene.  
         Table 2.1 The summary of PARP family member localization (from Vyas et al., 2013). 
                     
	  
	  
Abbreviations:	  PARP	  –	  poly-­‐ADP-­‐ribose	  polymerase,	  ARTD	  –	  ADP	  ribosyl	  transferase	  with	  	  	  	  	  	  	  
diphtheria	  toxin	  homology	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According to the enzymatic reaction catalyzed by PARP proteins and to the rules for biochemical 
classifications from International Union of Biochemistry and Molecular Biology (IUBMB) 
‘‘transferase’’ is an appropriate and accurate name for PARP enzymes (Hottiger et al., 2010). 
Some PARPs are also capable of only mono-ADP-ribosylation without poly-ADP-ribosylation 
activity. However all the PARP family members are referred to as poly-ADP-ribose 
polymerases, in a legacy of PARP1 discovery - the founder of the PARP family. Thus, majority 
of publications refers to these enzymes as PARPs.   
PARP1 is the major enzyme responsible for synthesis of PAR, a key modification to 
PARP1 functions  
The constitutive levels of PAR	  in unstimulated cells are usually very low (Ferro et al., 1978, Hilz 
et al., 1983, Kreimeyer et al., 1984). In contrast, upon mitogenic stimulus or genotoxic stress the 
PAR levels increase rapidly from 10 to 500 fold (see also 2.3.1). This transient PAR increase is 
in majority attributed to PARP1 activity, which alone produces up to 90 % of PAR levels within 
a cell (D'Amours et al., 1999). PARP1 is the most studied and thus the best characterized among 
the PARP family members. PARP1 modifies post-translationally various acceptor proteins, 
which could also contain a specific fold that recognizes exclusively PAR modification. Overall 
PAR can activate or inhibit activity of the acceptor molecule, impact its localization or complex 
formation with partner molecules (see also 2.3). PARP1, a highly abundant nuclear protein (up to 
106 copies/cell) and functions across the genome: modulating DNA methylation, repair, 
transcription, chromatin structure and chromosome organization (Krishnakumar and Kraus, 
2010, Kraus and Hottiger, 2013). 
2.1.2 PARP1 regulates DNA based processes 
PARP1 regulates the DNA damage response  
Almost since its discovery, PARP1 has been linked to maintenance of genome integrity (Durkacz 
et al., 1980, De Lorenzo et al., 2013). PARP1 is essential for base excision repair (BER), where 
recruitment of the BER scaffold protein X-ray cross-complementing protein 1 (XRCC1) is 
dependent on its PARylation at DNA damage sites. XRCC1 binds to variety of BER proteins 
thereby facilitating efficient repair of damaged bases (Okano et al., 2000, Izumi et al., 2003, 
Horton et al., 2008, Curtin, 2012). PARP1 positively regulates recruitment of meiotic 
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recombination 11 (MRE11) and nijmegen breakage syndrome protein 1 (NBS1) to double strand 
DNA beaks, thus promoting homologous recombination (HR) (Haince et al., 2008). 
Simultaneously PARP1 inhibits non homologous end joining repair (NHEJ) an alternative to HR. 
NHEJ inhibition occurs subsequent to disassociation from DNA of Ku proteins due to their 
PARylation. Ku proteins provide a scaffold to NHEJ (Wang et al., 2006). Many proteins 
involved in DNA repair and stress response e.g. XRCC1, XRCC6, tumor suppressor p53, cyclin-
dependent kinase inhibitor p21, mismatch-repair protein 6 (MSH6), nucleotide-excision repair 
protein (NER) xeroderma pigmentosum complementation group A (XPA) and type I 
topoisomerase (TOP1) share a specific motif called PAR binding motif (PB; Pleschke et al., 
2000). Thanks to this motif PARP1 could regulate a recruitment of various proteins important for 
the DNA repair to occur (see also 2.3.2). It is also known that loosening of chromatin 
condensation facilitates DNA repair via providing an access to DNA damage sites for DNA 
repair proteins (Aubin et al., 1982, Poirier et al., 1982, Panzeter et al., 1992). PARP1 fosters 
reorganization of chromatin structure upon DNA damage. For example: via PARylation of 
histones, recruitment of histone chaperone with AP-endonuclease activity (APLF1) and the 
chromatin remodeler ALC1 functionally involved in DNA repair as well (Ahel et al., 2009, 
Gottschalk et al., 2009, Eustermann et al., 2010; Mehrotra et al., 2011).  
PARP1 regulates transcription  
Similarly to the functions in DNA repair, PARP1 was shown to possess dual (activator and 
repressive) roles in transcription control. In early studies PARP1 was found to co-
immunoprecipitate with transcriptional factor TFIIC and PAR modify the TFIIC leading to 
repression of transcription (Slattery et al., 1983). Also, PARP1 was found to promote chromatin 
condensation in vitro thus inhibitory to transcription as well (Kim et al., 2004). This view of 
repressive PARP1 role in transcription predominated until PARP1 function in fly heat shock 
response was identified. Flies contain only one PARP protein, which corresponds to PARP1 
(Tulin et al., 2002). Drosophila melanogaster PARP (dPARP) was found to increase spreading 
(puffs) of polytene chromosomes, that include heat shock protein 70 (hsp70) loci, upon heat 
shock (HS). The puffing and subsequent expression of proteins from the puff region required 
dPARP activation and presence of PAR modification (Figure 2.2; Tulin and Spradling, 2003). 
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Figure 2.2 Drosophila melanogaster PARP is required for heat shock induced puffing and 
hsp70 expression (modified from Tulin and Spradling, 2003). A) The 87A and 87C	   polytene 
chromosome region before (left) and after (right) a 30-min heat shock (37°C). B) PARP-GFP is 
widespread in the 87A and 87C puffs (arrows). C) No poly-ADP-ribose signal was detected 
before heat shock (0 minutes). PAR signal increased during heat shock (grey color; 30 minutes) 
and again decreased after heat shock (45 minutes). D) Puffing does not take place in larvae fed 
with the PARP inhibitor for 1 hour before heat shock. E) Levels of Hsp70 protein are reduced in 
flies with catalytically deficient PARP (ParpCH1), when compared to wild type (wt) flies; 
normalized to actin levels.   
Similarly, like during the heat shock, PARP1 was found to enhance transcription of nuclear 
receptor target genes - progesterone receptor (PR) and estrogen receptor alpha (ERα). During the 
PR ligand addition (progesterone) PARP1 was found to be activated and cellular PAR levels 
increased (Figure 2.3; Wright et al., 2012). Strikingly, the ERα-regulated transcription of pS2 
gene (known also as trefoil factor 1, TFF1) was found to require an induction of a double DNA 
strand break at the pS2 promoter. The presence of the break and its PARP1 binding were shown 
as essential in ERα-dependent transcription activation (Ju et al., 2006). ERα and PARP1 were 
found to co-immunoprecipitate and ERα was PARylated by PARP1 in vitro (Zhang et al., 
2013a).  The heat shock and nuclear receptor studies of PARP1 importance, presented PARP1 as 
a protein that plays a co-activation function in transcription initiation. However a PARP1 role 
more aligned with PARP1 DNA repair functions at these loci cannot be dismissed. For example, 
the heat shock loci upon heat shock, requires phosphorylation of H2A.V histone variant. This 
modification in flies is considered a DNA damage mark (Baldi and Becker, 2013).  
PARP1 roles in transcription were evaluated in non-stressed cells as well (no ligand or heat 
shock treatment). Upon PARP1 stable knock-down in breast cancer cells (MCF-7), 204 genes 
out of 14500 genes (microarray tested) showed deregulation. Among these 204 genes: 115 genes 
were up-regulated and 89 were down-regulated, which was confirmed on selected genes via 
quantitative-PCR (Figure 2.4; Frizzell et al., 2009, Krishnakumar and Kraus, 2010). 
 
E	  
	  
13	  
	  
        
Figure 2.3 PAR rapidly accumulates following progesterone stimulation (from Wright et al., 
2012). PAR levels (green) increase in breast cancer cells treated with R5020 (progesterone) for 
15 min (first panel on the left). Levels of poly-ADP-ribose polymerase 1 (PARP-1) are shown in 
red (the middle panels). Merged PAR and PARP1 (the first panel on the right).  
An investigation of the molecular mechanism, found PARP1 to reside and regulate the chromatin 
structure at the transcriptional start site (TSS) of positively regulated genes. A regulation of 
chromatin structure by PARP1 was linked to PARylation and subsequent removal of the lysine 
specific demethylase 5B (KDM5B) from the regulated genes. In consequence a histone 3 lysine 
4 trimethylation (H3K4me3) favoring open chromatin was maintained. No PARP1 role in 
chromatin reorganization of the negatively regulated genes was observed (Krishnakmar and 
Kraus, 2010). 
 
Figure 2.4 RT-qPCR analysis of mRNA expression for six genes in MCF-7 cells with PARP-
1 knockdown (from Krishnakumar and Kraus, 2010). Each bar represents the mean plus the 
SEM, n=3. The differences observed for all genes except ABHD2 are significant (Student's t-test, 
p-value<0.05). The tested genes are: ABHD2 - abhydrolase domain-containing 2, GDF15 - 
growth differentiation factor 15, TMSL8 -	   thymosin-Like 8, SCN1A -	   sodium channel type I 
alpha subunit, NELL2 - NEL-like 2, ITPR1 - inositol 1,4,5-trisphosphate receptor 1. 
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2.1.3 Deregulation of PAR metabolism leads to human pathophysiology 
The associations between deregulated PAR metabolism and human pathophysiology are on the 
rise. Among them, the most extensively studied are the PARP family functions in carcinogenesis. 
If tumor origin comprises of 6 hallmarks (Figure 2.5), deregulated PAR metabolism and PARP 
family members were shown to impact all of them (Masutani et al., 2005, Hanahan and 
Weinberg, 2013).  
    
Figure 2.5 The hallmarks of cancer (from Hanahan and Weinberg, 2013). 
In an early discovery the occurrence of pancreatic cancer increased after DNA damage induced 
with streptozotocin, while PARP1 was inhibited with benzamides (Yamagami et al., 1985). Since 
then PARP1 was suggested to act as a tumor suppressor. These findings were further confirmed 
and expanded in mouse models with individually knocked out PARP1, PARP2, PARP4 or poly-
ADP-ribose glycohydrolase (PARG; see also 2.3.3). As summarized in Table 2.2 incidence of 
tumors across various tissues and across various genetic backgrounds (p53-/-, Ku80-/-) increased 
upon deregulation of PAR metabolism.  
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Table 2.2 The summary of susceptibility to carcinogenesis in mouse models of deregulated PAR 
metabolism (from Masutani and Fujimori, 2013). 
 
Currently 94 mutations of PARP1 are reported in the Catalog of Somatic Mutations in Cancer 
(COSMIC). The precise function in tumor development for the majority of these mutations was 
not confirmed yet. However a few mutations, like PARP1 single nucleotide polymorphism 
(SNP) Val762Ala (valine to alanine) were investigated in detail. This SNP decreases PARP1 
activity (Wang et al., 2007) and was linked to a higher risk of prostate cancers in Caucasians 
(Lockett et al., 2004) but also esophageal and lung cancers in Chinese populations (Hao et al., 
2004, Zhang et al., 2005). The same SNP was associated with decreased risk for glioma in 
Caucasians (Liu et al., 2009). Importantly not only mutations but also PAR metabolism and 
PARP1 protein levels can be considered as a tumor biomarker. For example, PARylation of 
proteins in peripheral blood leukocytes decrease more than 50 % in head, neck, breast and 
cervical cancers (Lakadong et al., 2010). PARP1 high expression levels were linked to poor 
clinical outcome of oral squamous cell carcinomas (Mascolo et al., 2012). 
The mechanisms of pathophysiology    
Carcinogenesis involving PARPs stem from deregulated DNA repair and transcription. PARP1, 
PARP2 and PARP3 are directly linked to participation in DNA repair. PARP1 especially was 
shown to control multiple DNA repair mechanisms. Lack of correct PAR metabolism temporally 
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and spatially leads to loss of heterozygosity (LOH) or chromosome translocations, which are 
aberrations often observed in carcinogenesis. These abnormalities are especially increased when 
PARP1/2 knock-out mice are challenged with DNA damage inducing agents like alkylating 
agents. Similar chromosome alterations and increased tumor rate are observed upon deletion or 
amplification of proteins downstream from PAR e.g. checkpoint with fork head associated 
(FHA) and RING domain	  (CHFR; Yu et al., 2005) or the chromatin remodeler ALC1 (Cheng et 
al., 2013; see also 2.4). Inadequate PAR degradation due to lack of PARG or	   ADP-
ribosylarginine hydrolase (ARH1), also leads to increased incidence of hepatocellular carcinoma 
and adenocarcinoma with increased metastases, respectively (Min et al., 2010, Kato et al., 2011).   
PARP1 was shown to co-regulate transcription of genes important for carcinogenesis upon 
retinoic acid or progesterone stimuli (Pavri et al., 2005, Wright et al., 2012). PARP1 acts as a co-
activator of the cellular oncogene c-FOS and the nuclear factor kappa-light-chain-enhancer of 
activated B cells	   (NF-κB), a transcription factor regulating inflammation (Hassa et al., 2005). 
Inflammation is observed during various human diseases including cancer. NF-κB transcription 
regulation is compromised upon PARP1 deletion and results in reduced levels of pro-
inflammatory cytokines in	  lipopolysaccharide (LPS) treated animals (Hassa and Hottiger, 1999, 
Oliver et al., 1999).  Inflammation related animal models with genetically depleted or chemically 
inhibited PARP1 exhibit resistance to tissue injury, lower organ inflammation rate and higher 
survival rate (Shall and de Murcia, 2000, Kraus and Hottiger, 2013). Levels of tumor necrosis 
factor alpha (TNFα), interleukin 6 (IL-6) and interleukin 10 (IL-10) are reduced in a Parp1-/- 
mice upon for example induction of polymicrobial sepsis with cecal ligation and puncture 
(Soriano et al., 2002). Both, the prolonged presence of DNA lesions and chronic inflammation 
are considered as important stages in cancer development (Davalos et al., 2010). Inflammation 
can stimulate epithelial-mesenchymal transition (EMT), leading to cancerous stem-cell 
development (Heldin, 2012). In cells undergoing anti-cancer drug treatment PARP1 inhibition 
reduces inflammatory damage (Mukhopadhyay et al., 2011).    
In addition, PARP family members were shown to be implicated in cancer metastasis (PARP1), 
angiogenesis (the PARP family, PARG; Pyriochou et al., 2008, Tentori et al., 2007, Lacal et al., 
2009, Pan et al., 2012), inhibition of apoptosis (PARP9/14/15) or induction of cell death via 
NAD+ depletion or PAR stimulation of apoptosis inducing factor (AIF; Yu et al., 2006), 
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induction of autophagy (PARP1; Munoz-Gamez et al., 2009; Rodriguez-Vargas et al., 2012, 
Kleine et al., 2012). 
PARP inhibitors reached clinical trials to treat cancer   
Functions of PARP family members have been recognized as an opportunity for targeted 
sensitization of tumor cells to genotoxic agents and radiotherapy. Although PARP1 knock-out 
mice are viable they are hypersensitive to ionizing radiation and to alkylating agents, both 
broadly used to treat cancer. Thus, it was considered that PARP1 inhibition could lead to specific 
tumor cell death (Soldatenkov and Smulson, 2000). Indeed, the breast and ovarian cancer 
susceptibility protein 1 (BRCA1) – and breast cancer susceptibility protein 2 (BRCA2)- mutant 
cells were 1000-fold more sensitive to PARP inhibitors, when compared to BRCA1/2- competent 
cells (Bryant et al., 2005, Farmer et al., 2005, McCabe et al., 2005).  
Normally BRCA1/2 mutations are acquired during tumor formation, leading to risk increase for 
breast (45-65 % risk) and ovarian cancers (11-39 % risk; Mackay and Szecsei, 2010). The non-
transformed cells possess a wild type, functional BRCA1/2. The absence of BRCA1/2 leads to 
absence of classic homologous recombination (HR) DNA repair pathway. Upon chemo- or 
radio-therapies, cancer cells with BRCA1/2 mutations presumably switch to alternative 
homologous recombination, while PARP1 primarily inhibits the error prone non-homologous 
end joining (NHEJ). In contrast, upon administration of PARP inhibitors, the NHEJ becomes 
predominant resulting in decreased stability and tumor cell death (Figure 2.6).  
This concept was followed by several pharmaceutical companies with various PARP inhibitors 
tested already in clinical trials. None of the inhibitors was approved by the Food and Drug 
Administration (FDA) until now. Clinical trials (phase I and II) suggest that PARP inhibitor 
treatment prolongs, to a variable degree, tumor progression free survival in BRCA1/2 mutant 
patients. Only subgroup of patients bearing BRCA1/2 mutations (4-74 %) responds to PARP 
inhibition, thus a long term benefit of the treatment remains to be determined. A concern is 
present regarding emergence of clones resistant to PARP inhibition therapy e.g. via reverse 
mutations mechanisms (Ashworth, 2008). During PARP inhibition, BRCA2 can further acquire 
mutations, which are able to restore BRCA2 function (Edwards et al., 2008, Barber et al., 2013).     
 
18	  
	  
 
Figure 2.6 Consequences of poly-ADP-ribose polymerase (PARP1) inhibition in (A) 
BRCA1/2-competent and (B) BRCA1/2-mutant cells (from Rosen and Pishvaian, 2014). A) 
Reactive oxygen species (ROS) cause DNA base lesions, normally repaired by the base excision 
repair (BER) pathway. The site of the damaged base is converted to a single-strand break (SSB) 
by one of several BER enzymes depending upon the lesion type. PARP1 then recognizes SSB and 
regulates assembly of a repair complex. In the presence of a PARP inhibitor, the SSB cannot be 
repaired and eventually becomes a double-strand break (DSB) or a collapsed replication fork 
during S-phase. In homology directed repair (HDR) competent cells, the DSB or collapsed 
replication fork is repaired in an error free manner by HDR. B) In BRCA1 or BRCA2 mutant cells, 
the classical HDR pathway is defective and cannot be utilized to repair DSBs or collapsed 
replication forks. Instead, the cells enter into a “toxic” deregulated non homologous end joining 
(NHEJ) pathway, leading to chromosomal instability, cell cycle arrest, and apoptosis. However, 
if the NHEJ pathway is blocked, the cells can repair the damage through an alternative HDR 
mechanism that is not well understood.  
 
2.2 The molecular mechanism behind PARP1 functions  
There are three major and interdependent PARP1 characteristics, which are key to understand the 
molecular mechanism of PARP1 activation and deactivation and thus, PARP1 physiological 
functions. These three characteristics encompass: (i) PARP1 domain composition and inter-
domain communication regulating PARP1 chromatin associations and activation in space and 
time; (ii) specific PARP1 interactions with various proteins in a cell; and (iii) external and 
internal stimuli triggering PARP1 signaling. 
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2.2.1 PARP1 contains six globular domains  
Since the PARP1's purification from calf thymus in the late 70s (Mandel et al., 1977) multiple 
studies aimed to decipher the structural composition of PARP1, which has a molecular-weight of 
116 kilodaltons (kDa). The very first study reported a presence of only two PARP1 fragments. 
The first fragment was found to mediate DNA binding and the second fragment contained 
multiple sites for PAR modification (Nishikimi et al., 1982). Next, an additional segment of 
PARP1 – a domain responsible for NAD+ binding (PARP1 substrate) - was identified (Kameshita 
et al., 1984). This characterization of distinct PARP1 domains is valid until today. In summary, 
the three main functional PARP1 fragments are: an amino-terminal DNA binding domain 
(DBD), a central automodification domain (AMD) and a carboxy-terminal catalytic domain 
(CD). Over the past years the fragment composition of PARP1 was further redefined (Figure 2.7; 
de Murcia, 1999). 
 
Figure 2.7 Schematic representation of human PARP1 domain composition (from Hassler 
and Ladurner, 2012). Zinc-finger 1 (ZFI) and zinc-finger 2 (ZFII) form the DNA binding domain 
(DBD), zinc-finger 3  (ZFIII), BRCA1 carboxy-terminal domain (BRCT), BRCT and flanking 
loop regions form the automodification domain (AMD), named after a conserved central motif 
(WGR), PARP regulatory domain (PRD), PARP family defining catalytic core required for basal 
activity ADP-ribosyl transferase (ART), PRD and ART form the catalytic domain. 
As shown on Figure 2.7 the DBD is composed of two zinc finger domains (ZFI/ZF1 and 
ZFII/ZF2) which contain the characteristic Cys(Cysteine)-Cys-His(Histidine)-Cys zinc finger 
motif (Uchida et al., 1987, Lamarre et al., 1988, Gradwohl et al., 1990). The DBD is followed by 
an additional zinc finger fold (ZFIII/ZF3), which was found to mediate inter-domain contacts 
crucial in PARP1 activation (Langelier et al., 2008 and 2010). The third zinc finger does not bind 
to DNA alone in vitro (Tao et al., 2008) and does not reduce, when mutated, the binding to DNA 
of the full length PARP1 (Langelier et al., 2010). Between DBD and ZF3 resides a	   bipartite 
nuclear localization signal (NLS) and a caspase-3-cleavage site (Schreiber at el., 1992, Tewari et 
al., 1995). The AMD fragment contains the BRCA1 carboxy-terminal domain (BRCT), found to 
mediate protein-protein interactions for example of PARP1 with XRCC1 during DNA repair. 
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The carboxy-terminal CD contains the PARP signature motif, which binds NAD+ (Simonin et al., 
1990). This is the most conserved region across PARP family members across all species. Next 
to the CD, on the left, resides WGR motif, named after the conserved amino acid sequence in the 
motif (Tryptophan, Glycine, Arginine). WGR functions in DNA binding and inter domain 
contacts mediating PARP1 activation (Langelier et al., 2012). The structures of all individual 
domains or fragments of PARP1 are available (Figure 2.8). The nearly the full length X-ray 
structure of PARP1 (missing ZF2 and BRCT) bound to double strand break on DNA is known as 
well (Langelier et al., 2012). 
2.2.2 The DBD is important for DNA binding and PARP1 activation   
Already the early experiments have demonstrated the importance of damaged DNA as a co-
factor for PARP1 activity (Benjamin, 1980; Ohgushi, 1980). The DNA breaks were found to be 
exclusively recognized by DBD via ZF1 and ZF2 (Zahradka & Ebisuzaki, 1984, Uchida et 
al.,1987, Lamarre et al., 1988, Mazen et al., 1989). Over the years a contribution of each zinc 
finger to DNA break recognition and subsequent PARP1 activation became extensively studied, 
although with partially contrasting results. For example one study where binding of zinc (Zn2+) 
was abolished via mutagenesis, reported that ZF2 is a major part of the DBD involved in a 
specific recognition of a nick on a single stranded DNA. Lack of functional ZF1 resulted in only 
a minor reduction in DNA binding (Gradwohl at el., 1990). Another study found however that 
ZF1, next to ZF2, is actually important for a detection of a nick or a break on single stranded 
DNA (ssDNA) and subsequent PARP1 activation. In addition the importance of functional ZF2 
in recognition of a nick on double stranded DNA (dsDNA) was diminished (Ikejima et al., 1990).  
Various residues between ZF1 and ZF2, but also residues within N-terminal part of the central 
automodification domain (AMD) were suggested to mediate PARP1 activation upon DNA 
binding. These residues, when mutated, however did not compromise DNA binding (Trucco et 
al., 1996). Such inter-domain interactions were further confirmed with the identification and 
crystallization of the third zinc finger (ZF3), which is important for transmission of a DNA 
bound state to the catalytic domain (Langelier et al., 2008 and 2010). The transmission of DNA 
bound state to the molecule's activation, was suggested to be facilitated via dimerization of 
PARP1 molecules (Mendoza-Alvarez et al., 1993, Pion et al., 2005). At first, the identified ZF3 
was claimed to be important in PARP1 dimerization (Langelier at al., 2008).  
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Figure 2.8 The structures of human PARP1 protein (from Hassler and Ladurner, 2012). A) 
Zinc finger I (ZFI) in complex with blunt-ended DNA. ZFI binds the minor groove side. 
Important loop residues for DNA recognition (F44) and WGR interaction (D45) are indicated. B) 
Zinc finger II (ZFII) in complex with blunt ended DNA. ZFII binds also from the minor groove 
side. Important loop residues for interaction with ZFI (V144, P149) are indicated. C) hetero-
dimeric complex between ZFI and ZFII from 2 different PARP1 molecules and a 3 prime 
recessed DNA. Note that ZFI binds the major groove of the DNA in the complex. D) Zinc finger 
III (ZFIII) domain. Important residues are highlighted. E) NMR structure of the BRCA1 
carboxy-terminal domain (BRCT) domain. The location of the flanking flexible automodification 
region including experimentally verified sites of ADP-ribosylation are indicated. F) NMR 
structure of the WGR domain, named after the defining W and R residues. These residues 
mediate DNA contacts (W) and interaction with ZFI and PRD (R). G) X-ray structure of the 
catalytic domain consisting of PARP regulatory domain (PRD) and ADP-ribosyl transferase 
(ART) domain of PARP1 in complex with a nonhydrolyzable NAD+ analogue. The NAD+ 
analogue is bound at the PAR binding site and an additional NAD+ molecule is modeled into the 
catalytic site. Catalytic triad residues (red, HYE) and PRD residues mediating catalytic activation 
(green) are highlighted. H) X-ray structure of a near full-length PARP1 (lacking ZFII domain and 
automodification region, dotted grey) in complex with blunt-ended DNA. The DNA binding 
mode shown here is mutually exclusive with the one in C.  
A	   B	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However, a subsequent nuclear magnetic resonance (NMR) spectroscopy study by the same 
authors ruled out the possibility of dimerization (Langelier et al., 2010). In contrast, studies 
favoring monomerization of PARP1 were reported as well. For example, based on measurements 
of PARP1 catalysis rate, it was concluded that PARP1 is most likely monomeric (Ikejima et al., 
1987). Other studies left the question of PARP1 dimerization unsolved, concluding that, if the 
enzyme auto-modifies itself, kinetic analysis as a function of protein concentration cannot 
discriminate between monomolecular or bimolecular mechanism (Honegger et al., 1989). 
2.2.3 Structural insights into zinc finger interactions with DNA 
ZF1 and ZF2 bind the DNA break differently   
The work over the molecular mechanism of PARP1 binding to DNA and PARP1's subsequent 
activation, was facilitated by the X-ray determination of the crystal structure of PARP1-DBD 
bound to DNA break (Ali et al., 2012).   
The N-terminal segment of human PARP1 encompassing both zinc fingers (residues 5–202) was 
crystallized as bound to 11 base pair long duplex DNA with single-base 5′ overhang on each end. 
The PARP1-DBD structure, bound to the each end of the single DNA duplex was refined at 3.1 
Å resolution. Both zinc fingers interact with DNA via sugar-phosphate backbone grip and the 
base stacking loop. Majority of the contacts with the DNA phosphodiester backbone are formed 
by the residues 15-22 and 119-126 for ZF1 (residues 6-91) and ZF2 respectively (residues 107-
122). In ZF1, residues 16-Ser-Gly-Arg-Ala-19 project into the major groove, with Arg18 
contacting the edges of the base pairs. In ZF2, residues 120-Ser-Asn-Arg-Ser-123 project to 
minor groove with Arg122 making interactions with base pairs like Arg 18 of ZF1 (Figure 2.9).  
The interface between ZFs suggests PARP1 dimerization  
Despite similarity of architecture between the zinc fingers, they interact with DNA differently. 
The major difference is the loop between β-strands 2 and 3. In case of ZF2 the loop (Leu 151, Ile 
154) projects into DNA, over the 3 prime end (Figure 2.10 A). The same loop region in ZF1 does 
not make contact with DNA, however overlies the projecting loop of ZF2, which results in a 
hydrophobic interface between ZF1 and ZF2. The interface is made between residues Met43, 
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Figure 2.9 PARP1-DBD interactions with DNA (from Ali et al., 2012). The interactions are 
based on the X-ray structure of DNA Binding Domain (DBD) bound to DNA with a single base 
5´ overhang A) Zinc finger 1 (ZF1) DNA-interacting surface (colored by electrostatic potential, 
with positive in blue and negative in red) interacts with the sugar-phosphate backbone of the 
overhanging strand and the major groove. B) Details of ZF1 and DNA interactions, centered on 
the polar interaction of Arg34 (R34) and a DNA phosphate group. C) Zinc finger 2 (ZF2) DNA-
interacting surface (colored by electrostatic potential, with positive in blue and negative in red) 
interacts with the sugar-phosphate backbone of the recessed strand and the minor groove. D) 
Details of ZF2 and DNA interactions, centered on the polar interaction of Arg138 (R138) and a 
DNA phosphate group. 
 
Phe44, Val48 of ZF1 against Val144, Pro149, Gln150, Gly152 and Met153 (Figure 2.10 B). 
Interestingly, the complex of DBD with DNA suggested that both zinc fingers must come from 
two PARP1 molecules, because the linker connecting two zinc fingers on the same molecule is 
too short to span the distance and interactions observed in the crystal. This result suggests that 
PARP1 dimerizes via N-terminal on DNA substrate. The dimerization was tested and indeed 
confirmed experimentally using the linker deletion approach and the UV-laser cutting array 
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evaluating the recruitment of DBD wild type and mutants to the sights of DNA damage (Ali et 
al., 2012).    
 
 
Figure 2.10 DNA-end binding by the ZnF1-ZnF2 complex (from Ali et al., 2012). A) 
Molecular surface of the DNA-end binding structure formed by PARP1 ZnF1 and ZnF2 domains 
extending across the surface of the DNA end and interacting with both grooves of the duplex. The 
3′ recessed end of one strand is on the left, and the 5′ overhanging end of the other strand is on the 
right. B) Detail of the interface between the tips of the β-2–3 connecting loops of ZnF1 and ZnF2, 
which form the bridge overlying the terminal base pair of the duplex. Transparent molecular 
surface and carbon atoms are colored by domain, with ZnF1 in cyan and ZnF2 in gold.  
 
There are two opposing models for DNA break binding by PARP1  
In addition to the structure of DBD bound to DNA (Figure 2.9), two different structures were 
reported: (i) two zinc fingers, each bound alone to blunt ended duplex DNA (Figure 2.8 A and B; 
Langelier et al., 2011), and (ii) nearly full length PARP1 bound to blunt ended DNA (Figure 2.8 
H; Langelier et al., 2012). ZF2 in both structures (single ZF and DBD; Langelier et al., 2011, Ali 
et al., 2012) interacts with DNA in the same manner. Significant differences occur in the case of 
A	  
B	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ZF1 which binds to DNA with opposite polarities in both structures. In both structures the 
backbone grip uses the same conserved arginine (Arg34) residue to bind to the phosphate 
backbone, but the entire domain is flipped such that arginine (Arg18) is directed into the DNA 
major groove (the Ali structure) rather than the minor groove (the Langelier structure). Moreover 
β-2–3 loop (the Ali structure) engages in a stacking interaction with the corresponding loop in 
ZFII (Figure 2.10) which is not at all observed in the Langelier structure.  
The third structure, the nearly full length PARP1 structure (missing ZF2 and BRCT domains) 
sheds light on cooperative interactions between PARP1 domains outside of the DBD. This 
structure reveals that interface of PARP1 molecule with broken DNA is distributed over ZF1, 
ZF3 and WGR (Langelier et al., 2012). Mainly ZF1 binds DNA via ribose-phosphate backbone 
grip and the base stacking loop in sequence-independent manner. The N-terminal region of ZF3 
domain binds to the DNA on the same side as ZF1. The WGR domain binds to the 5 prime-
terminus of the break, with the DNA backbone held between the central β-sheet of WGR and the 
α-helix that runs parallel to the β-sheet. WGR contacts with DNA extend the contacts made by 
the ZF1 base stacking loop which rests on the nucleotide bases at the end of the DNA. The 
mutagenesis of residues of ZF1, ZF3 and WGR which mediate DNA contact reduce PARP1 
activity. Moreover binding to DNA of ZF1, ZF3 and WGR promotes allosteric distortion of the 
PRD, suggesting the CD activation (Figure 2.8 H). None of the Langelier structures supports 
dimerization of PARP1 over the DNA. The Langelier structures favor monomerization of 
PARP1.  
ZF2 was eliminated from the almost full length PARP1 study, because ZF2 was assumed to be 
not essential in studies over PARP1 activity. This conclusion was based on the findings were 
PARP1 missing ZF1 or ZF2 was evaluated for its automodification capability by SDS-PAGE. 
The results found ZF1 to be essential for PARP1 automodification, whereas ZF2 was obsolete. A 
similar outcome was detected in fibroblasts transiently transfected with PARP1 missing ZF1 or 
ZF2. Upon DNA damage induction with hydrogen peroxide only PARP1 missing ZF1 did not 
show PAR staining in the nucleus. However when it comes to DNA binding in vitro, the 
importance of zinc fingers changed. ZF2 as individual domain had 100-fold higher affinity to 
DNA, in comparison to ZF1 alone. A deletion of ZF2 from full length PARP1 reduced DNA 
affinity 3-fold, whereas deletion of ZF1 almost not at all (Langelier, et al., 2011). Various DNA 
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structures –duplex DNA containing an overhang or a nick or blunt were evaluated in this activity 
study of zinc fingers. In summary, these are major differences which needed to be 
experimentally addressed especially via in vivo approaches. 
2.2.4 The mechanism of DNA target site selection by, and activation of PARP1 
PARP1 binds to distorted DNA in vitro and in vivo 
In the aftermath of the report, that broken DNA stimulates the enzymatic activity of PARP1 the 
molecular and functional characteristics of the interactions between PARP1 and DNA became 
extensively studied in vitro (Benjamin, 1980, Ohgushi, 1980). PARP1 was found to bind various 
forms of broken and closed circular DNA (Menissier-de Murcia et al., 1989). In addition to the 
DBD, the automodification domain of PARP1 (without the DBD) was shown to weakly interact 
with unbroken and 222 base pair long DNA fragment. However this interaction did not lead to 
the enzymatic activation (Uchida et al., 1987, Buki et al., 1989, Mazen et al., 1989). The 
catalytic domain alone does not bind to DNA (Thibodeau et al., 1993). In addition to broken 
DNA, other distorted DNA structures like hairpins, cruciforms, loops and AATT rich sequences 
positively correlated with PARP1 binding and stimulation (Lonskaya et al., 2005).  
Recently, the interaction of PARP1 and DNA were again reevaluated. PARP1 full length and N-
terminal fragment (residues 1-486, from ZF1 to BRCT domain) shown preference for free DNA 
with bent or curved conformations induced by a nick or an AATT insert over a blunt or DNA 
with overhangs. PARP1 full length exhibited between 1.4 - 3 fold, higher affinity (for tested 
DNA fragments) when compared to N-terminal fragment. Both of the PARP1 constructs (N-
terminal and full length) bound stronger to nucleosomes than to free DNA. Importantly, PARP1 
bound to nucleosomes only in presence of DNA arms (linker DNA). PARP1 full length bound 
significantly stronger to tested DNA fragments (up to 50 fold) in comparison to N-terminal 
PARP1 fragment. PARP1 binding to DNA/nucleosome did not correlate strongly with PARP1 
activity (Clark et al., 2012).  
Of course, it is of high interest if these in vitro PARP1 associations with DNA/nucleosomes have 
the same character in vivo. Accordingly, PARP1 full length and its product PAR were visualized 
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via immunofluorescence to be enriched over DNA breaks introduced with a 780 nm long 
wavelength laser in a cell (Haince et al., 2008; Figure 2.11).  
 
 
Figure 2.11 Sites of DNA damage marked with phosphorylated H2A.X showed high 
concentration of poly-ADP-ribose polymerase 1 (PARP1) enzyme and a product of its 
activity, poly-ADP-ribose (PAR) (from Haince et al., 2007).  
 
From genome wide PARP1 enrichment data analysis (in no DNA damage conditions) it was 
found that PARP1 resides at 758 promoters (1517 tested genes). These PARP1 associations with 
chromatin were shown to be specific only to transcription start sites (TSS) with weak ChIP-chip 
(chromatin immunoprecipitation coupled with DNA microarray) signal proceeding into the gene 
body, and no detectable enrichment upstream from the TSS. The presence of PARP1 at these 
sites correlated with depletion of histone 1 (H1; Figure 2.12). The exact mechanism behind 
specific enrichment of PARP1 over TSS was not tested (Krishnakumar et al., 2008). 
Unfortunately none of the in vivo studies evaluated the importance of zinc fingers directly for 
association with chromatin.  
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Figure 2.12 Distinct patterns of genomic localization for H1 and PARP-1 (from 
Krishnakumar et al., 2008).  Heat maps of H1 and PARP-1 ChIP-chip data for 1517 promoters 
tiled from -25 kb to +5 kb (kilobase) relative to the transcription start site (TSS). The promoters 
are ordered top to bottom based on increasing intensity of the PARP-1 signal in a 10 kb window 
surrounding the TSS. PARP1 signal is centered over TSS (0 kb), whereas H1 signal is around 
TSS (upstream and downstream from TSS).  
The histone code regulates PARP1 association at the heat shock loci   
Already the early in vitro studies showed that PARP1 does not bind directly core histones: H2A, 
H2B, H3 or H4 (Buki et al., 1995). However these histones, when embedded into a nucleosome 
in vitro, are readily associated with PARP1 (Kim et al., 2004). In vivo, PARP1 and nucleosome 
associations were nicely illustrated by studies over mammalian, heat shock inducible human 
Hsp70.1 promoter. This promoter contains nucleosomes with incorporated macroH2A1.1 histone 
variant, which contains a macrodomain tail. The macrodomain recognizes chains of PAR, and 
was shown to be important for PARP1 associations with this Hsp70.1 promoter. When 
macroH2A.1.1 was mutated and thus unable to bind PAR, PARP1 did not show association with 
the Hsp70.1 promoter (Figure 2.13). This work showed an importance of PARylation mediated 
PARP1 association to Hsp70 promoter.  
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Figure 2.13 PARP1 levels at Hsp70.1 promoter (from Ouararhni et al., 2006). The amount of 
PARP-1 associated in vivo with the Hsp70.1 promoter in the stable cell lines expressing mutated 
mH2A1.1 is much lower compared with PARP1 association with the Hsp70.1 promoter in the 
stable cell lines expressing WT-mH2A1.1. WT - wild type, (HS; −) non heat-shocked and (HS; +) 
heat-shocked (30 minutes at 42°C).  
 
Upon heat shock the PARP1 bound fraction to the Hsp70 promoter increased at 5 minutes post 
stimuli. With time: 10, 20 and 30 minutes both PARP1 and macroH2A1.1 showed gradual 
displacement from the promoter (Ouararhni et al., 2006).  Investigation of in vivo associations of 
PARP1 with chromatin revealed that among proteins co-immunoprecipitated with PARP1 are: 
histones H4, H3, H2A, and H2B (Pinnola et al., 2007). Histone 1 (H1) was shown to be an 
antagonist of PARP1 binding in vitro and in vivo (Kim et al., 2004, Krinskakumar et al., 2008). 
When PARP1 was immobilized on the beads and incubated in vitro with reconstituted histone 
octamers, H3 and H4 were found to interact with PARP1 the strongest. In addition, the N-
terminal tail of H4 was found to be a more potent PARP1 activator that broken DNA. However, 
PARP1 missed its DBD in this experiment, suggesting overactive PARP1 in the reaction 
(Pinnola et al., 2007). Thus, the interaction with histones of PARP1 was probably PAR 
mediated. When H4 was assembled together with other histones into an octamer the H4 role in 
PARP1 activation was lost, due to potential inhibitory effect of H2A (Pinnola et al., 2007). 
Importantly, mass spectrometry identified that many lysines and glycines of all of the histones 
are actually in vivo PARylated by PARP1 (Zhang et al., 2013b).  
After the discovery of Drosophila melanogaster PARP (dPARP) activity requirement for the 
heat-shock-induced puffing and transcription of hsp70 in Drosophila larvae (Tulin and Spradling 
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2003), subsequent studies investigating PARP1 chromatin association and the histone code at 
Drosophila melanogaster heat shock loci followed. The H2A.V (H2A.X/H2A.Z variant in 
mammals) acts as the negative regulator of PARP1 association to chromatin. Upon depletion of 
H2A.V from hsp70 promoter, PARP1 residency over the loci increases (Figure 2.14). Whereas in 
wild type flies, H2A.V is phosphorylated by Jil1 kinase, which leads to activation of PARP1, 
then removal of H2A.V resulting in correct hsp70 transcription (Kotova et al., 2011, Thomas et 
al., 2014). Fly PARP was found as necessary for both transcription-independent and -dependent 
nucleosome loss during HS (Petesch and Lis, 2008). 
 
 
Figure 2.14 PARP1 occupancy at the hsp70 promoter (from Kotova et al., 2011). Chromatin 
immunoprecipitation (ChIP) profiles of PARP1 at hsp70 loci in flies with wild type (WT) levels 
of H2A.V (blue), depleted H2A.V (green) and depleted PARP1 (red).    
 
Inactive dPARP resides at hsp70 loci prior to heat shock at TSS exclusively. Upon HS, dPARP 
moves into the gene body and PAR levels become detectable. The association of dPARP with 
hsp70 loci seems to be controlled by at least two mechanisms. Prior HS dPARP association is 
PAR independent thus, probably zinc finger mediated. During HS dPARP association is PAR 
dependent. As shown by loss of dPARP from hsp70 loci upon chemical inhibition of dPARP or 
PAR degradation via treatment with enzyme degrading PAR – PARG (Petesch and Lis, 2012). 
The association of dPARP at hsp70 loci was found to be modulated by Tip60 mediated 
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acetylation of H2A and H4. The acetylation led to dPARP activation. The knock down of 
dPARP did not affect levels of acetylation upon HS (Petesch and Lis, 2012).  
An evaluation of dynamicity of dPARP interactions with chromatin in vivo found that dPARP 
exchanges between chromatin domains faster than a canonical histone H2A. This study was 
conducted in the fly salivary glands via fluorescence recovery after photobleaching (FRAP). The 
fluorescence intensity recovery rate depended on the chromatin domain: euchromatin and 
heterochromatin. On average, the half time recovery (representing 50 % recovery of the bleached 
spot) was 100 seconds (Figure 2.15).  
It is known that PARP1`s DNA binding to the target sites will be affected by histone 
modification and the chromatin structure. However more studies deciphering these determinants 
are needed.    
 
Figure 2.15 Comparative FRAP analysis of dPARP protein dynamics in vivo (from Pinnola 
et al., 2007). Comparative analysis of the recovery after photobleaching for recombinant protein 
is shown, including PARP-EGFP – poly-ADP-ribose polymerase labelled with enhanced Green 
Fluorescent Protein. PARG-EGFP – poly-ADP-Ribose glycohydrolase labelled with enhanced 
Green Fluorescent Protein, H1-EYFP – histone 1 labelled with enhanced Yellow Fluorescent 
Protein, H2A-ECFP – histone H2A labelled with enhanced Cyan Fluorescent Protein.  
 
2.2.5 Posttranslational modifications modulate PARP1 activity  
The cellular signaling, during DNA repair or transcription, encloses dynamic and regulatory 
interplay between various posttranslational modifications. It is known that in addition to 
automodification with PAR moieties, PARP1 becomes post-translationaly modified and 
regulated by various PTMs. 
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Phosphorylation activates PARP1  
Phosphorylation was the first PTM of PARP1 identified. Initially the phosphorylation was 
considered as a negative modification to PARP1's activity, based on in vitro PARP1 
modifications by protein kinase C (PKC; Tanaka et al., 1987, Bauer et al., 1992). However, the 
subsequent studies found links to PARP1 phosphorylation as stimulatory. For example, 
extracellular-signal-regulated kinases 1 and 2 (ERK1/2) were shown to stimulate PARP1 activity 
up to 75 % in vitro. However, only ERK2 regulated PAR levels in vivo	  (Kauppinen et al., 2006). 
Both, AMP-activated protein kinase (AMP-K) and c-Jun-N-terminal kinase 1 (JNK1), upon 
hydrogen peroxide- induced cell death, activated PARP1 (Walker et al., 2006, Zhang et al., 
2007). Recently, a comprehensive study predicted over 20 phosphorylation sites across the whole 
PARP1 molecule with NetPhosK and Phoscan algorithms. Next the predications were compared 
with results from subsequent mass spectrometry analysis of the recombinant PARP1 that has 
been incubated with PKC, ERK1/2, Ca2+/calmodulin-dependent protein kinase II (CaMK-II), 
JNK1 and cyclin dependent kinase 5 (CDK5). This analysis identified most the known 
phosphorylation sites today (Gagne et al., 2009). The mutagenesis of some of the phosphorylated 
residues proved their physiological importance. For example, mutagenesis of serines (S) residing 
in zinc finger 1 (ZF1) abolished the recruitment of PARP1 molecule to DNA damage sites 
induced with a laser (Figure 2.16; Gagne et al., 2009). The evaluated serines reside in vicinity of 
residues involved in DNA break recognition and interface contact between ZF1 and ZF2, thus 
phosphorylation presence or absence may alter zinc finger ability to engage with DNA. 
Acetylation activates PARP1  
Acetylation of PARP1 is studied as comprehensively as phosphorylation. PARP1 was found to 
be acetylated at lysines: Lys-498, Lys-505, Lys-508, Lys-521 and Lys-524 upon activation of 
nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) dependent transcription 
in vivo. The transcription was induced with bacterial lipopolysaccharides (LPS) or tumor 
necrosis factor alpha (TNFα). The PARP1 acetylation was found to be p300/CBP dependent and 
was detectable only in presence of deacetylase inhibitors. The acetylation strengthened the 
interactions between PARP1 and transcription factor p50 in vivo (Hassa et al., 2003 and 2005).  
The co-incubation of PARP1 with p300/CBP-associated factor (PCAF) acetyltransferase resulted 
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in enhanced PARP1 activity in vitro. In vivo, acetylation of PARP1 decreased and increased 
upon PCAF knock down and overexpression respectively. Sirtuin 1 (SIRT1) and histone 
deacetylase 1 (HDAC1) were found to deacetylate PARP1 in vivo and to decrease PARP1 
activity upon deacetylation in vitro. Moreover, cardiomyocytes under mechanical stress where 
shown to contain more PAR in mice lacking SIRT (SIRT-/-) when compared to WT mice 
(Rajamohan et al., 2009).  
 
 
Figure 2.16 Evaluation of PARP1 phosphorylation importance on recruitment to DNA 
breaks (from Gagne et al., 2009). S41 Erk-1 phosphorylation site located in the first zinc finger 
motif of PARP-1 reveals altered recruitment kinetics at sites of DNA damage following laser 
microirradiation. The spatial dynamics of GFP-tagged single and triple glutamate- and aspartate-
substituted derivatives that mimic a permanently phosphorylated protein (S27D-S32E-S41E) 
were investigated by microirradiation-induced DNA damage using a 750-nm laser. The relative 
fluorescence intensity at the microirradiated region of HeLa cells was normalized and plotted as a 
function of time after integrating data from at least five low-expressing cells. The error bars 
represent the standard error. 
 
SUMOylation and ubiquitination deactivate PARP1  
Similarly to many other proteins, PARP1 becomes SUMOylated as well (Vertegaal et al., 2004, 
Rosas-Acosta et al., 2005, Blomster et al., 2009). PARP1 was found to be modified 
PARP1-­‐WT	  
PARP1-­‐S27D	  
PARP1-­‐S32E	  
PARP1-­‐S41E	  
PARP1-­‐S27D-­‐S32E-­‐S41E	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predominantly by small ubiquitin-related modifier 3 (SUMO3). The SUMO modification can be 
reversed by SUMO1/sentrin specific peptidase 1 and 3 (SENP1 and SENP3), which knock down 
contributes to elevated levels of sumoylated PARP1 in HEK293T cells. The specific acceptor 
residue of PARP1 molecules was predicted by the SUMOsp analysis program to be lysine 486.    
This residue indeed when mutated abrogates SUMO signal from PARP1 in vitro and in vivo. 
PARP1 with or without the SUMO modification (introduced by SUMO3) shows the same mono- 
and poly-ADP-ribosylation activity in vitro. PAR levels were found to be comparable in cell 
with damaged DNA, regardless of endogenous or overexpressed levels of SUMO3. 
SUMOylation was however found to prevent p300 mediated acetylation of PARP1. 
Correspondingly, a sumoylation-deficient PARP1 mutant has a higher acetylation status than 
wild-type PARP1 (Messner et al., 2009). Additional PARP1 SUMOylation sites were identified 
to be K203 and K512 (Martin et al., 2009, Zilio et al., 2013).  
SUMO2 mediated SUMOylation of PARP1 can lead to enhanced ubiquitination by Ub E3 Ring 
Finger Protein 4 (RNF4) ligase and subsequent degradation of PARP1. Such regulation was 
found to take place during transcription burst at the heat shock loci (Martin et al., 2009). Lack of 
SUMOylation reduces mRNA levels from the heat shock loci. Similarly, Ub E3 RNF198 ligase 
checkpoint with forkhead and ring finger domains (CHFR) was found to be rapidly recruited to 
the sites of DNA damage site, thanks to the PAR-binding zinc finger (PBZ) motif. This ligase 
recognizes specifically auto-PAR-modified PARP1 molecules and ubiquitinates them at least at 
K68 and K63 residues. The ubiquitination of PARP1 leads to proteasome mediated PARP1 
degradation. Lack of CHFR leads to delay of DNA damage site repair (Liu et al., 2013).  
Interestingly, poly-ubiquitination of PARP1 in vitro did not inhibit its ADP-ribose activity 
(Wang et al., 2008).  
Mono-ADP-ribosylation activates PARP1  
DNA breaks are perceived as major inducers of PARP1 activity. Interestingly PARP1 was shown 
to be activated thanks to mono-ADP-ribosylation, introduced by poly-ADP-ribose polymerase 3 
(PARP3)	   in vitro in absence of DNA (Loseva et al., 2010). In addition, in vivo mono-ADP-
ribosylation by sirtuin 6 (SIRT6) appears to enhance PARP1 activity as well (Mao et al., 2011). 
Currently it is assumed that mono-ADP-ribosylation could serve as a base for further extension 
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of PAR chain and/or triggers certain conformational change within PARP1 molecules fostering 
PARP1 activation.  
Methylation activates PARP1 
Methylation is the most recent PTM of PARP1 identified. The modification is introduced in vitro 
and in vivo by SET and MYND domain containing histone methyltransferase (SMYD2) on 
lysine 528 of PARP1 and leads to increased PARP1 activity. HeLa cells with induced oxidative 
DNA damage due to hydrogen peroxide treatment show reduced or elevated levels of PAR 
depending on SMYD2 reduction via knock down or overexpression, respectively (Piao et al., 
2014).  
2.2.6 Open questions  
The variety of cellular functions regulated by PARP1 is on the rise. The interdependence of these 
processes can be especially difficult to interpret in human patho-physiology, where PAR 
metabolism plays a significant role. Despite the recent progress regarding the molecular 
mechanism of PARP1 activation via identification of the X-ray PARP1 structures bound to DNA 
more studies are needed (see also 2.2.3). To truly decipher PARP1's physiological functions it is 
important to gain a full spatiotemporal understanding of PARP1's in vivo interactions with DNA 
as a major PARP1 inducer (see also 2.2.2). The predominant view is that PARP1, in its dormant 
state, is constantly associated with chromatin. At the same time, upon variety of stimuli, a 
conformational change within PARP1 molecule triggers its activation. But, if PARP1 was 
associated across the genome, how does it specifically recognize its target sites and specifically 
become activated at these sites? This question is especially valid in the context of non-stress 
conditions (no DNA damage, no heat shock and no hormone treatment). In transcription PARP1 
can function as co-activator or co-repressor. How, are these two contrasting outcomes (co–
activation or co-repression) spatially and temporally resolved? Further, what are the regulatory 
steps in PAR mediated chromatin reorganization? Both, condensation and de-condensation are 
possible (Wacker et al., 2007, Tallis et al., 2014). Clues to answer these questions exist, but 
limitations and shortage of information as well. Pivotal to answer these questions is an exact 
mechanism of DNA target selection and PARP1 activation in detail. It is clear that upon presence 
of DNA breaks, PARP1 binds to the breaks via the DBD. What is less clear is the role each zinc 
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finger plays in DNA break recognition and transmission of DNA bound state to the catalytic 
domain. The current structural models are incompatible (see also 2.2.3). It is not clear how 
PARP1 becomes enriched at gene promoters. The studies over heat shock gene containing 
macroH2A1.1 suggest a PAR-dependent immobilization of PARP1 (see also 2.2.4). Its appears 
that in vivo analysis of PARP1's chromatin association via fluorescence microscopy, genome 
wide studies can advance and answer some of these confusions. Finally, after PARP1 becomes 
associated with chromatin, what immediate role will it play in chromatin structure organization? 
A depletion of ISWI chromatin remodeler, but recruitment at the same time of ALC1 chromatin 
remodeler seems to trigger a specific cellular program upon localized PAR signaling. Moreover, 
a relatively new is an aspect of PAR importance in triggering phosphorylation and ubiquitination 
cascades at sites of PARP1 activity. The crosstalk between these three regulatory PTMs is of 
high importance in disease diagnosis and treatment.  
2.3 Life of poly-ADP-ribose (PAR) 
2.3.1 Insights into PAR synthesis    
Despite the high abundance of the enzymes capable of PAR synthesis (see also 2.1.1), the usual 
cellular levels of PAR are very low, unless a cell counteracts the DNA damage with mechanisms 
involving PARP1 activity. In result PAR levels increase transiently. Majority of PAR within the 
cell is synthesised by PARP1. In detail, activated PARP1 catalyzes transfer of the ADP-ribose 
moiety from NAD+ substrate (with release of nicotinamide) to specific amino acid residues on 
itself or acceptor proteins. At first is introduced a single unit of mono-ADP-ribose, which is 
further elongated (up to 200 units) and branched (every 20-50 units). ADP-ribose units are linked 
by glycosidic ribose-ribose 1 -> 2 bonds (O-glycosidic ribose–ribose). Poly-ADP-ribose is 
negatively charged due to presence of two negatively charged phosphate groups per ADP-ribose 
(Tanaka et al., 1977, Alvarez-Gonzalez and Jacobson, 1987, D'Amours et al., 1999, Hottiger et 
al., 2010, Barkauskaite et al., 2013; Figure 2.17).  
The heterogeneity of PAR polymers in size and structure allows for flexible contacts with the 
target proteins and assembly of multi protein complexes, underlying the diversity of PAR 
functionality as a PTM. Residues that become ADP-ribosylated were found to be aspartic acid, 
glutamic acid, lysine, arginine, cysteine and asparagine (Hassa et al., 2006). PARP1 auto-
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modifies itself with PAR, as well. The mass spectrometry study which favored identification of 
ADP-ribosylation on aspartic acid (Asp) and glutamic acid (Glu) residues, pinpointed 37 sites 
which become ADP ribosylated upon activation of PARP1 (Figure 2.18; Zhang et al., 2013b) 
 
 
Figure 2.17 The cycle represent the anabolic and catabolic reactions in the metabolism of 
poly-ADP-ribose (from D'Amours et al., 1999). The PAR cycle proceeds counterclockwise. The 
pink circle in the middle of the scheme represents a hypothetical protein acceptor modified on a 
glutamic acid residue (c-COOH group shown).  
 
In addition to PARP1 auto-modification sites, the mass spectrometry study identified PAR Asp 
and Glu modifications representing in total 340 proteins. Gene Ontolgy analysis of PARylated 
peptides revealed that the modified proteins are important for chromosmome organization, DNA 
repair, transcription and RNA splicing (Zhang et al., 2013b). Majority of these modifications 
were absent in the samples pretreated with two recent PARP inhibitors (olaparib and AG14361; 
Zhang et al., 2013b).  
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Figure 2.18 The aspartic acid (Asp) and glutamic acid (Glu) sites on PARP1 molecule which 
become ADP-ribosylated (from Zhang et al., 2013c).  
 
PARP1 is a protein that predominantly acts on the chromatin fiber via PAR modification of itself 
and acceptor proteins regulating positively or negatively processes occurring on chromatin. This 
regulation can encompass at least one of the following mechanisms: (i) recruitment or depletion 
of certain proteins, (ii) regulation of complex formation and activity via regulation of protein – 
protein interactions, or (iii) regulation of protein activity including target recognition (Althaus et 
al., 1999). Importantly poly and mono–ADP-ribose are reversible modifications with half time in 
order of minutes (see also, 2.3.3; Alvarez-Gonzalez and Althaus, 1989). 
2.3.2 Specific recognition of PAR  
Poly-ADP-ribose binding motif (PBM) 
Majority of PARylated proteins share the poly-ADP-ribose binding motif (PBM) shown on 
Figure 2.19 (Pleschke et al., 2000, Gagne et al., 2008). The PBM is composed of hydrophobic 
and basic residues downstream from positively charged residues. This motif is not only present 
in DNA repair associated proteins, but also proteins involved in chromatin structure 
reorganization, transcription, replication, apoptosis or cell cycle checkpoint. The PBM often 
overlaps with important regulatory protein domains, thus addition of PAR to the PBM can 
modulate folding of the domain, protein-protein or protein-ligand interactions. 
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Figure 2.19 Scheme of Poly-ADP-ribose Motif, PBM (from Krietsch et al., 2013). A) The motif 
is primarily composed of a hydrophobic and basic amino acid core flanked by a cluster of 
positively charged residues [. . .K/R. . .]. Each box represents one amino acid position. B) The 
refined poly-ADP-ribose (PAR) binding signature confirmed the overall basic nature of the PBM 
but represents a minimal stand-alone version of the motif, the K/R-rich N-terminal cluster being 
dispensable for efficient binding. Outside the dual [KR][KR] site, there are additional preferences 
for hydrophobic amino acids (positions 1, +1 and +2), mostly those with alkyl side chains. The 
basic [KR][KR] doublet is an important requirement for the PBM since most substitutions in this 
region result in a substantially reduced binding affinity for PAR. 
Macrodomains recognize ADP-ribose   
Already the early reports found	   poly-ADP-ribose glycohydrolase (PARG) as a major enzyme 
regulating the turnover of PAR (Miwa and Sugimura, 1971). However an exact domain 
responsible for PAR recognition and hydrolysis remained unknown until 2005. The 
macrodomain was identified in the core histone variant macroH2A, as an unusually long C-
terminal tail (Pehrson et al., 1992). Subsequently the ability of the macrodomain to selectively 
recognize ADP-ribose was determined via isothermal titration calorimetry (ITC) studies of the 
macrodomain with ADP-ribose and related nucleotides. Moreover a crystal structure of Afl1521 
macrodomain (Archaeoglobus fulgidus) bound to ADP and ADP-ribose was determined (Figure 
2.20; Karras et al., 2005). Similarly to the PARP catalytic domain, the macrodomains are 
evolutionary conserved and thus found, not only in vertebrates but also, in genomes of plants 
(Arabidopis thaliana), viruses (Rubella and Hepatitis E), bacteria (Salmonella typhimurium, 
Listeria; Till and Ladurner, 2009). In humans, so far, 12 macrodomain containg proteins were 
identified.  
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Figure 2.20 Structure of the complex formed between Af1521 and ADP-ribose (from Karras 
et al., 2005). The ADP-ribose molecule is bound by the Af1521 (Archaeoglobus fulgidus) 
macrodomain in an L-shaped cleft. The ADP-ribose ligand is shown as a ball-and-stick model. 
 
The macrodomains are not identical. Their structural differences predetermine macrodomain 
containing protein to act solely as a reader of mono-ADP-ribose or poly-ADP-ribose, or to act as 
a reader and eraser of the modification as well. A globular macrodomain comprises of six-
stranded mixed β-sheet and five α-helices, which form a cleft for the ligand. The binding occurs 
via stacking interaction with the adenine ring, strengthened via the interactions with the 
pyrophosphate of ADP-ribose, and with specificity provided by hydrogen bonding with the distal 
ribose (Karras et al., 2005, Till and Ladurner, 2009, Han et al., 2011). Sequence differences 
among macrodomains determine specificity for various NAD+ metabolites: O-acetyl-ADP-
ribose, ADP-ribose, poly-ADP-ribose. For example the macrodomain containing ALC1 binds 
exclusively PAR.  
Poly-(ADP-ribose)-binding zinc finger (PBZ) 
Classically zinc fingers are viewed as DNA and RNA binding domains. It turned out that C2H2 
zinc fingers can mediate protein-protein interactions via PAR binding, thanks to 6-8 amino acid 
spacer with the following consensus [K/R]xxCx[F/Y]GxxCxbbxxxxHxxx[F/Y]xH (b = basic 
residue, x = any residue; Ahel et a., 2008). Poly-ADP-ribose binding zinc finger (PBZ) is 
conserved across eukaryotes with an exception of yeast. For example, one and two PBZ domains 
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are present in checkpoint with forkhead and ring finger domains (E3 ubiquitin protein ligase) 
(CHFR) and aprataxin and PNKP like factor (APLF) proteins, respectively.   
Alternatives to the PBM  
An additional PAR binding fold is the GAR domain, named after a high content of glycine and 
arginine residues. The GAR domain motif lacks hydrophobic residues like the PBM motif, and is 
found mostly in proteins involved in RNA metabolism or proteins which are associated with 
chromatin. One of the proteins that are regulated by PAR and contain GAR is meiotic 
recombination 11 homolog A (MRE11) part of the MRN complex protein which mediates DNA 
break end resection, facilitating DNA repair (Haince et al., 2008, Ying et al., 2012). Additional 
motifs to GAR are the following: the RNA recognition motif (RRM; Clery et al., 2008) and 
Serine/Arginine repeats (SR; Long and Caceres, 2009). RRMs are found in proteins that bind to 
RNA and ssDNA. These motifs can be found in combination on one protein. For example, 
alternative splicing factor 1 (ASF) contains on N-terminal RPM and on C-terminal SR domain 
(Malanga et al., 2008) or heterogeneous nuclear ribonucleoproteins (hnRNPs) contain RPM and 
GAR (Han et al., 2010). Proteins that bear these motifs are involved in control of	  mRNA stability 
and splicing, DNA replication, chromatin remodeling, telomere maintenance,	  DNA repair and 
genome stability (Gagne et al., 2003). 
WWE domain 
The recently discovered WWE domain is shared across 12 proteins in humans. The motifs name 
is attributed to highly conserved amino acids: W (tryptophan) and E (glutamate), flanked by non-
conserved residues (Wang et al., 2012). Interestingly proteins containing WWE domain, bear 
either E3 ligase domain or PAR catalytic domain.  
PAR binding regulatory motif and oligonucleotide/oligosaccharide binding fold   
The identification of motifs that specifically recognize PAR seems to be continuous. The recent 
additions encompass PAR-binding regulatory (PbR) motif, which is critical to the recruitment 
and full activation of checkpoint kinase 1 (CHK1; Min et al., 2013). The 
oligonucleotide/oligosaccharide-binding (OB) fold is classically known for ssDNA or RNA 
binding. Unexpectedly the OB fold of human ssDNA-binding protein 1 (hSSB1) was found to 
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bind PAR and to be recruited to the sites of DNA damage thank to the OB-fold (Zhang et al., 
2014).     
2.3.3 Macrodomains remove PAR  
The extent of ADP-ribosylation of proteins within a cell depends greatly on the enzymes 
producing this modification, but also on the activity of enzymes responsible for removal of ADP-
ribose. Similarly to its rapid synthesis, PAR chains are as well rapidly removed, in order of 
minutes (Wielckens et al., 1983 and 1984, Alvarez-Gonzalez et al., 1989). The first PAR 
degrading enzyme, poly-ADP-ribose glycohydrolase (PARG) was found early on (Miwa and 
Sugimura, 1971), however the mechanistic insights into PAR binding and hydrolysis came only 
recently (Slade et al., 2011, Dunstan et al., 2012). To a surprise at first, the X-ray structure of 
bacterial PARG (derived from Thermomonospora curvata), revealed that the catalytic center is 
essentially a macrodomain with a loop region that contains the PARG signature sequence (GGG-
X6 − 8-QEE).  
The PARG signature motif is shared among PARG proteins from protozoa to humans. The 
bacterial PARG is exo-glycohydrolase, which means that the protein binds the terminal ADP-
ribose unit of PAR. The canonical PARG structures suggested that it is possible that PARG can 
bind not only terminal ADP of PAR, but also intra ADP units of the chain, which accounts for 
additional endo-glycohydrolitic activity of PARG activity (Kim et al., 2012, Tucker et al., 2012). 
PARG cleaves the O-glycosidic ribose–ribose bonds between ADP-ribose units, which are 
originally introduced by PARP1 and any other PARP polymerase. Upon cleavage free ADP 
ribose is released (Ueda et al., 1972, Slade et al., 2011). Recent reports also suggest that a second 
hydrolase, ARH3, exhibits the analogous activity to PARG predominantly removing PAR in 
mitochondria (Niere et al. 2012). More studies are however needed, because ARH3 was mostly 
reported to cleave OAADPR, a product of NAD+ - dependent protein deacetylases of the sirtuin 
family (Ono et al., 2006, Mueller-Dieckmann et al. 2006). Importantly ARH3 does not contain 
the macrodomain fold.  
PARG is unable to cleave the ester bond between the terminal ADP-ribose unit and the ADP-
ribosylated glutamate (Slade et al, 2011), thus not capable of the complete removal of PAR from 
the acceptor protein. This function is carried on by three enzymes: terminal ADP-ribose protein 
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glycohydrolase (TARG1/C6orf130; Sharifi et al. 2013), MacroD1 and MacroD2 (Jankevicius et 
al. 2013, Rosenthal et al., 2013, Barkauskaite et al., 2013). All three enzymes reverse mono-
ADP-ribosylation. In addition, C6orf130 can release PAR chains from the PAR modified 
molecule, acting specifically at the glutamate-ADP-ribose ester bonds. PARP1 can be directed 
for proteasome degradation thanks to	  ubiquitination, thus further generation of PAR is prevented 
(for details see 2.2.5, SUMOylation and ubiquitination deactivate PARP1).  
2.4 ALC1 in PAR biology  
The analysis of the genetic basis of hepatocellular carcinoma (HCC) as a major cause of primary 
liver cancers revealed an amplification of region 21 on the long arm of chromosome 1 (ch1q21) 
in over 50 % of patients (Marchio et al., 1997, Wong et al., 1999, Qin et al., 1999, Guan et al., 
2000). Further investigation of this region (ch1q21) led to an identification of ALC1 loci 
(amplified in liver cancer 1) as a potential oncogene, which when overexpressed in nude mice 
indeed led to increased tumorigenicity and metastasis (Ma et al., 2008). Sequence analysis of 
ALC1 showed that the protein contains N-terminaly placed SNF2 domain (ATPase domain) and 
interestingly a macrodomain fold placed on C-terminus (see also 2.3.2). Due to 45 % sequence 
identity between SNF2 domains between ALC1 and CHD1 (chromodomain-helicase DNA 
binding protein 1) chromatin remodeler, ALC1 was named as well chromodomain-helicase DNA 
binding protein 1-like (CHD1L). 
2.4.1 ALC1 is PAR dependent  
The C-terminal macrodomain of ALC1 binds PAR in vitro. Importantly PAR binding by the 
macrodomain is indispensable for ATPase activity of ALC1, but not sufficient. In addition, it 
appears that ALC1 needs to be modified by PAR in order to stimulate ATPase domain activity. 
Thus, ALC1 with two functional domains, in presence of PARP1, NAD+ and DNA is able to 
hydrolyse ATP and remodel a mono nucleosome in vitro (Figure 2.21 A and B; Gottschalk et al., 
2009). Upon ALC1 mediated sliding of a mono-nucleosome, the accessibility of HhaI cutting 
site increases, otherwise protected by the nucleosome. At the same time, normally unprotected 
XhoI site becomes protected by a nucleosome. In presence of PARP1 inhibitor, ALC1 loses its 
nucleosome remodeling functions (Figure 2.21 C; Gottschalk et al., 2009). 
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Figure 2.21 ALC1 has PARP1 and NAD+ dependent nucleosome remodeling and binding 
activities (from Gottschalk et al., 2009). A) Scheme of a positioned nucleosome (nuc) and length 
of HhaI and XhoI cleavage products. B) ATPase assays were performed  with the indicated 
combinations of recombinant F-Alc1, Parp1, NAD+, and oligonucleosomes. C) DNA or 
reconstituted nucleosomes were monitored for restriction enzyme accessibility after incubation 
with ATP (lanes 3, 5, 7–13) or ATPS (lane 4) and wild-type or mutant Alc1, Parp1, NAD, or 2 
mM benzamide. 
 
Similarly like in vitro, the functional macrodomain is essential for ALC1's interactions with 
PARP1 in vivo. ALC1 deficient in PAR binding (D723A) is not enriched over the laser induced 
DNA damage sites, known to undergo increase of PARP1 and PAR levels (see also 2.2.4). The 
recruitment of ALC1 to the damage sites is exclusively dependent on active PARP1. Upon 
siRNA mediated depletion of PARP1 the recruitment of ALC1 is lost (Figure 2.22; Gottschalk et 
al., 2009). 
B	  A	  
C	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Figure 2.22 ALC1's recruitment after microirradiation depends on its macrodomain and on 
PARP1 activity (from Gottschalk et al., 2009). A) Recruitment of EYFP-ALC1 and PARP1-
mCherry to the site of microirradiation (between arrows). B) Loss of ALC1's macrodomain 
abrogates PARylation-induced recruitment of ALC1 to chromatin. C) Kinetics of recruitment (n 
= 6) to microirradiated sites of wild-type (black) and D723A macrodomain mutant (blue) ALC1, 
or recruitment of wild-type ALC1 after PARP1 knockdown (red). 
 
A more detailed investigation of ALC1's dependence on active PARP1, revealed that both 
proteins cooperatively bind to DNA or nucleosomes in vitro. In result, formed PARP1-ALC1-
DNA/nucleosome complex is stable and prevents release of PARP1 from the complex, despite 
addition of DNA substrate normally readily bound by PARP1 (Figure 2.23). The PARP1-ALC1-
nuclesome complex in vitro protects PAR degradation by PARG (Figure 2.24; Gottschalk et al., 
2012).   
A	  
B	  
C	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Figure 2.23 Cooperative binding of PARP1 and ALC1 to nucleosomes (from Gottschalk et 
al., 2012). Biotinylated DNA or mononucleosomes reconstituted with HeLa cell histones were 
immobilized on streptavidin beads and incubated for 5 minutes with PARP1 and NAD+, with or 
without ALC1 and ATP. After addition of competitor DNA, reactions were incubated for the 
indicated times (3, 10 or 30 minutes). PARP1 and ALC1 in bound and unbound fractions were 
detected via western blotting. 
 
Figure 2.24 The ALC1 macrodomain protects PAR chains from PARG digestion (from 
Gottschalk et al., 2012). Reactions performed contained PARP1 and wild type or mutant ALC1, 
without or with 5 ng PARG. Marker lanes (M) show the total reaction products synthesized in a 
reaction containing nucleosomes and PARP1. Free ATP runs at the position indicated by the 
asterisk 
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2.4.2 Nuclear functions of ALC1 and their physiological consequences   
In addition to hepatocellular carcinoma (HCC), the analysis of ALC1 overexpression in 
colorectal carcinoma, ovarian and bladder cancers suggested that ALC1 can serve as biomarker 
of tumor progression and survival prognosis in patients (He at al., 2012, Ji et al., 2013, Tian et 
al., 2013, Hyeon et al., 2013). The disease free survival (DFS) time of patients overexpressing 
ALC1 was around 6 months shorter, when compared to patients with negative ALC1 levels 
(Figure 2.25). Over 30 mutations within cDNA of ALC1, spanning both the domains and the 
linker region, were reported in the catalogue of somatic mutations in cancer (COSMIC). The 
precise function for the majority of these mutations in tumor development was not evaluated yet.  
 
 
Figure 2.25 Kaplan-Meier disease free survival (DFS) curve of HCC patients in correlation 
with CHD1L (ALC1) expression (from Chen et al., 2010). The median disease free survival 
(DFS) time in the CHD1L-negative (ALC1 negative) HCC patients was 11.8 months (95 % 
confidence interval, 4.4–19.2 months; n = 24, blue line), whereas the median DFS in CHD1L-
positive (ALC1 positive) patients was only 6 months (95 % confidence interval, 3.1–8.9 months, 
n = 29, red line). 
 
ALC1 has six mRNA isoforms, from which 5 encode a protein. The overexpression of human 
ALC1 in mice, in addition to endogenous Alc1, leads to development of spontaneous tumors 
(including HCC) in the offspring of these transgenic mice (n=10/41, 24.4 %). Tumor formation 
was not observed in wild-type littermates (n=39; Chen at el., 2010).  Functional studies showed 
that overexpression of ALC1 in transgenic mice fosters cell proliferation, acceleration of G1/S 
phase transition and inhibition of apoptosis, which was linked to RNA up-regulation of cyclins 
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(A, D1 and E), cyclin-dependent kinases 2 and 4 (CDK2 and 4) and down-regulation of 
retinoblastoma protein (Rb),	   cyclin-dependent kinase inhibitor 1B (p27Kip1) and tumor 
suppressor p53 (Chen et al., 2009). Similarly to PARP1, ALC1 was linked to functions in DNA 
repair and transcription, however with little molecular mechanistic details. So far, it is known 
that ALC1 overexpression leads to elevated levels of H2A.X phosphorylation (a marker of DNA 
damage) 1 hour post DNA damage induction with phleomycin (Figure 2.26). The same effect 
was, however not observed when DNA damage was induced with hydrogen peroxide or gamma 
radiation. 
 
Figure 2.26 Phosphorylated H2A.X levels assessed by fluorescence-activated cell sorting 
analysis in cell lines of the indicated genotype, 1 hour after 300 mM phleomycin treatment (from 
Ahel et al., 2009).  
 
Overexpression of ALC1 was linked to transcriptional control of two genes namely: Rho guanine 
nucleotide exchange factor 9 (ARHGEF9) and testican-1 (SPOCK1; Figure 2.27 A and B). 
ALC1 was found	  via ChIP-PCR to reside upstream of TSS of these genes. For ARHGEF9 no 
specific localization of ALC1 was reported, whereas ALC1 at SPOCK1 was found between -
0.2kb to (-) 1.5kb in comparison to TSS. Importantly, both of the genes are highly expressed in 
HCC and promote tumorigenicity (Chen et al., 2010, Li et al., 2013).	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Figure 2.28 ALC1 regulates transcription of two genes linked to tumorigenicity (from Chen 
et al., 2010 and Li et al., 2013). mRNA levels of A) SPOCK1 and B) ARHGEF9 increase and 
decrease upon ALC1 overexpression or knock-down, respectively. 
In addition to ALC1 roles in tumor formation, ALC1`s missense mutations in vicinity to the 
macrodomain, were linked to congenital anomalies of the kidneys and urinary tract (CAKUT). 
CAKUT comprise ~15 % of all congenital anomalies detected prenatally and found in more than 
250 syndromes and in more than one-third of chromosome aberrations. Thus functions of ALC1 
for cellular homeostasis are of great importance (Brockschmidt et al., 2012). 
2.4.3 Open questions 
Chromatin structure affects all processes requiring DNA template. Among many chromatin state 
modifiers, so called chromatin remodelers play a primary role in: movement, eviction and 
reorganization of nucleosomes, which directly regulate accessibility of DNA regulatory elements 
(Clapier and Cairns, 2009). Thus, a specificity and control of DNA use can be achieved through 
an activation or inhibition of a particular chromatin remodeler. ALC1, specifically regulated by 
PAR modification was linked to DNA repair and transcription. The molecular details of ALC1 
functionality are however missing. Reported so far, a critical to cancer genesis, deregulation of 
transcription by ALC1 lacks convincing basis. The effect of ALC1 overexpression as a 
chromatin remodeler linked to transcription regulation of two genes (ARHGEF9 and SPOCK1) 
may be simply a secondary effect of a global chromatin structure alteration. No negative controls 
were reported neither. Moreover, especially interesting would be to determine the PARP1 
importance in ALC1`s recruitment to DNA transcription sites. Moreover, a precise identification 
of ALC1 enrichment sites genome wide (promoters, gene body, enhancers and etc.) would help 
to further evaluate an importance of ALC1 role on regulation of histone variant incorporation or 
eviction and nucleosome position.   
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In addition, the findings that PARP1`s association with chromatin is regulated in vitro via ALC1 
is intriguing (Figure 2.23). PARP1`s association with chromatin is crucial to its activity, thus 
time of   Taking into account that PARP1 can be removed from chromatin via caspase 7 cleavage 
(Erener et al., 2012) or ubiquitin mediated degradation (Liu et al., 2013) it is possible that PAR 
readers like ALC1 actively regulate PARP1`s binding to chromatin as well. Therefore it is of 
high interest, if a stable complex (PARP1-ALC1-nucleosome) forms in vivo as well, and what 
consequences the PARP1-ALC1-nucleosome complex bears on regulation of PARP1 association 
with a DNA break, PAR levels and eventually DNA repair mechanism regulation.  
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2.5 Aims of this Ph.D. thesis 
After a few decades of research concerning poly-ADP-ribose (PAR) and poly-ADP-ribose 
polymerase 1 (PARP1), the exact mechanisms that govern PARP1 genome integrity and 
transcription functions are far from being completely understood. Despite these limitations, the 
significance of PARP1 regulatory functions in human physiology regulation is already 
recognized. For example, chemical compounds that inhibit PARP1 activity are currently 
evaluated in clinical trials as inducers of synthetic lethality of BRCA1/2-deficient tumor cells. 
However, precautions must be taken. PARP1 impacts human physiology homeostasis and is 
considered e.g. a tumor suppressor (for details see 2.1.3). Thus inhibition of PARP1 activity may 
lead to undesirable and currently unknown off-target effects.  
Therefore, a detailed understanding of the PARP1 functional roles in regulation of chromatin-
associated processes like DNA repair, replication and transcription must be carefully obtained. 
Among many chromatin state modifiers, ATP-dependent chromatin remodelers play a crucial 
role in movement, eviction and reorganization of nucleosomes, which directly regulate 
accessibility of DNA regulatory elements. Thus, specificity and control of access to distinct 
DNA loci can be achieved through the activation or inhibition of a particular chromatin 
remodeler, like the PAR-regulated remodeller amplified in liver cancer ALC1. 
The first goal of this Ph.D. thesis answers a long-standing call to advance the PARP1 field. I 
aimed to gain insights into the PARP1 molecular mechanism of activation, which is a 
cornerstone to all chromatin-based PARP1 functions. I aimed to identify the in vivo mechanism 
of PARP1's recognition and binding to DNA lesions and promoters, including the specific roles 
of the DNA Binding Domain in this process. For detailed aims, please see 4.1 section (pages 69-
70). 
The second goal of this Ph.D. thesis was to get detailed mechanistic insights into the roles of the 
PAR-dependent ATP-utilizing remodeller ALC1 in the regulation of transcription. For detailed 
aims, please see 5.1 section (pages 99-100).   
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3 Materials and methods   
3.1 General materials 
Table 3.1 provides an overview of general materials used in this study.  
Table 3.1 Materials used in the study. 
Name  Manufacturer  
Acetone  Fisher Scientific  
Acrylamide Bio-Rad 
Agarose Denville Agarose HS 
Ammonium chloride (H4ClN) Fluka  
Amonium sulfate (NH4)2SO4 Fluka  
Ampicilin  Sigma 
β-mercapto-ethanol Fluka  
Bromophenol blue  Sigma  
Bovine Serum Albumine (BSA)  Sigma  
Chloramphenicol  Sigma 
Coverslips  Thermo Scientific 
Cryo Tubes TM Vials  Nunc  
Dithiothreitol (DTT) Biomol 
dNTPs PCR Nucleotide Mix Roche  
Ethylendiamine tetra acetate (EDTA) Sigma  
Ethanol (EtOH; molecular grade) Pharmaco-AAPER, Sigma 
Ethidium Bromide (EtBr) Bio-Rad 
Salmon sperm DNA Sigma 
Formaldehyde (35 %) Merck  
Glycerol Fisher Scientific  
Glycine  Sigma  
HEPES Sigma  
Isopropanol Sigma (molecular grade) 
Kanamycin Sigma 
Methanol (MeOH) Pharmco-AAPER 
Milk powder  Frema Reform 
Multiwell dishes: 6-well, 12well and 24-well Nunc 
Nonident P-40 (NP40) Fluka 
Object slides 76 x 26 mm Thermo Scientific 
Petri dishes (different sizes) Nunc  
Poly-L-lysine Sigma 
Ponceau S AppliChem 
Sodiumdodecylsulfate (SDS) Sigma 
Sodium chloride (NaCl) Sigma 
Sodium hydrogen carbonate NaHCO3 Merck  
Tetramethylethylenediamine (TEMED) Sigma  
TRIS Base Sigma 
Triton X-100 Fisher Scientific  
Trypsin EDTA Sigma 
Tween20  Sigma  
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Table 3.2 The cell lines used in this work and cell culture media requirements. 
No.  Cell line  Media composition  
1 HeLa-Kyoto wild type (cervical carcinoma) DMEM (Life Technologies,  no. 
11880-028), 10 % FBS  
2 HeLa-Kyoto-PARP1 knock-down (cervical carcinoma) 
(previously generated in Ladurner laboratory; Ali et al., 
2012) 
DMEM (Life Technologies, no. 11880-
028), 10 % FBS, puromycin (1:200, 
Gibco) 
3 *Michigan Cancer Foundation-7 cells (MCF-7) 
(adenocarcinoma) 
 
DMEM (Life Technologies, no. 11880-
028 or  no. 21063-029),10 % FBS 
4 *MCF-7-human-ERα-GFP  
(provided by Dr. Huet from Univ. of Rennes, Reid et al., 
2003) 
DMEM (Life Technologies, no. 11880-
028 or  no. 21063-029), 10 % FBS, 
hygromycin (1:200, Gibco) 
5 *M.D. Anderson - metastatic breast cancer cells  
MDA-MB231-human-ERα  
(provided by Dr. Reid from IMB Mainz, Reid et al., 
2003) 
DMEM (Life Technologies, no. 11880-
028 or  no. 21063-029), 10 % FBS  
 
6 *MDA-MB231-human-ERα-GFP 
(provided by Dr. Reid from IMB Mainz, Reid et al., 
2003) 
DMEM (Life Technologies, no. 11880-
028 and no. 21063-029), 10 % FBS  
7 *T47D (ductal carcinoma)  
(provided by Dr. Reid from IMB Mainz) 
RPMI (Life Technologies, no. 11835-
063 or no. 116967), 10 % FBS  
8 U2OS-wild type (osteosarcoma)  DMEM (Life Technologies, no. 11880-
028),10 % FBS 
9 U2OS-ALC1-YFP (osteosarcoma) 
(previously generated in Ladurner laboratory) 
DMEM (Life Technologies, no. 11880-
028), 10 % FBS, hygromycin (1:200, 
Gibco) 
10 U2OS-HP1alpha-YFP (osteosarcoma) 
(provided by Dr. Ellenberg from EMBL) 
DMEM (Life Technologies, no. 11880-
028), 10 % FBS, Geneticin (G418; 
1:100, Gibco) 
*Prior to hormone treatment the cells were washed once with PBS (RT) and kept for 48 hours in regular media 
where standard fetal bovine serum (Invitrogen, heat inactivated) was replaced with charcoal stripped FBS (Life 
Technologies, no. 12676029), DMEM or RPMI lacked phenol red. 
54	  
	  
3.2 Cell Culture and Cell Lines  
The cell lines used in this work and particular cell line media requirements are listed in Table 
3.2. The cells were grown in 37°C with 5 % CO2 level. All the media were supplemented with 
50 U/ml penicillin and 50 mg/ml streptomycin (Sigma). Prior to hormone treatment the cells 
were washed once with PBS and kept for 48 hours in regular media where standard fetal bovine 
serum (FBS, Invitrogen, heat inactivated) was replaced with charcoal stripped FBS (Life 
Technologies, no. 12676029) and  Dulbecco's Modified Eagle Medium (DMEM) or	   Roswell 
Park Memorial Institute (RPMI) 1640 with no phenol red. The hormone treatment was one of the 
following: (i) 10 nM or 100 nM estradiol (Sigma, no. 8750), (ii) 10 nM or 100 nM progesterone 
(promegestone, R5020, Perkin Elmer no. NLP004005), (iii) 10 µM all trans retinoic acid (Sigma, 
no. R2625). Depending on the assay the cells were treated with the hormone for 20 minutes, 30 
minutes or 3 hours. When indicated the cells were treated with PARP1 chemical inhibitor (one of 
the following): 1 µM, 5 µM and 15 µM AG14361 (Selleckchem, no. S2178), or 1 µM and 5 µM 
olaparib (Selleckchem, no. S1060). The inhibitors were added 40 minutes before the hormone 
stimulation, and kept within media upon treatment with hormones. The experiments were 
conducted on cells with low passage number. For long term storage the cells were first 
suspended in freezing media (FBS with 10 % DMSO), transferred to Cryo-Tubes and stored in 
liquid nitrogen. 
3.3 Chromatin immuno-precipitation (ChIP)   
The following is the modified ChIP protocol originally from Krishnakumar et al., 2008. The cells 
(MCF-7 wild type, U2OS wild type, U2OS-ALC1-YFP) were always collected from 90 % 
confluent 10 cm dish plate. The cells were rinsed once with room temperature (RT) PBS (Sigma, 
no. 8537). Next, the crosslinking fixative was added (1 % formaldehyde in PBS, RT) and kept 
for 10 minutes. The cells were treated with 2.5 M glycine for 5 minutes (4°C). All the buffers 
and PBS contained protease inhibitors (Complete EDTA-free Protease Inhibitor Cocktail Roche, 
no. 11873580001). After quenching with glycine the cells were rinsed three times with ice cold 
PBS and collected with the cell scraper. The cells were centrifuged for 5 minutes at 3000 rpm 
(4°C). The excess of PBS was removed and the cell pellet was snap frozen in liquid nitrogen and 
stored at -80°C before use (no longer than 2 months). When further processed, the cells were 
suspended in the lysis buffer (1 % SDS, 10 mM EDTA, 50 mM Tris-HCl pH 7.9) and incubated 
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on ice for 10 minutes. Next, the DNA was sheared to desirable size (200 base pairs or 500 base 
pairs) with use of Covaris S220 (sonication in 1ml tube with and without the fiber and the 
Covaris settings: Peak Incident Power 105 Watt, Duty Factor  25 %, Cycle Burst  200 counts, 
time 10 minutes or 18 minutes). The sheared DNA was span for 10 minutes at 14000 rpm at 
10°C. The supernatant was kept and diluted 10 times in the dilution buffer (0.5 % Triton-X100, 2 
mM EDTA, 150 mM NaCl, 20 mM Tris-HCl pH 7.9). Next, protein sepharose A or G from GE 
Healthcare (50 % slurry in 10 mM Tris-HCl pH 8.1 and 1 mM EDTA) was added to the 
supernatant for 2 hours at 4°C (with constant rotation). Next the beads (sepharose) were removed 
following the 1 minute spin at 3000 rpm at 4°C. The supernatant was incubated with specific 
antibodies over-night (o/N), including the constant rotation at 4°C (see 3.4 for details regarding 
the used antibodies). Next, protein A or G sepharose was added and incubated for no longer than 
2.5 hours at 4°C. The agarose beads were washed four times for 3 minutes each wash in wash 
buffer (0.25 % NP-40, 0.05 % SDS, 2 mM EDTA, 20 mM Tris pH 7.9, 250 mM NaCl). The 
beads were rinsed only briefly in Tris-EDTA buffer. Finally, the protein-DNA complexes were 
eluted with elution buffer (50 mM, Tris pH 8.0, 1 mM EDTA and 1 % SDS). To reverse 
crosslinking the samples were kept at 65°C O/N followed by addition of proteinase K for 1 hour 
at 55°C. Digestion of RNA (RnaseA 10 mg/ml at 37°C for 30 minutes) was followed by DNA 
purification with MiniElute columns (Qiagen). The presence of specific DNA was evaluated via 
quantitative PCR (see 3.11 section for details). Data was analyzed as usual by taking the cycle 
threshold (Ct) values. The signal for all samples was adjusted relative to the total input fraction. 
The following primers were used for the target genes. Primers were designed with Primer3Plus 
software and analyzed with BLAST (Basic Local Alignment Search Tool) not to match other 
sequence than the targeted gene.    
ABHD2_upstream_0.5kb_forward AGGCCCTAGTTCCAAGGCTA 
ABHD2_upstream_0.5kb_reverse ACCCGAAGGAGAGGAAAAGA 
ABHD2_upstream_1kb_forward AGCCCACTGTTCCTTGTCAC 
ABHD2_upstream_1kb_reverese GAGCCTGAAACTGCTTTTGC 
ABHD2_downstream_0.5kb_forward GCTCACTCCTGGGTCTTCAG 
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ABHD2_downstream_0.5kb_reverse CCGAACTCGGTAAATGTGCT 
ABHD2_TSS_forward GCCTCCACTCTGAGGAACAG 
ABHD2_TSS_reverse TTGTTCATTGGGCAGTTCAG 
GDF15_upstream_0.65kb_forward AGGGGCTTTTTGCGTAGAGT 
GDF15_upstream_0.65kb_reverse AAGGGCAACCTTGATGTGTC 
GDF15_downstream_0.5kb_forward AATATCCTGGATCCCCTTGG 
GDF15_downstream_0.5kb_reverse CACACCCCCATTGTTTCTCT 
GDF15_TSS_forward CTCAGATGCTCCTGGTGTTG 
GDF15_TSS_reverse CTCGGAATCTGGAGTCTTCG 
ITPR1_upstream_0.5kb_forward CAGAGGCTGCTCCTAAATGG 
ITPR1_upstream_0.5kb_reverse CAGGGCTCAGAGAAATCAGG 
ITPR1_downstream_0.5kb_forward AGGGCGGAGCAGATTAAATA 
ITPR1_downstream_05kb_reverse GGCTAGGAGCTCGGATTTCT 
ITPR1_TSS_forward GAGCCCTAAGCAGCGTGTAG 
ITPR1_TSS_reverse CTCTCCAAGAGCTCCGAATG 
RAPGEF4_upstream_forward CCTAAGCCAGTTGACCCAGA (negative control) 
RAPGEF4_upstream_reverse AAATGAAGCCGCTAGGAACA (negative control) 
RAPGEF4_TSS_forward GTAACTCCCGACGACAGCTC (negative control) 
RAPGEF4_TSS_reverse CTGTCACAGCCTGGAAACAA (negative control)  
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3.4 Immuno-precipitation (IP)  
The cells were washed once with PBS (RT) and: (i) not crosslinked (ii) crosslinked, or (iii) 
crosslinked and Covaris sonicated. All the steps were conducted the same as described in the 
ChIP section (see 3.3 for details).  Instead of DNA, the proteins were eluted via treatment of the 
beads with SDS-loading buffer for 10 minutes at 95°C. The IP efficiency was evaluated via 
Western Blot. The following antibodies were used anti-GFP (Ladurner laboratory, own stock), 
serum-ALC1 (serum from rabbits immunized with ALC1 peptide as an antigen, for details see 
3.7). The most suitable concentration of the antibodies (in each case) was determined via titration 
experiment.  
3.5 Determination of protein concentration 
Protein concentration was determined using the Bradford assay. The protein sample (1–10 µl) 
was added to 1 ml of 5-fold diluted Protein Assay reagent (Bio-Rad) and incubated for 10 
minutes at RT. The absorbance of the samples was measured at 595 nm in 1 cm path – length 
cuvette. The concentration of the protein sample was determined based on the standard curve 
prepared with a solution of known protein concentrations (Bio-Rad).  
3.6 Protein separation and Western Blot  
Proteins were separated according to their size via standard sodium dodecyl sulfate	  
polyacrylamide gel electrophoresis (SDS-PAGE) system. Prior to loading on the gel, the protein 
samples were mixed with SDS loading buffer and incubated at 95°C for 5 minutes. After the 
separation on the gel the proteins were transferred to nitrocellulose (Protran Whatman) or 
polyvinylidene fluoride (PVDF) membrane (Millipore) in transfer buffer at 60 V for 60 minutes 
at 4°C. After 1 hour blocking in 5 % milk in PBST (PBS buffer, 0.05 % Tween 20) at RT 
proteins were incubated with protein specific primary antibody in PBST O/N at 4°C. Next, the 
excess of the primary antibody was washed away via three washes with PBST at RT for 10 
minutes (each wash). The horseradish peroxidase (HRP) coupled secondary antibody was kept in 
PBST for 1 hour at RT, followed by 3 washes in PBST at RT for 10 minutes. The secondary 
antibodies were used in 1:10000 ratio: anti-rabbit-HRP (Bio-­‐Rad, no. 172-­‐1019) and anti-mouse-
HRP (Bio-Rad, no. 170-­‐6516). The membrane was developed with Immobilon Western 
Chemiluminescent HRP Substrate (Millipore, WBKLS0050) and Fuji medical X-­‐ray films 
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(Super RX). When necessary the membranes where stripped from antibodies in order to reuse the 
membrane. The membranes were incubated in Western blot stripping buffer for 15 minutes at 
RT. Subsequently the buffer solution was discarded and the membrane was washed for 1 hour 
with PBST and again blocked with 5 % milk in PBST as before. Typically the membranes were 
stripped and reused to evaluate the protein loading with antibody against α-Tubulin (1:10.000, 1 
hour at RT). The incubation with the primary antibody and the steps afterwards were conducted, 
as just described. 
SDS protein sample loading buffer 
125 mM Tris-HCl pH 6.8 
10 % β-mercaptoethanol 
4 % SDS 
20 % glycerol 
0.004 % Bromophenol Blue 
 
Stacking gel 
5 % weight per volume (w/v) acrylamide 
0.1 % (w/v) bis-acrylamide 
60 mM TRIS-HCl pH 6.8 
0.1 % (w/v) SDS 
0.05 % (w/v) APS 
0.05 % (v/v) TEMED 
 
Separating gel 
8–16 % (w/v) acrylamide 
0.16–0.33 % (w/v) bis-acrylamide 
375 mM TRIS-HCl pH 8.8 
0.1 % (w/v) SDS 
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0.05 % (w/v) APS 
0.05 % (v/v) TEMED 
 
Laemmli running buffer 
63 mM Tris HCl 
10 % glycerol 
2 % SDS 
0.0025 % Bromophenol Blue pH 6.8 
 
Western Blot transfer buffer 
3.1 g/l Tris base 
14.4 g/l glycine 
10 % MeOH 
 
Western blot stripping buffer  
SDS 10%  
Tris HCl pH 6.8 (0.5 Molar)  
0.8 % ß-mercaptoethanol  
 
3.7 Generation of antibodies 
The peptides corresponding to PARP1 individual zinc fingers (ZF1 and ZF2), and ALC1 
individual domains (ATPase and macrodomain) were recombinantly expressed and purified via 
affinity chromatography by Dr. Markus Hassler (Ladurner laboratory). The individual zinc 
fingers corresponding to 1-111 amino acids (ZF1) and 112-214 amino acids (ZF2) of PARP1 
were mixed in a 1:1 ratio with an adjuvant. The Titer Max Gold was used for the first injection 
and Freund`s Adjuvant Incomplete for the following injections.	  Before the start of immunization, 
the blood was collected (pre-immune serum) and tested for reactivity against the recombinant 
antigen. Two rabbits were injected with 100 µg of the antigen (50 µg of each zinc finger were 
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mixed) per each injection. In total, five immunizations every 6 weeks followed. Starting from the 
second immunization, ten days after the injection 20 ml of blood was collected. The collected 
blood was kept for 2 hours at RT. Next, the blood was centrifuged for 10 minutes at 4000 rpm at 
RT. The supernatant was transferred to a new tube and centrifuged again for 15 minutes at 15000 
rpms at 4°C. Collected supernatant was heat inactivated for 30 minutes at 56°C. The collected 
serum was stored at -20°C. The generated antibodies were evaluated via the Western blot. The 
antibody against PARP1 was generated at LMU Adolf-Butenandt-Institute Animal Facility. 
The ALC1 antibodies corresponding to ATPase domain (31-556 amino acids) and macrodomain 
(615-878 amino acids) were generated at Eurogentec (Belgium) according to the company`s 
protocol. Blood from four rabbit bleeds was provided, including pre-immune serum. The 
specificity of generated antibody was tested via the Western blot and immuneprecipitation.    
3.8 Small interfering RNA (siRNA) mediated gene knock-down   
Prior to the transfection, the cells were seeded in 6 well plates (105 cells/well) in the standard 
media. The following day the cells were washed once with PBS and treated with respective 
siRNA mixed with oligofectamine (Life Technologies, no. 12252-011) according to the 
manufactures guidelines. Prior to addition to the cells, the Opti-MEM, siRNA and 
oligofectamine mixture was incubated for 20 minutes at RT.  The cells were kept for 12 hours in 
the solution containing siRNA (ALC1, Dharmacon, no. M014368-01 or PARP1 from Ambion 
no. 4390824 and Dharmacon, no. L006656-03), Opti-MEM (Life Technologies, no. 31985-070) 
and standard DMEM or RPMI media deprived of serum. Next, the cells were washed once with 
PBS and kept for 48 hours in the standard media, including serum till the follow up experiments 
were conducted and total RNA was extracted. The siRNA from Dharmacon are composed of 
highly specific four siRNA targeting various exons of the targeted gene.  
3.9 Total RNA extraction  
Before the total RNA extraction the cells were washed once with PBS. Total RNA was extracted 
as follows, 0.5 ml of Trizol (Life Technologies, no. T9424) was added per 90 % cell confluent 
10 cm dish. Cells were collected with the cell scraper and homogenized via pipetting. The 
samples were centrifuged for 10 minutes at 14000 rpm at 4°C. Supernatant was collected and left 
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for 5 minutes at RT, before mixing it with 0.1 ml chloroform (Sigma, the molecular grade) and 
roughly vortex mixed (15 seconds). Next, the samples were left for 15 minute incubation in RT, 
followed by spinning for 15 minutes at 12000 rpm at 4°C. The upper layer was collected and 
mixed with 0.25 ml of isopropanol (Sigma, the molecular grade) and let it stand for 10 minutes at 
RT. Next, the samples were centrifuged for 10 minutes at 12000 rpm at 4°C. The resulted pellet 
was washed with 0.5 ml of 75 % EtOH via short vortexing and centrifugation for 5 minutes at 
7500 rpm at 4°C. Pellet was air dried for 5-10 minutes and dissolved in nuclease free water. The 
extracted RNA concentration and purity were tested with NanoDrop 1000 Spectrophotometer. In 
case the RNA purity was low, based on the ratio of absorbance at 260:280 nm (ca. 2.0) and 
260:230 nm (ca. 2.0-2.2), the RNA was further purified with use of RNeasy Mini Kit (Qiagen, 
no. 74104). The extracted RNA was stored at -80°C till further use (no longer than 1 month). 
3.10 Synthesis of complementary DNA  
The extracted total RNA was thawed on ice and the RNA concentration was again tested using 
the NanoDrop 1000 Spectrophotometer. Total RNA (500 ng) was used for cDNA synthesis with 
SuperScript II Reverse Transcriptase kit (Invitrogen, no. 18064-014) according to the standard 
protocol with use of random primers	  (Invitrogen, no. 48190-011).  
3.11 Quantitative PCR (qPCR) 
qPCR was conducted on the Applied Biosystems 7500 Fast Real-Time PCR system using fast 
SYBR green master mix (Applied Biosystems). In order to quantify mRNA levels of tested 
genes the detected Ct values were normalized to Ct values of the control gene GAPDH. The 
sequences (5` > 3`) of the primers for the tested genes are below. Primers specificity was 
analyzed with BLAST not to match other sequence than the targeted gene. The sequences of 
primers come from Hah et al., 2011 for estrogen receptor alpha (ERα) regulated genes, from Le 
May et al., 2012 for retinoic acid receptor (RAR) regulated genes and Wright et al., 2012 for 
progesterone receptor (PR) regulated genes.       
CASP7_forward CTGGGTGGGTACTTCCTTCA 
CASP7_reverse TGTGGTCTCCTAGACGTTGC 
C-FOS_forward CCGGGGATAGCCTCTCTTAC 
C-FOS_reverse GTGGGAATGAAGTTGGCACT 
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DUSP1_forward CAGCTGCTGCAGTTTGAGTC 
DUSP1_reverse AGAGGTCGTAATGGGGCTCT 
EGFR_forward GGCAGGTCTTGACGCAGTGG 
EGFR_reverse TGTTTGGGACCTCCGGTCAG 
FAM117B_forward ATTCTACCCAGGCCTCCAGT 
FAM117B_reverse CAGAGGAGATTGGCATGTGA 
GAPDH_forward AGCTCACTGGCATGGCCTTC 
GAPDH_reverse ACGCCTGCTTCACCACCTTC 
GDF15_forward CTACAATCCCATGGTGCTCA 
GDF15_reverse TATGCAGTGGCAGTCTTTGG 
GFRA1_forward GCCATATTTGGCTGTGGTCT 
GFRA1_reverse CGGAGGACAATCAGCTCTTC 
GREB1_forward GACCTGCCAAATGGAAGAAG 
GREB1_reverse AAAGCCATGTCCTTCCACAC 
ITPR1_forward TGCCTCCACAATTCTACG 
ITPR1_reverse TGAATGTCCCACAGTTGC 
PDK4_forward ACCCAAGCCAGATTGGAAGCA 
PDK4_reverse AACTGTTGCCCGCATTGCATT  
SMAD3_forward TTGTCCAGTCCCAACTGTAAC  
SMAD3_reverse GTCAACTGGTAGACAGCCTCAAA 
TFF1_forward GGAGCAGAGAGGAGGCAAT 
TFF1_reverse GGCGCAGATCACCTTGTT 
TGM2_forward CGAGCCCTGGTAGATAAA 
TGM2_reverse TAAGAGATGCTGTGGAGGAG 
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3.12 Generation of PARP1 and ALC1 fluorescently tagged constructs and 
mutagenesis   
Zinc finger 1 (residues 1–111), Zinc finger 2 (residues 112–214), DNA binding domain (DBD, 
1-214 amino acids), full length Δ zinc finger 1 (112-1014), full length Δ zinc finger 2 (Δ112-
214), full length Δ catalytic domain (Δ660-1014) and full length (FL, 1-1014 amino acids) 
PARP1 constructs and PARP2 were PCR amplified from cDNA and introduced into pmEGFP-
N1 plasmid (Clontech) via NheI and SmaI restriction sites (the restriction enzymes from New 
England Biolabs). Single residue mutants of PARP1 DBD and FL were generated using 
QuikChange site-directed mutagenesis (Stratagene). For expression of PARP1-mCherry, PARP1 
was PCR amplified from cDNA and introduced into pmCherry-N1 plasmid (Clontech) via NheI 
and SmaI sites. For expression of EYFP-ALC1 and mCherry-ALC1, ALC1 was PCR amplified 
from cDNA and introduced into pEYFP-C1 and mCherry-C1 (Clontech) via BglII and EcoRI 
restriction sites (the restriction enzymes from New England Biolabs) respectively. All constructs 
were sequence verified via use of primer sequences spanning the both sides of the insert (GATC 
Biotech Sequencing service). Constructs expressing monomeric (1x) and triple (3x) EGFP were 
kindly provided from Dr. Ellenberg`s laboratory (Bancaud et al., 2009). Plasmids were amplified 
in Escherichia coli (DH5α) and purified with Plasmid Midi Kit (Qiagen).  
3.13 Plasmid DNA transfection  
A day before a transfection, the cells were seeded in 8-well Lab-Tek chambered coverglass (3 x 
104 cells/well) from Nunc (no. 155411). The transfections of plasmids were carried with 
Effectene Transfection Reagent (Qiagen, no. 301425) in case of FCS, FRAP and FLIP 
experiments.  For the remaining experiments (live cell imaging) the transfection reagent XFECT 
(Clontech, no. 631317) was used. Both reagents were used according to the manufactures 
guidelines with usual amount of plasmid DNA no higher than 1 µg per well. Transfected cells 
were analyzed the next day.  
3.14 Fluorescence Correlation Spectroscopy (FCS)  
FCS experiments were performed on Leica TCS SP2 AOBS FCS2 system. The confocal 
microscope was equipped with a diode laser (405 nm wavelength) with maximum output of 50 
mW, an argon laser (488 nm) with maximum output of 50 mW and 63×/1.4–numerical objective 
water-immersion. The typical acquisition time was 60 seconds (3 times for 20 seconds) and the 
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same laser intensities were used for all the conditions and constructs (488 nm laser set to 11 %). 
Data was acquired with Vista 3.6.22 program. The autocorrelation function was calculated with 
Fluctuation Analyzer software (version 1.2, developed by Dr. Malte Wachsmuth at EMBL). The 
autocorrelation function, ACF = G(τ) was fitted to the formula (equation 1) for anomalous 
diffusion allowing detection of one or two components (with use of OriginPro software) 
 
𝐴𝐶𝐹 =
1
N
∗ 1 −   Θ1 +   Θ1 ∗ exp −
x
τT1
−   Θ2 + Θ2 ∗ exp −
x
τT2
∗
f1
1 + xτD1
!!
sqrt 1 +
x
τD1
!!
κ!
+
1 − f1
1 + xτD2
!!
sqrt 1 +
x
τD2
!!
κ!
 
 
(Equation 1) 
Here, N denotes the number of particles, f1 - the percentile of the first component, 𝛕𝐃𝟏 and 𝛕𝐃𝟐 
are diffusion times for the first and the second component respectively, κ (kappa) is the structure 
parameter of the microscopes focal volume (the ratio of the axial and lateral focus radius), α1 and 
α2 are anomaly parameters for the first and the second component respectively. Additional 
parameters for fitting the FCS curve consider the EGFP photophysical dynamics, like triplet 
state, which probability is given by Θ and relaxation time (τT). Each component was considered 
separately, thus τT1 correspond to component one, and τT2 correspond to component two 
(Müller et al., 2009). Typical fits had the coefficient of determination	   (R2) values above 0.95 (0 
means a poor fit, 1 means a very good fit).  
The lateral radius of the confocal volume (ω o) in used experimental setting has been determined 
by FCS measurements of Alexa Fluor 488 C5 maleimide (Invitrogen, Molecular Probes) 
dissolved in water at RT, which diffusion coefficient (D) is well known (Müller et al., 2009). 
Thus the ω o was calculated according to the equation 2.  
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(Equation 2) 
Once ω o was calculated it was possible to calculate the diffusion coefficient (D) for all FCS 
measured PARP1, HP1α and EGFP constructs, according to the equation (3). Time of diffusion 
(τ) was calculated with equation (1). 
 
(Equation 3) 
The accuracy of the equation was consulted with Dr. Malte Wachsmuth (Cell Biology and 
Biophysics, EMBL, Heidelberg). Results shown in the results section combine the measurement 
from at least 10 cells per each condition tested. In addition there were at least three 
measurements taken in each cell to eliminate not representative cells. The measurement spot was 
chosen randomly, however the nucleoli and nuclear periphery were avoided. Only cells with very 
similar levels of GFP signal were chosen for the measurements. During imaging the cells were 
kept in CO2-independent imaging medium (Gibco) supplemented with 10 % (v/v) FBS (Gibco), 
1 mM sodium pyruvate (Sigma) and 2 mM L-glutamine (Sigma), 100 U/ml penicillin and 100 
µg/ml streptomycin (Sigma). 
3.15 Fluorescence Recovery After Photobleaching (FRAP) 
FRAP experiments were performed on a Leica SP2-AOBS confocal microscope or a 
PerkinElmer UltraView Vox spinning-disk microscope. Both systems were equipped with a 
diode laser (405 nm wavelength) with maximum output of 50 mW and an argon laser (488 nm) 
with maximum output of 50 mW or 75 mW, and 63×/1.4–numerical objective water-immersion 
and 63×/1.4–numerical objective oil-immersion objectives for Leica SP2 and PerkinElmer Vox, 
respectively. In all experiments the photobleached region corresponds to a 3 µm wide square. For 
bleaching, the argon laser was set to 100 % transmission (Leica) and 80 % transmission 
(PerkinElmer). Fluorescence recovery quantification was performed with freely available ImageJ 
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(http://fiji.sc/Fiji). Fluorescence of a bleached region was background subtracted and normalized 
to the total intensity, also background subtracted. FRAP was conducted in no–DNA-damage and 
DNA-damage conditions. DNA damage across the whole nucleus was induced with the 405-nm-
wavelength diode laser set to 60–80 % transmission for 0.8 s. Before DNA damage induction, 
cells were sensitized with Hoechst 33285 dye (0.5 mg/ml) for at least 10 minutes. The FRAP 
curves were fitted with use of OriginPro software to the following equation (number 4), 
according to the two dimensional (2D) diffusion model (Im et al., 2014). Diffusion coefficient 
for unbound molecules was determined in no DNA damage conditions.   
𝑦 = 𝑦0 − 𝐴1
∗ erf 2 ∗
a
sqrt 4 ∗ D ∗ x − x0
−
sqrt 4 ∗ D ∗ x − x0
sqrt 4 ∗ 3.1416 ∗ a!
∗ 1 − exp −4 ∗
a!
4 ∗ D ∗ x − x0
!
− A2
∗ exp −koff ∗ x − x0  
(Equation 4) 
Here, A denotes the depth of the photobleached region, y0 denotes percentile of unbound 
molecules, x0 corresponds to the last time point before the photobleach, a corresponds to a size 
of the phtobleached region, D – diffusion coefficient, koff - disassociation rate (release event per 
second). The accuracy of the equation was evaluated by Dr. Malte Wachsmuth (Cell Biology and 
Biophysics, EMBL, Heidelberg). The results presented in the result section combine the 
measurement from at least 10 cells per condition tested. The measurement spot was chosen 
randomly, however nucleoli and nuclear periphery were avoided. Only cells with very similar or 
almost identical levels of GFP signal were chosen for the measurements. During imaging the 
cells were kept in CO2-independent imaging medium (Gibco) supplemented with 10 % (v/v) 
FBS (Gibco), 1 mM sodium pyruvate (Sigma) and 2 mM L-glutamine (Sigma), 100 U/ml 
penicillin and 100 µg/ml streptomycin (Sigma).  
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The average residence time (tres, seconds) in the chromatin bound state was calculated according 
to the equation 5: 
tres = 1/koff   
(Equation 5) 
3.16 Fluorescence Loss in Photobleaching (FLIP) 
FLIP experiments were performed on a Leica SP2-AOBS confocal microscope with 63×/1.4–
numerical objective water-immersion objective. The microscope was equipped with the FLIP 
wizard. After each photo-bleach, a photo was acquired. Each photobleach was followed by one 
imgae frame, till the total fluorescence from the cell was depleted. The bleach spot was fixed 
across all the cells spanning- height (14 µm) and width (1 µm). Images were analysed with 
ImageJ software. Only cells with very similar or almost identical levels of GFP signal were 
chosen for the measurements. During imaging the cells were kept in CO2 - independent imaging 
medium (Gibco) supplemented with 10 % FBS (Gibco), 1 mM sodium pyruvate (Sigma) and 2 
mM L-glutamine (Sigma), 100 U/ml penicillin and 100 µg/ml streptomycin (Sigma). 
3.17 Time lapse microscopy  
Time lapse imaging of cells expressing human-ERα-GFP and cells transfected with PARP1-
mCherry or ALC1-mCherry (upon estrogen treatment) was performed on a Zeiss AxioObserver 
Z1 confocal spinning-disk microscope equipped with an AxioCam HRm CCD camera (Zeiss) 
through a Zeiss Plan/Apo 63×/1.4 oil-immersion objective lens. The images were taken every  30 
– 60 seconds for 1 or 2 hours. Images were analysed using ImageJ. During all of the fluorescence 
microscopy experiments cells were kept at 37°C in a CO2 - independent imaging medium 
(Gibco) supplemented with 10 % FBS (Gibco), 1 mM sodium pyruvate (Sigma) and 2 mM L-
glutamine (Sigma), 100 U/ml penicillin and 100 µg/ml streptomycin (Sigma).	  Only cells with 
very similar or almost identical levels of GFP signal were chosen for the measurements.  
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3.18 Immunofluorescence (IF) 
Cells grown on Lab-Teks (3 x 104 cells/well) were washed once in PBS (RT) and fixed with a 
freezing solution (methanol 70 % and acetone 30 %) for 10minutes in -20°C or 4 % 
formaldehyde for 10 minutes at RT. Formaldehyde fixation was used only in case of PAR 
staining upon progesterone treatment. Subsequently the cells were rinsed 3 times in PBS (4°C in 
case of MeOH, or RT in case of formaldehyde) and kept in blocking solution (5 % milk and 0.05 
% Tween20 in PBS) for 60 minutes at RT and stained with primary antibodies (1:1000) at 4°C 
o/n. The next day, the cells were washed three times in PBS (0.05 % Tween20) for 10minutes 
(each time). Secondary antibody (1:500) was kept for 1 hour at RT and was followed by three 
washes with PBS (0.05 % Tween20) for 10 minutes (each time) and processed. During the 
second wash the PBS contained Hoechst 33342 (final concentration: 0.1 µg/ml) in order to stain 
nuclei. The used antibodies are the following: anti-PAR (H10; Ladurner laboratory stock), Alexa 
Fluor® 488 anti-mouse (Invitrogen, no. A11001), Alexa Fluor® 488 anti-rabbit goat (Invitrogen, 
no. A11008), Alexa Fluor® 568 anti-mouse (Invitrogen, no. A11004). The images were acquired 
with Zeiss AxioObserver Z1 confocal spinning-disk microscope equipped with an AxioCam 
HRm CCD camera (Zeiss). The results were analysed with freely available Cell Profiler software 
http://www.cellprofiler.org/.  
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4 Results and Discussion I 
   The mechanism of PARP1's binding to DNA in vivo 
4.1 PARP1 is primarily activated upon binding to DNA   
There are two models regarding the mechanism of PARP1 activation. According to the widely 
accepted model, PARP1 is activated by DNA breaks (see also 2.2.2-2.2.4). The less established 
model proposes that PARP1 is activated by its posttranslational modifications and by histone 
variants (see also 2.2.4-2.2.5). The first model is aligned with PARP1 functions in DNA repair, 
and the second model was proposed to explain PARP1 functions in transcription. A major 
difference between the models is that PARP1 activation is either coupled to or decoupled from 
DNA binding. The predominant model relies on the fact that PARP1 binds to DNA via its N-
terminal DNA Binding Domain (DBD). Upon DNA binding, PARP1 undergoes an	  
intramolecular conformational rearrangement and subsequently becomes activated. This 
conformational rearrangement is supported by the X-ray structure of the nearly full-length 
PARP1 bound to blunt ended DNA (Langelier et al., 2012). The structural evidence for the 
alternative model is missing. It is not known how exactly the DBD-mediated interactions of 
PARP1 with chromatin differ between the models in space and time in vivo. A proper 
understanding of PARP1's chromatin interactions and activation would provide valuable insight 
into PARP1's functions in DNA repair and transcription. Thus it is crucial to fully understand 
and validate the DNA-coupled and decoupled activation of PARP1.    
The predominant model is based on the critical function of the DBD that triggers PARP1 
activation upon DNA binding. The DBD is composed of two zinc fingers: zinc finger 1 (ZF1) 
and zinc finger 2 (ZF2). The exact roles and importance of these two zinc fingers recognizing  
DNA breaks have been debated for the last 30 years (for details see 2.2.2-2.2.3). Unfortunately, 
the three recent X-ray structures of zinc fingers bound to DNA are mutually exclusive and thus 
inconclusive in solving the debate. These structures disagree in ZF2's importance in DNA break 
recognition and transmission of the bound state to the catalytic domain of PARP1. The X-ray 
structure of the DBD (two zinc fingers together) bound to broken DNA suggests that ZF2 plays 
the major role in DNA break recognition. But the X-ray structures of individual zinc fingers and 
the nearly full-length PARP1 (lacking ZF2 and BRCT domains) indicate that ZF2 is dispensable 
70	  
	  
for DNA binding (Langelier et al., 2011 and 2012). The structures also	   show different DNA 
binding modes. The individual zinc fingers bind DNA via the minor groove (Langelier et al., 
2011), whereas the DBD structure binds DNA via the major groove (for details see 2.2.3). In 
addition, the DBD structure reveals that ZF1 engages in a hydrophobic interface between ZF1 
and ZF2. This interface is possible due to dimerization of PARP1 molecules over the DNA 
break. The X-ray structures of individual zinc fingers and the nearly full-length PARP1 instead 
favor monomerization of PARP1 (for details see 2.2.3). These contrasting functions of zinc 
fingers require a comprehensive reevaluation in order to fully understand PARP1's binding to 
DNA and subsequent activation.  
The mechanism of PARP1 activation has mainly been studied in vitro. However these 
biochemical and structural approaches do not account for the effect of cellular architecture on 
studied biochemical processes. The contribution of macromolecular crowding, confinement and 
adsorption are difficult to recapitulate in a sample tube (Minton, 2006). Yet PARP1's in vivo 
interactions with chromatin are affected by many soluble macromolecules, which foster or 
weaken PARP1's specific or non-specific interactions across multiple crowded micro 
environments. The in vivo insights into the mechanism of PARP1 activation and PARP1's 
association with chromatin in its dormant state are missing.   
Therefore, I investigated the properties of PARP1's chromatin interactions using cellular and 
biophysical approaches. In particular, I aimed to:  
o Measure quantitatively, via diffusion-reaction models, PARP1's diffusion and chromatin 
associations with high spatiotemporal resolution. 
o Identify the minimal unit of PARP1 required for PARP1's binding to DNA/chromatin. 
o Identify specific roles of each of the two zinc fingers in the DNA Binding Domain with 
respects to binding initiation and control of a bound state, which is the prerequisite for 
PARP1 activation.  
4.2 Towards the in vivo dynamics of PARP1 binding to DNA 
My work on the molecular mechanism of PARP1 activation was facilitated by a collaboration 
with Dr. Lawrence Pearl from Sussex University (United Kingdom). The Pearl laboratory solved 
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the X-ray structure of DBD bound to a DNA duplex molecule with a single base 5´ overhang. 
The structure revealed which ZF1 and ZF2 residues are important for DNA binding (for more 
details see 2.2.3). As shown in Figure 4.1, the Arg34 (ZF1) and Arg138 (ZF2) are critical for 
zinc finger binding of DNA via the phosphate group. I mutated these residues (R34 and R138) 
from arginine to glutamic acid (R34E, R138E) and evaluated their importance in zinc finger 
binding of DNA.  
 
 
 
Figure 4.1 Interactions of PARP1 zinc fingers with DNA (modified from Ali et al., 2012). The 
interactions are based on the X-ray structure of DNA Binding Domain (DBD) bound to DNA 
with a single base 5´ overhang. A) Zinc finger 1 (ZF1) DNA-interacting surface (colored by 
electrostatic potential, with positive in blue and negative in red) interacts with the sugar-
phosphate backbone of the overhanging strand and the major groove. B) Details of ZF1 and DNA 
interactions, centered on the polar interaction of Arg34 (R34) and a DNA phosphate group. C) 
Zinc finger 2 (ZF2) DNA-interacting surface (colored by electrostatic potential, with positive in 
blue and negative in red) interacts with the sugar-phosphate backbone of the recessed strand and 
the minor groove. D) Details of ZF2 and DNA interactions, centered on the polar interaction of 
Arg138 (R138) and a DNA phosphate group. 
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These single residue changes were introduced via site-directed mutagenesis of both PARP1 full-
length (PARP1-FL) and DBD-only (PARP1-DBD) constructs. In addition, I obtained the 
constructs with individual domains deleted: zinc finger 1, zinc finger 2 or the catalytic domain 
(CD). All the constructs were tagged consistently on the carboxyl-terminus with enhanced green 
fluorescent protein (EGFP; Figure 4.2; for details see Materials and Methods). Together, the 
constructs provided eleven possible combinations for testing the importance of PARP1 domains 
in binding DNA and PARP1 activation.   
            
Figure 4.2 Schematic overview of the constructs investigated in this study. All constructs in 
the box are derived from poly-ADP-ribose polymerase 1 (PARP1). The used abbreviations 
correspond to:  AMD – automodification  domain, CD – catalytic domain, ΔCD –deletion of the 
catalytic domain, DBD – DNA Binding Domain, FL - full length, R34E – arginine to glutamic 
acid mutation of residue 34, R138E – arginine to glutamic acid mutation of residue 138, WT - 
wild type, ZF1 – zinc finger 1, ΔZF1- deletion of the zinc finger 1, ZF2- zinc finger 2, ΔZF2 – 
deletion of the zinc finger 2, HP1α - heterochromatin protein 1 alpha, EGFP- enhanced Green 
Fluorescent Protein: monomeric (1x) and triple (3x), PARP2 – poly-ADP-ribose polymerase 2, 
YFP – Yellow Fluorescent Protein. The domain composition was simplified. PARP1, PARP2 and 
HP1α were tagged on C-terminus with EGFP (PARP1 and PARP2) or YFP (HP1α). The red bar 
in zinc fingers indicates the introduced mutation.  
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The study was conducted in HeLa Kyoto cells with stably depleted endogenous PARP1 via 
siRNA-mediated knock down (previously created in the Ladurner laboratory). I confirmed the 
efficiency of the knock-down before and throughout the study (Figure 4.3).  
 
 
 
 
 
   
 
Figure 4.3 PARP1 is efficiently knocked-down in HeLa-Kyoto cell line with stable 
expression of siRNA anti-PARP1. Whole-cell protein extracts from HeLa-Kyoto wild-type 
(WT) cells (on the left) and Hela-Kyoto with stable expression of siRNA anti-PARP1 (siRNA 
PARP1) cells (on the right) were analyzed via SDS-PAGE and visualized by western blot with 
anti-PARP1 and anti-Tubulin (loading control) antibodies. Both antibodies detected proteins of 
the expected size: 116 kDa for PARP1 and 55 kDa for Tubulin. PARP1 is efficiently depleted in 
the HeLa Kyoto siRNA PARP1 cell line (upper panel). Loading of protein extract on SDS-PAGE 
was identical, as indicated by α-Tubulin levels (lower panel). Marker indicating the size of the 
protein is indicated on the left in kilodaltons (kDa). WT PARP1 corresponds to cells treated with 
non-target specific siRNA (mock control). 
The generated PARP1 constructs were transiently expressed in these cells and only cells with 
very similar fluorescence intensity were chosen for the analysis. Upon transient expression, the 
PARP1 variants showed homogenous distribution across cell nuclei with enrichment within 
nucleoli, as expected from immunofluorescence staining of endogenous PARP1. The DBD 
constructs did not contain a nuclear localization signal (NLS), so as expected both nucleoplasmic 
and cytoplasmic localizations were observed (Figure 4.4).  
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Figure 4.4 Evaluation of expression pattern of PARP1-FL and PARP1-DBD in HeLa cells. 
A) Endogenous poly-ADP-ribose polymerase 1 (PARP1) full length (FL) is homogenously 
distributed within nucleus (N), with partial enrichment in nucleolus (Nuc). PARP1 was detected 
with anti-PARP1 antibody via immunofluorescence (IF) conducted on fixed HeLa wild type cells. 
B) PARP1- DNA Binding Domain (DBD), fused to enhanced Green Fluorescent Protein (EGFP), 
is distributed within nucleus (N) and cytoplasm (C). C) PARP1-FL fused to EGFP shows 
identical cellular distribution to endogenous PARP1-FL. PARP1-DBD and PARP1-FL (B and C) 
were transiently expressed in HeLa Kyoto cells depleted of endogenous PARP1. The constructs 
were visualized via live cell imaging based on EGFP fluorescence. Showed photos are 
representative of all PARP1-DBD and PARP1-FL constructs used in this study. Fluorescent 
signal is shown in gray.     
The generated PARP1 constructs were used in a comprehensive, spatio-temporal analysis of 
PARP1's mobility and binding to chromatin in vivo. I primarily used two fluorescence 
microscopy techniques: Fluorescence Correlation Spectroscopy (FCS) and Fluorescence 
Recovery After Photobleaching (FRAP). These two non-invasive methods are complementary to 
each other and ideal to probe PARP1's activation mechanism in living cells, as explained below.  
4.3 Basis of Fluorescence Correlation Spectroscopy and Quantification   
FCS requires that the protein of interest is fluorescently labelled, however it is not an imaging 
technique. FCS measures fluorescence intensity and its fluctuations in time. Because PARP1 is 
fluorescently labelled with EGFP, upon laser excitation, PARP1-EGFP becomes a source of 
fluorescence intensity via emission. This intensity is not stable in time, because proteins are 
mobile and they leave or enter the position (confocal volume) where the measurement is taken 
with variable frequency. Thus, mobility of labelled proteins is a source of fluorescence intensity 
fluctuations. The average length and amplitude of these fluctuations are determined by a 
temporal autocorrelation analysis. The FCS results are represented as ACF - autocorrelation 
function curve - G(τ), which provide information on the number of tested molecules (Y-axis) and 
the mean diffusion time (τ) in microseconds (µs) that the molecules spend in the observation 
volume (X-axis; Figure 4.5). In summary, FCS measures the fluctuations, which can be 
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biophysically modeled to determine the mobility (diffusion) of the fluorescently tagged protein. 
Mobility of proteins can change for example by binding to chromatin (Wachsmuth et al., 2008).  
 
 
 
Figure 4.5 Fluorescence Correlation Spectroscopy (FCS) monitors fluctuations in 
fluorescence intensity in time (modified from Wachsmuth et al., 2008). 1) A cell contains a 
fluorescently labelled protein (green). A laser is focused within the cell (blue dot) and a 
measurement of fluorescence is acquired. 2) A magnified view of the confocal focus (the place 
where the laser is placed and the measurement taken), across which fluorescently tagged proteins 
can enter and leave, as shown by black line trajectories. The protein of interest (gray circle) is 
tagged with a fluorescent protein e.g. EGFP (green circle). 3) Movement of fluorescently tagged 
proteins results as fluctuation of fluorescence intensity in time. 4) Intensity fluctuations are 
represented as a graph: the autocorrelation function curve of number of molecules (Y-axis) and 
time (X-axis). 
At first, the FCS results can be analysed qualitatively. A qualitative difference in mobility 
between two proteins or two tested conditions will be represented by a distinctive separation of 
the FCS curves when plotted together. As shown in Figure 4.6, the investigated pentameric 
EGFP diffuses slower in the nucleolus (higher τ) than in the nucleus (lower τ). The difference in 
diffusion of pentameric EGFP is caused by the higher molecular crowding environment in the 
nucleolus (Bancaud et al., 2009).   
In addition to qualitative analysis, the FCS results could be fitted with biophysical models. The 
modelling of FCS data allows quantification of the mean time (µs) spent by the investigated 
protein in the confocal volume, the diffusion time (τ). Identification of the mean diffusion time 
value enables calculation of the diffusion coefficient (D, µm2/sec) for each of the proteins tested. 
Lower diffusion time will correspond to a higher diffusion coefficient. FCS offers a high 
temporal resolution in a scale of microseconds (µs) thus even small changes in mobility among 
tested proteins can be detected (Wachsmuth et al., 2008). 
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Figure 4.6 Pentameric EGFP (5x) diffuses slower in nucleolus (orange) than it diffuses in 
nucleus (red) (modified from Bancaud et al., 2009). Autocorrelation function curves (normalized 
to 1 - representing 100 % of molecules) are distinctive and separated in diffusion time (τ) due to 
different molecular crowding in nucleus and nucleolus. The mobility of EGFP 5x is reduced and 
thus FCS curve is shifted to the right, when compared with the FCS curve of EGFP 5x in the 
nucleus. Measured FCS data (red and orange triangles) are fitted only with a trend line.  
 
The standard models used for FCS fitting are: anomalous diffusion model with one component 
and anomalous diffusion model with two components. Each component represents a population 
that can be characterized by the same mean diffusion time. If fitting of the model with measured 
data results in detection of one component, it means that all measured molecules undergo a 
homogenous behavior, for instance free diffusion. If two components (two populations) were 
detected, it means that measured molecules undergo heterogenous behavior, for instance: 
diffusion (first component) and diffusion coupled with binding (second component). Kinetic 
modeling of FCS data allows one to determine a percentage of molecules belonging to each 
component (Michelman-Ribeiro et al., 2009; for details see Materials and Methods). In my FCS 
experiments, I used two previously characterized controls: enhanced Green Fluorescent Protein 
(EGFP) and heterochromatin protein 1 alpha (HP1α). EGFP does not bind to chromatin, thus it 
served as a negative control. HP1α was shown to associate with chromatin, thus it served as a 
positive control (diffusion plus chromatin binding).  
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Figure 4.7 Representative fitting of EGFP and HP1α FCS measurements with anomalous 
diffusion model. A) The FCS curve of EGFP has a typical smooth decay typical for the samples 
with one component only. B) The FCS decay curve for HP1α has a typical hump, suggestive of 
two components and indeed the best fit of HP1α FCS measurements was achieved with two 
component anomalous diffusion model. The construct names indicate: EGFP – enhanced Green 
Fluorescent Protein, HP1α – heterochromatin protein 1 alpha. FCS measurements were 
conducted in: (i) HeLa Kyoto (siRNA PARP1) cells transiently transfected with EGFP (24 hours) 
and (ii) U2OS cells stably expressing HP1α-YFP. FCS measurements were acquired only within 
nuclei at randomly chosen positions avoiding the nucleoli and nuclear periphery (n > 15 cells per 
construct).  
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EGFP and HP1α were fitted with one and two component anomalous diffusion models, 
respectively (Figure 4.7). The identified mean diffusion time and diffusion coefficients for both 
controls in my experiments were consistent with previously reported results (Wachsmuth et al., 
2000, Müller et al., 2009). 
 
                                   
Figure 4.8 Types of diffusion (from Wachsmuth et al., 2008). Time trajectory of a molecule is 
represented by color transition from red (beginning) to yellow (end). The diffusion types: Free 
diffusion with a linear correlation of distance and time. Anomalous diffusion occurs in the 
presence of (randomly organized) obstacles where the distance deviates from linear correlation 
with time. The area covered by molecules is smaller. In the case of confined diffusion, the 
motion of a particle is restricted to the highlighted confinement area. The distance does not 
change significantly in time.  
In addition to the quantification of the diffusion time (τ), the fitting of measured FCS data with 
kinetic models identifies the anomaly parameter (α). Each protein diffuses across a certain area 
of space. This movement in space is measured in square micrometers per second (µm2/sec), the 
unit representing the diffusion coefficient (D). The anomaly parameter refers to diffusion of 
observed proteins taking consideration of space and time and their mutual correlation. So, for 
each diffusing protein a correlation between a diffused distance (mean square displacement, 
MSD) and time needed for it can be calculated. For freely diffusing molecules, the correlation 
between the distance and time is linear. In such a case, the anomaly parameter is equal to 1. 
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However when diffusion slows down for example due to chromatin binding, the correlation 
between distance and time is no longer linear. The anomaly parameter is thus not equal to 1, but 
it deviates towards 0 or above 1 (α < 1, or α > 1; Figure 4.8; Wachsmuth et al., 2003 and 2008). 
In my experiments, the measured anomaly parameter for EGFP was 1 (α = 1) and HP1α above 1 
(α > 1), which agreed with previously reported results (Wachsmuth et al., 2000, Müller et al., 
2009). 
 
4.4 PARP1-DBD primarily diffuses within the nucleus, with weak chromatin 
associations   
The PARP1 protein is composed of three functional fragments: a DNA binding domain (DBD), 
an automodification domain (AMD) and a catalytic domain (CD). An in vitro evaluation of the 
DNA binding affinity of each of these fragments indicated that the DBD has the highest affinity 
towards DNA. The AMD showed only weak affinity towards DNA and the CD did not bind 
DNA at all (for details see 2.2.2 and 2.2.4). The role of the DBD and its affinity to chromatin in 
vivo however is not known. Therefore to directly test it, I used FCS to analyze the diffusion and 
chromatin binding of the DBD in living cells. The FCS analysis of PARP1 DBD constructs was 
conducted in cells during interphase, under normal cell culture conditions, with no external 
stimuli. In this condition, nuclear PAR is not detectable by immunofluorescence (IF) with 
antibodies against PAR (see Figure 5.5 A). 
At first, I evaluated via FCS the DBD-WT (wild type), and found the mobility to be as high as 
that of EGFP (a negative control). A high mobility means that DBD-WT molecules diffuse 
rapidly within the nucleus. The FCS measurements of DBD-WT and EGFP formed two distinct 
populations when plotted as the autocorrelation function (ACF; Figure 4.9). However this 
distinction in slightly different diffusion time (X-axis) is not a true indication of the differences 
in diffusion, due to the different size of the evaluated molecules. The bigger DBD molecules (44 
kDa, including EGFP) are less mobile than smaller EGFP molecules (27 kDa).  
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Figure 4.9 Mobility of PARP1-DBD is similar to EGFP molecule within nucleus. HeLa 
Kyoto siRNA PARP1 cells were transiently expressed (24 hours) with PARP1-DBD-EGFP or 
EGFP. The mobility of the transfected constructs was evaluated with FCS. The results were 
plotted as autocorrelation function normalized to 1, representing 100 % of molecules (Y-axis), τ - 
time spent in a confocal volume (observation volume; X-axis). DBD-WT – PARP1 DNA 
Binding Domain wild-type (green); EGFP – enhanced Green Fluorescent Protein (red). Each 
ACF curve represents a single FCS measurement in a new cell (n > 20 cells per construct). 
The mobility of EGFP in living cells is unobstructed, meaning that EGFP freely diffuses within 
the nucleus with no binding to chromatin or other proteins (Wachsmuth et al., 2000). Similar 
FCS results between DBD-WT and EGFP suggested that DBD-WT does not bind extensively to 
chromatin. In order to evaluate this, FCS was conducted on DBD constructs with mutagenized 
single residues crucial in DNA binding (R34E and R138E). In addition the FCS measurements 
were biophysically modelled. The best fit of DBD measurements was with one component 
anomalous diffusion model. All the DBD constructs (wild-type, R34E and R138E) have similar 
mean diffusion time (τ) ~ 600 microseconds ± 150 microseconds (Figure 4.10). An introduction 
of the mutation into either of the two zinc fingers did not change the mobility of the DBD. To 
rule out a possibility that perhaps one zinc finger mediates short-lived interactions with 
chromatin, individual zinc fingers were tested as well. The resulting diffusion times for ZF1 and 
ZF2 are lower than for the DBD, but again the size of the ZFs plays a role (~35 kDa, including 
EGFP). Thus decrease of diffusion time is caused by the size of ZF vs. DBD (Figure 4.10).   
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Figure 4.10 PARP1-DBDs require similar diffusion time to diffuse across the measured 
position (confocal volume). HeLa Kyoto siRNA PARP1 cells were transiently transfected (24 
hours) with individual PARP1-DBD-EGFP constructs or individual PARP1-ZF-EGFP (X-
axis): WT – wild-type (red), ZF1 - zinc finger 1 (green), ZF2 – zinc finger 2 (dark blue), R34E – 
DNA Binding Domain with single residue mutation R34E (light blue), R138E – DNA Binding 
Domain with single residue mutation R138E (pink). The mobility of transfected constructs was 
evaluated with FCS. The curve fitting yielded mean diffusion time (τ) across the confocal 
volume. Each box plot is composed of FCS measurements taken in more than 10 cells. In each 
cell the measurement was taken in 3 randomly chosen sites in the nucleus avoiding nucleoli and 
nuclear periphery. Only cells with similar fluorescence intensity were selected. The horizontal 
lines (whiskers) represent the maximum and minimum values, the box signifies the upper (75th) 
and lower quartiles (25th), the median is represented by a short line within the box and the mean 
is represented by a square within the box. 
A calculation of mean and comparison of diffusion coefficients between the constructs further 
confirms low binding of the DBD to chromatin. The diffusion coefficients (D) of the tested 
DBDs are not significantly different, taking into account the standard deviation (SD): DBD-WT 
with D = 13.50,	  ± 3.04 μm2/sec, DBD-R34E with D = 11.57 ± 3.54	  μm2/sec, and DBD-R138E 
with D = 13.72 ± 1.5 μm2/sec (Table 4.1). In summary, this data suggests that the DBD in vivo, 
unlike in vitro, does not bind extensively or retain on chromatin. If DBD engaged with 
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chromatin, these interactions would have to be infrequent and undetectable in comparison to 
predominant diffusion.  
Table 4.1 Summary of FCS results for PARP1: DNA Binding Domain (DBD) and zinc fingers 
(ZFs). 
Tested	  protein	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Diffusion	  coefficient	  (D)	  	  	  	  	  	  	  	  	  	  	  	  Anomaly	  parameter	  (α)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  mean	  ±	  SD*	  (μm2/sec)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  mean	  ±	  SD*	  
PARP1-­‐DBD-­‐wild	  type	   13.50	  ±	  3.04	   0.92	  ±	  0.07	  
PARP1-­‐DBD-­‐mutated	  (R34E)	   11.57	  ±	  3.54	   1.00	  ±	  0.07	  
PARP1-­‐DBD-­‐mutated	  (R138E)	   13.72	  ±	  1.50	   0.98	  ±	  0.05	  
PARP1-­‐zinc	  finger	  1	   17.23	  ±	  2.48	   0.95	  ±	  0.05	  
PARP1-­‐zinc	  finger	  2	   18.00	  ±	  5.72	   0.98	  ±	  0.07	  
(1x)	  EGFP	  (negative	  control)	   23.14	  ±	  3.87	   1.00	  ±	  0.05	  
*SD-Standard Deviation. 
4.5 PARP1-FL primarily diffuses within the nucleus, with weak chromatin  
associations   
An in vitro evaluation of the DNA binding affinity of PARP1 full-length and PARP1 DNA 
Binding Domain indicated that the full-length binds DNA with up to several fold higher affinity 
than DBD (for details see 2.2.4). Thus, it can be that in a crowded in vivo environment the DBD 
alone is not stable in binding to, or cannot be retained, on chromatin, and therefore the high 
diffusion coefficient for DBD-WT was observed. It could be that other domains of PARP1 are 
important for in vivo DNA binding by PARP1. I directly tested this using the same approach and 
same cellular conditions as for FCS tests of DBD constructs. I tested analogous constructs like 
DBDs however in PARP1 full-length context. The results of FCS were biophysically modelled 
and the best fit was achieved with one component anomalous diffusion model.  
The PARP1 full-length wild-type molecules surprisingly again showed a relatively high mean 
diffusion time, and the DNA binding mutants were not significantly different. All the full-length 
constructs, including the proteins with deleted individual zinc fingers had a similar mean 
diffusion time of ~ 1800 ± 150 microseconds (Figure 4.11). The FCS analysis of 
heterochromatin protein 1 alpha (HP1α) revealed two fractions of molecules via a fit with two 
component anomalous diffusion model, in agreement with previously published results (Müller 
et al., 2009). HP1α is a protein well-known to bind chromatin: the first fraction of HP1α 
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represents molecules that are predominantly diffusing, and the second fraction with the mean 
diffusion time above 31 milliseconds represents HP1α bound to chromatin (see Figure 7.2). 
 
       
Figure 4.11 PARP1 full-length (FL) constructs require similar diffusion time to diffuse 
across the confocal volume. HeLa Kyoto siRNA PARP1 cells were transiently transfected (24 
hours) with individual PARP1-FL-EGFP constructs: WT – wild-type (red), R34E – single 
residue mutation R34E (green), ΔZF1 – deleted zinc finger 1 (dark blue), R138E –single residue 
mutation R138E (light blue), ΔZF2 –deleted zinc finger 2 (pink). HP1α– heterochromatin protein 
1 alpha, and EGFP – monomeric enhanced Green Fluorescent Protein were also FCS tested and 
plotted. Each box plot is composed of FCS measurements taken in at least 15 cells. In each cell 
the measurement was taken in 3 randomly chosen sites in the nucleus avoiding nucleoli and 
nuclear periphery. Only cells with similar fluorescence intensity were selected. The horizontal 
lines (whiskers) represent the maximum and minimum values, the box signifies the upper (75th) 
and lower quartiles (25th), the median is represented by a short line within the box and the mean 
is represented by a square within the box. The second component for HP1α was superimposed, 
for detailed view see Figure 7.2. 
The high mobility of the PARP1 full-length molecule is consistent with the observed high 
mobility of PARP1-DBD. The difference in the mean diffusion time is caused by size 
differences: PARP1-FL (143 kDa) and PARP1-DBD (44 kDa). These FCS results indicate that 
PARP1 in vivo is a protein that is predominantly not associated with chromatin, in contrast to the 
in vitro results. Quantification of a diffusion coefficient for each of the full-length PARP1 
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constructs (Table 4.2) further supports a conclusion that PARP1 in unstimulated cells (no 
excessive DNA damage) does not bind stably to chromatin and freely diffuses within the nucleus 
with D = 4.64 ± 1.04	  μm2/sec.  
Table 4.2 Summary of FCS results for PARP1-FL (full length) constructs.  
Tested	  protein	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Diffusion	  coefficient	  (D)	  	  	  	  	  	  	  	  Anomaly	  parameter	  (α)	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  mean	  ±	  SD*	  (μm2/sec)	  	  	  	  	  	  	  	  	  	  	  mean	  ±	  SD*	  	  
PARP1-­‐FL-­‐wild	  type	   4.64	  ±	  1.04	   0.89	  ±	  0.05	  
PARP1-­‐FL-­‐mutated	  (R34E)	   4.93	  ±	  1,41	   0.94	  ±	  0.07	  
PARP1-­‐FL-­‐Δ	  zinc	  finger	  1	   4.51	  ±	  0.69	   0.90	  ±	  0.07	  
PARP1-­‐FL-­‐mutated	  (R138E)	   5.15	  ±	  1.16	   0.90	  ±	  0.06	  
PARP1-­‐FL-­‐Δ	  zinc	  finger	  2	   5.90	  ±	  1.20	   0.93	  ±	  0.05	  
HP1α	  (1st	  component;	  positive	  control)	   6.74	  ±	  2.73	   0.98	  ±	  0.06	  
HP1α	  (2nd	  component;	  positive	  control)	  	  	   0.28	  ±	  0.08	   >1.00	  
(1x)	  EGFP	  (negative	  control)	   23.14	  ±	  3.87	   1.00	  ±	  005	  
*SD-Standard Deviation. 
4.6 Free diffusion is characteristic of all nuclear PARP1 molecules  
The identification of PARP1 molecules as freely diffusing and not bound to chromatin in vivo 
was surprising.	  In vitro findings suggest that PARP1 is chromatin-associated, thus I considered 
possible limitations of FCS that could potentially affect the in vivo understanding of PARP1 
interactions with chromatin. FCS is an approach that can investigate from 1 to 1000 molecules 
present within the region of interest, at width of ~ 200 nanometers. The highest temporal 
resolution of FCS is 1 second. I considered a hypothetic scenario, where perhaps some PARP1 
molecules are chromatin-associated, even longer than the detectable second component of HP1α 
protein (Figure 4.11 and 7.2). If this was the case, it would be possible that FCS measurements 
missed the PARP1 chromatin-associated molecules. Therefore, I investigated diffusion of all 
PARP1 molecules present in nuclei via Fluorescence Loss in Photobleaching (FLIP).  
FLIP is an imaging technique that measures redistribution of fluorescent proteins in time. The 
fluorescence intensity is continuously decreased via photobleaching (high laser intensity 
illumination). A repetitive series of photobleaching alternates with a repetitive time series of 
images that record fluorescence redistribution. Usually, one bleach cycle is followed by one 
image acquisition cycle until the fluorescence is completely depleted. The loss of fluorescence 
intensity (Y-axis) is recorded in time (X-axis). The results thanks to the steepness of the curve 
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allow one to qualitatively distinguish between molecules that diffuse within the nucleus, from 
those that do not diffuse but for example are bound to chromatin (Figure 4.12; Wachsmuth et al., 
2008).  
 
 
 
Figure 4.12 Fluorescence Loss in Photobleaching (FLIP) monitors redistribution of 
fluorescence intensity (modified from Wachsmuth et al., 2008). 1) A cell contains a 
fluorescently labelled protein (green). A pre-bleach time series of images is acquired in a state of 
equilibrium, where fluorescence intensity is evenly distributed within a cell. The initial level of 
fluorescence intensity is normalized to 1 representing 100 % of the signal. 2) A magnified view 
of the confocal focus. In a region of interest (ROI), the fluorescence is reduced via a rapid 
photobleach (high intensity laser illumination). The bleached ROI is seen as a black circle 
depleted of fluorescence.	  Usually one bleach cycle is followed by one image acquisition cycle 
untill the fluorescence is completely depleted. 3) The change of fluorescence intensity (Y-axis) in 
time (X-axis) is plotted as a FLIP curve.   
In case of free diffusion of molecules like EGFP, the fluorescence signal is depleted in the order 
of minutes. When proteins are characterized by diffusion coupled with binding interactions, the 
fluorescence signal is depleted in a significantly longer time. The FLIP experiments determined 
that PARP1-EGFP signal is completely lost in 600 seconds (Figure 4.13). Triple EGFP (81 kDa), 
with no interaction partners, was photobleached only slightly faster (500 seconds). PARP2 (90 
kDa, including EGFP) of a similar size to EGFP, is photobleached in a similar time as EGFP. 
This result confirms that there are no tightly chromatin-bound subpopulations of PARP1 that 
could have been missed with FCS. PARP2 contains DNA-binding motifs, however PARP2 
molecules showed a similar behavior to PARP1. This suggests that lack of chromatin association 
by nuclear PARPs could be shared within the PARP family.  
 
 
A scheme representing typical steps in FLIP 
1      2              3 
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Figure 4.13 FLIP confirms that PARP1 is freely diffusing protein. Mobility of PARP1-FL-EGFP, 
PARP2-EGFP and EGFP (3x) were analyzed via fluorescence loss in photobleaching (FLIP). 
Experiments were conducted in HeLa Kyoto (siRNA PARP1) cells transiently transfected with 
PARP1 (light blue) PARP2 (pink) and EGFP (3x) (yellow) constructs. The fluorescence (normalized 
to 1, Y-axis) of all constructs was depleted within 600 seconds or less, as was the case for EGFP (X-
axis) suggesting that none of the proteins is tightly bound to chromatin. Each curve is an average of at 
least 10 measurements for each condition.     
4.7 PARP1 binds to DNA upon induction of DNA damage 
According to the established model, PARP1 is activated upon binding to a DNA break. Under 
the standard cell culture conditions deprived of stressful stimuli like heat shock or DNA damage, 
PAR levels are not detectable. Upon induction of DNA damage, for example via laser 
irradiation, PARP1 binds to DNA breaks and PAR cellular levels are rapidly elevated (see Figure 
2.11). From the kinetic modelling, I knew that my FCS measurements are conducted on a 
number of molecules from 50 to 200 within a ~ 200 nanometer-wide confocal volume (for 
details see Materials and Methods). Thus, I considered the possibility that there are not enough 
DNA target sites (DNA breaks) across the genome for PARP1 to bind under standard cell culture 
conditions. I tested this hypothesis via FCS measurements on cells that underwent DNA damage. 
Single and double-stranded DNA breaks were induced within the whole nucleus with a 405 
nanometer laser (for details see Materials and Methods). The FCS measurements were acquired, 
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immediately following DNA damage induction. Strikingly, the fitting of FCS results with one 
component anomalous diffusion yielded 2.6-fold increased values of diffusion time for PARP1-
WT molecules (Figure 4.14).  
 
 
 
Figure 4.14 PARP1-full length-wild type molecules undergo diffusion coupled with binding 
upon DNA damage induction. HeLa Kyoto siRNA PARP1 cells were transiently transfected (24 
hours) with PARP1-FL-WT construct. FCS measurements were taken in two conditions: no DNA 
damage (red) and DNA damage (green).	  The DNA damage was induced with a 405 nm laser on 
cells pretreated with Hoechst 33342 (final concentration: 0.1 µg/ml) for at least 10 minutes. Each 
box plot is composed of FCS measurements taken in at least 10 cells. In each cell the 
measurement was taken in 3 randomly chosen sites in the nucleus avoiding nucleoli and nucleus 
periphery. Only cells with similar fluorescence intensity were selected. The horizontal lines 
(whiskers) represent the maximum and minimum values, the box signifies the upper (75th) and 
lower quartiles (25th), the median is represented by a short line within the box and the mean is 
represented by a square within the box. 
The increase of diffusion time suggests that under DNA damage PARP1 undergoes a transition 
from freely diffusing protein (no DNA damage) to a protein with limited diffusion. This means 
that PARP1 could bind chromatin frequently. Under DNA damage, it was possible to fit PARP1 
FCS data with two component anomalous diffusion similarly to HP1α. The outcomes were the 
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following: the first freely diffusive fraction was present in the majority (at least 64 % of 
molecules) and the second fraction which underwent diffusion coupled with binding started to be 
detectable (up to 36 % of molecules). The diffusion time of the second fraction was in the range 
of 20 – 200 milliseconds (data not shown). These FCS experiments of PARP1 diffusion post-
DNA damage induction were however difficult to conduct, due to high photobleaching of 
PARP1-EGFP molecules while FCS measurements were acquired. Thus, many measurements 
had to be discarded during the analysis. FCS therefore was no longer an adequate technology to 
reliably investigate mobility of the remaining PARP1-FL constructs. FCS measurements are 
suitable to investigate interactions of molecules which are short lived, below 1 second in time 
(Michelman-Ribeiro et al., 2009). Upon increase of DNA binding sites due to DNA damage, 
PARP1 presumably becomes immobilized on chromatin and apparently the mean diffusion time 
in a confocal volume exceeds the upper limit of FCS. Therefore a different complementary 
approach had to be deployed. I continued the analysis with use of FRAP, which has a time 
resolution over 1 second (from a few seconds to a few minutes).   
4.8 Two functional ZFs are essential and sufficient for PARP1 to bind DNA  
A free diffusion of PARP1-DBD and PARP1-FL constructs was explicitly evaluated via FCS in 
no DNA damage conditions. I employed FRAP to test PARP1-DBD and PARP1-FL construct 
(wild type and DNA binding mutants) diffusion and chromatin binding under laser-induced DNA 
damage condition. 
FRAP is an imaging technique that measures redistribution of fluorescent proteins in time. The 
first images (pre-bleach) are taken when a cell is in the state of equilibrium. This series of images 
serves for normalization purpose where 100 % of fluorescence intensity is represented as 1. At 
equilibrium, the fluorescently tagged proteins are evenly distributed within a cell, according to 
the endogenous protein localization. This equilibrium is perturbed via a photobleach (high laser 
intensity illumination) of fluorescence in the selected region of the cell (region of interest, ROI). 
The bleach results in spatial reduction of fluorescence intensity in ROI. Post-bleach, a series of 
images is taken in order to record the redistribution of fluorescence intensity from the non-
bleached region to the bleached region. Observation is continued until the fluorescence 
equilibrium is reached again. This redistribution of fluorescence intensity (Y-axis) is recorded in 
time (X-axis) and plotted as a FRAP recovery curve (Figure 4.15; Wachsmuth et al., 2008). The 
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redistribution of fluorescence intensity can change by diffusion and binding of the investigated 
protein. Thus FRAP is ideal to study PARP1 in vivo interactions with chromatin. The FRAP data 
can be biophysically modelled. 
 
 
 
Figure 4.15 Fluorescence Recovery After Photobleaching (FRAP) monitors redistribution of 
fluorescence intensity (modified from Wachsmuth et al., 2008). 1) A cell contains a 
fluorescently labelled protein (green). A pre-bleach time series of images is acquired in a state of 
equilibrium, where fluorescence intensity is evenly distributed within a cell. 2) In a region of 
interest (ROI), the fluorescence is reduced via a rapid bleach (high intensity laser illumination). 
The bleached ROI is seen as a black stripe across the cell. 3) The post-bleach time series of 
images is acquired until the equilibrium is reached again. The grey stripe represents diffusion of 
fluorescent molecules from non-bleached region to the bleached region. 4) The change of mean 
fluorescence intensity (Y-axis) in time (X-axis) is plotted as a FRAP curve.  
 
At first, I tested the diffusion and binding of PARP1-DBD molecules: wild-type and DNA 
binding mutants (R34E and R138E). Prior to the FRAP measurements, the cells underwent DNA 
damage induction via a laser treatment exclusively within the nucleus (for details see Materials 
and Methods). Upon induction of DNA breaks, the DBD-WT molecules showed full 
fluorescence recovery in about 15 seconds. Under the same DNA damage conditions, the DBD 
DNA binding mutants (R34E or R138E) showed full fluorescence recovery in only 6 seconds. 
The diffusion of DNA binding mutants was identical to diffusion of DBD-WT mutants but in no 
DNA damage conditions (Figure 4.16). Thus, only the DBD-WT with two functional zinc fingers 
showed reduced diffusion upon DNA damage conditions. A mutation of any of the residues 
important for the DNA binding by DBD, results in no change in diffusion. Thus these results 
suggest that DBD-WT undergoes slower diffusion because of temporal immobilization due to 
A	  scheme	  representing	  the	  typical	  steps	  in	  FRAP	  
1	   	   	  	  	  	  	  	  	  2	   	   	  	  3	   	   	   	   	  	  	  	  	  	  	  	  4	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DNA break recognition and binding. This result suggested that both functional zinc fingers are 
essential for DNA binding by DBD (Figure 4.16).  
 
                    
Figure 4.16 Only PARP1-DBD-WT binds DNA upon induction of DNA damage. FRAP 
experiment were conducted in HeLa Kyoto cells (siRNA PARP1) which transiently expressed 
individual DNA Binding Domain (DBD) poly-ADP-ribose polymerase 1 (PARP1) constructs: 
WT – wild-type (black and purple), R34E – single residue mutation R34E (turquoise), R138E – 
single residue mutation R138E (dark blue). The mutated single residues interfere with DNA 
binding. Prior to DNA damage induction with a 405nm laser, cells were pretreated with Hoechst 
33342 (final concentration of 0.1 µg/ml). Plotted FRAP curves are the mean measurements from 
at least 15 cells for each construct. FRAP recovery curves were superimposed with trend lines. 
 
According to the in vitro evaluation of DNA binding affinity of PARP1 full-length and PARP1 
DNA Binding Domain, the full-length molecule has at least a several fold higher affinity to DNA 
than DBD alone (for details see 2.2.4). Thus, I tested the importance of domains outside of the 
DBD for PARP1 binding to the DNA breaks in vivo. The identical DNA damage and FRAP 
conditions to the PARP1-DBD FRAP analysis were used for measurements of PARP1-full 
length diffusion and binding to chromatin. I tested analogous constructs to DBDs however in a 
PARP1 full-length context. The FRAP analysis indeed showed that PARP1-FL-WT molecules 
become significantly immobilized on chromatin stronger than PARP1-DBD. Strikingly, despite 
laser-induced DNA damage neither of the PARP1-FL-R34E nor the PARP1-FL-R138E had 
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reduced mobility and immobilization. Both of the PARP1 full-length mutants deficient in DNA 
binding recovered in the same time as PARP1-FL in no DNA damage conditions (Figure 4.17). 
Thus, only the PARP1-WT with two functional zinc fingers showed reduced diffusion in DNA 
damage conditions. These results suggest that domains outside of DBD are important for 
immobilization of PARP1 molecule on the break, however after PARP1 is already bound to 
DNA thanks to DBD. In summary, both zinc fingers composing the DBD function in a 
cooperative unit in DNA binding by PARP1. The DBD is sufficient for DNA break recognition 
and actual break binding. 
 
              	  
Figure 4.17 Only PARP1-FL-WT binds DNA upon induction of DNA damage. FRAP 
experiment were conducted in HeLa Kyoto cells (siRNA PARP1) which transiently expressed 
individual full-length poly-ADP-ribose polymerase 1 (PARP1) constructs: WT – wild-type (black 
and purple), R34E – single residue mutation R34E (turquoise), R138E – single residue mutation 
R138E (dark blue). The single reside mutations interfere with DNA binding. Prior to DNA 
damage induction with 405nm laser, cells were pretreated with Hoechst 33342 (final 
concentration of 0.1 µg/ml). Plotted FRAP curves for each construct are the averaged 
measurements from at least 15 cells. 
In order to precisely quantify how long PARP1 is bound to DNA breaks - residency time (tres), 
the FRAP curves representing PARP1-FL molecules (wild-type, R34E and R138E) were fitted 
with a two-dimensional model accounting for diffusion and binding (for details see Materials and 
Methods). The modeling allows one to quantify a diffusion coefficient (D), and dissociation 
FRAP	  analysis	  of	  PARP1-­‐FL	  under	  DNA	  damage	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rate (koff) meaning how often PARP1 dissociates from a DNA break in a given time (here, one 
second). Under no DNA damage conditions, thus low number of DNA breaks, PARP1 was 
calculated to be represented by D = 2.92 ± 0.51	  μm2/sec.  In the presence of DNA breaks, the 
diffusion coefficient was on average ~ 20-fold reduced to D = 0.15 ± 0.16 μm2/sec. A reduction 
of diffusion coefficient due to induction of DNA damage was only detectable for PARP1 wild-
type molecules and none of the DNA binding PARP1 mutants. Thus, the reduced diffusion was 
caused by PARP1's association to chromatin. The immobilization of PARP1 on chromatin lasts 
on average ~ 18.2 seconds. The results of fitting are summarized in Table 4.3. Due to the 
predominant diffusion of PARP1-FL DNA-binding mutants (R34E and R138E) it was not 
possible to determine residency time or dissociation rate for these constructs.  
Table	  4.3	  Summary	  of	  FRAP	  results	  for	  PARP1	  full-­‐length	  constructs.	  
	  
Tested	  protein	  
	  
	  
Diffusion	  coefficient	  (D)	  	  
	  	  	  	  	  	  	  mean	  ±	  SD*	  (μm2/sec)	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
 
koff	  (sec-­‐1)	  
mean	  ±	  SD	  
	  	  
tres (seconds) 
mean ±	  SD	  
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  No	  DNA	  damage	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  Under	  DNA	  damage	  	  
PARP1-­‐FL-­‐wild	  type	   2.92	  ±	  0.51	   0.15	  ±	  0.16	   0.055	  ±	  0.055	   18.18	  ±	  18.18	  
PARP1-­‐FL-­‐mutated	  (R34E)	   2.92	  ±	  0.51	   2.92	  ±	  0.51	   n.d	   n.d	  
PARP1-­‐FL-­‐mutated	  (R138E)	   2.92	  ±	  0.51	   2.92	  ±	  0.51	   n.d	   n.d	  
*SD	  –	  Standard	  Deviation,	  n.d	  –	  not	  possible	  to	  determine,	  Koff	  -­‐	  disassociation rate (release event per second), tres – 
residence time on chromatin (seconds).  
 
The results depicted on Figure 4.16 and Figure 4.17 have been published as:  
Ali AA, Timinszky G, Arribas-Bosacoma R, Kozlowski M, Hassa PO, Hassler M, Ladurner AG, 
Pearl LH, Oliver AW. . The zinc-finger domains of PARP1 cooperate to recognize DNA strand 
breaks. Nat Struct Mol Biol. 2012 Jun 10;19(7):685-92 
4.9 Dissociation of PARP1 from DNA is coupled to PARP1 activity 
According to the FRAP findings, the functional DBD is sufficient for PARP1 to bind DNA. 
However with PARP1-FL is at least 4 times longer immobilized on chromatin in comparison to 
PARP1-DBD. Full fluorescence recovery of PARP1-FL molecules takes about 70 seconds 
(Figure 4.18 A) whereas PARP1-DBD recovers in just 15 seconds. Thus once PARP1 is bound 
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to chromatin, other domains seem to regulate PARP1 chromatin association. According to the 
predominant model, PARP1 is activated due to DNA binding. I tested how activation 
sequentially regulates the chromatin-bound state of PARP1. The PARP1-FL-ΔCD (catalytic 
domain) was assayed via FRAP under typically used DNA damage conditions. Strikingly, 
PARP1 with a deleted catalytic domain is immobilized on chromatin even longer than PARP1-
FL molecules. The fluorescence recovery of PARP1-FL-ΔCD molecules is minimal, which 
means that diffusion of PARP1 molecules is no longer predominant, but PARP1 is stably bound 
to DNA breaks (Figure 4.18 A and B).  
 
 
             
Figure 4.18 PARP1's release from chromatin is coupled to PARP1's catalytic activation. 
FRAP experiments were conducted in HeLa Kyoto cells (siRNA PARP1) which transiently 
expressed individual full-length poly-ADP-ribose polymerase 1 (PARP1) constructs: A) WT – 
wild-type and B) ΔCD – deleted catalytic domain. Prior to DNA damage induction with a 405nm 
laser, cells were pretreated with Hoechst 33342 (final concentration of 0.1 µg/ml). Plotted FRAP 
curves for each construct are the mean measurements from at least 15 cells. FRAP recovery 
curves were superimposed with trend lines. 
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4.10 Discussion  
The outcome of my work provides for the first time a comprehensive and quantitative in vivo 
analysis of: (i) PARP1's nuclear diffusion coupled to DNA target site selection, together with (ii) 
specifics of DBD's each zinc finger role in binding to DNA, a prerequisite to PARP1's activation. 
(i) PARP1 diffuses freely within the nucleus  
Presented findings of PARP1 as freely scanning the nuclear milieu with diffusion coefficient 
above 4.64 ± 1.04 μm2/sec (in no DNA damage conditions; FCS tested) challenge the 
predominant view of PARP1 as a constantly chromatin-associated protein. This past notion came 
in majority from in vitro studies, where indeed PARP1 showed high affinity towards DNA and 
nucleosomes promoting chromatin condensation and replacement of histone 1 (H1) from linker 
DNA (Kim et al., 2004; see also 2.2.4). My in vivo findings suggest the opposite – that PARP1 
only weakly associates with chromatin, under no excessive DNA damage. And only upon the 
induction of DNA breaks, does PARP1 bind these breaks and become temporally immobilized 
on chromatin (Figure 4.17). The free diffusion of PARP1 agrees with findings that most of the 
molecules probed in the nucleus show rapid exchange between various chromatin sites 
(Lippincott-Schwartz et al, 2001; Patterson and Lippincott-Schwartz, 2002, Hager et al, 2002; 
Phair et al, 2004; Beaudouin et al, 2006).  
The first insights into the nature of PARP's association with chromatin in vivo came from PARP1 
mobility studies in Drosophila melanogaster (Pinnola et al., 2007; see also 2.2.4). The fly 
genome encodes only one PARP (corresponding to PARP1; Tulin et al, 2002), whereas the 
human genome encodes 17 PARPs (Vyas et al., 2013). FRAP analysis in the salivary glands of 
flies revealed that Drosophila melanogaster PARP (dPARP) exchanges between chromatin 
domains faster than a canonical histone H2A. The exchange rate of dPARP varied between 
euchromatin and heterochromatin regions. On average the FRAP half-time recovery 
(representing 50 % recovery of the bleached spot) was around 100 seconds. The half time FRAP 
recovery for human PARP1 was significantly shorter, less than 5 seconds. This high difference 
between FRAP results for fly and human PARP1 may be attributed to the fact that flies contain 
only one PARP protein in comparison to 8 nuclear PARPs in humans with perhaps redundant 
functions and thus weaker chromatin association. Of course, the difference in size of the genome 
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or differences in chromatin organization (additional histone variants and chromatin factors in 
higher eukaryotes) may play a difference as well.         
In addition, I did not observe significant differences in PARP1 nuclear mobility that would 
suggest different diffusion within euchromatin or heterochromatin regions in mammalian cells, 
unlike dPARP. Particular enrichment of PARP1 (endogenous or transiently expressed) within 
nuclei, if PARP1 was trapped in heterochromatin region, neither was observed in cells evaluated 
via fluorescence microscopy (HeLa Kyoto, U2OS, MCF-7 and MDA-66). However I did not test 
PARP1 mobility in environment with labelled euchromatin or heterochromatin allowing me to 
distinguish between two chromatin states.  
(ii) All of the PARP1 molecules show analogous cellular behavior    
In addition to the FRAP study of dPARP, another study that evaluated human PARP1 via FRAP 
was conducted. This PARP1 mobility study in HeLa cells found PARP1 to be gradually enriched 
over laser-induced DNA damage as fast as 1 second (Haince et al., 2007). This past in vivo study 
provided insights into PARP1's chromatin associations in living cells and suggested that PARP1 
may not be constantly chromatin-associated. However the used classical and only qualitative 
FRAP approach was limited in its spatial and temporal resolutions. The bleached areas in the 
experiment encompassed a big part of the nucleus (Haince et al., 2007). Thus the final 
information on PARP1 mobility was only an average of hundreds of thousands of PARP1 
molecules, which could have undergone completely different mobility, when considered 
individually. Moreover, no analysis of the actual mechanism and domain importance for target 
DNA selection and binding by PARP1 was conducted. I investigated the PARP1 diffusion and 
interaction behavior in living cells with FRAP and two additional, complementary methods: 
Fluorescence Correlation Spectroscopy (FCS; 1-1000 molecule resolution) and Fluorescence 
Loss in Photobleaching (FLIP; 100 % of tagged molecules in a cell). The outcomes of my work 
suggest that PARP1 recognizes its target sites via free diffusion, which is representative of all 
molecules.  
A free diffusion of PARP1 allows the protein to weakly and frequently interact with multiple 
genome sites. This type of PARP1 interaction with chromatin allows PARP1 to monitor DNA 
target sites constantly and rapidly engage with chromatin when required, for example upon 
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detection of a DNA break. According to the predominant model of PARP1 activation, the protein 
becomes activated upon DNA binding. The fast diffusion of PARP1 molecules and lack of 
continuous binding to chromatin, unless there are DNA breaks, may thus explain very low levels 
of PAR within a cell (see Figure 5.5 A). Simply, no binindg corresponds to lack of PAR within 
the nucleus.  
The PARP1 DBD binds to DNA 4 times shorter than the PARP1 full-length molecules (Figure 
4.16 and 4.17). PARP1 with deleted the catalytic domain becomes strongly immobilized on 
chromatin (Figure 4.18). A variation in chromatin-immobilization time of PARP1, depending on 
domain composition suggests that there is most likely an intramolecular interaction between 
PARP1 domains leading to catalytic activation based on the signal originating from DNA-bound 
zinc fingers. Such an intradomain communication was suggested by the X-ray crystal structure of 
nearly full-length PARP1 molecule bound to DNA (see also 2.2.3), however the X-ray structure 
misses the ZF2 and BRCT domains, thus it is not clear what the final interaction between the 
domains is. Prolonged immobilization of PARP1 missing the catalytic domain could be caused 
by three mechanisms, which could be addressed experimentally. First, PARP1 does not 
automodify itself with PAR, thus its association with chromatin has no negative feedback 
promoting disaasociation. Second, PAR modification is required to recruit proteins (kinases or 
ubiquitinases) that will negatively regulate association of PARP1 with chromatin (for details see 
2.2.5 and 2.3.3). Third, perhaps the catalytic domain, upon NAD+ binding, releases zinc fingers 
from a DNA break.   
(iii) PARP1's mobility is hindered    
Interestingly, my observations suggest that PARP1 could interact with chromatin or other 
proteins, when not bound to chromatin. This conclusion is based on the fact that the predicted 
diffusion coefficient (D) for PARP1 based on the proteins size is ca. 6 μm2/sec. Quantification of 
FCS data for PARP1 full-length found the molecules to diffuse with diffusion coefficient of 4.64 
± 1.04	   μm2/sec. There are two possible explanations for the difference between predicted and 
measured D. The first could be that PARP1 forms a homo/hetero complex with other molecules 
and thus diffuses slower. The second would be that PARP1 diffuses slower due to PAR 
modification or other posttranslational modifications (see also 2.2.5). A combination of these 
two models is possible as well.  For example, if PARylated PARP1 diffused across the nucleus it 
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could be recognized and temporally immobilized by a macroH2A1.1 histone variant that 
specifically recognizes and binds PAR. This hypothesis needs an evaluation. For example, 
PARP1 mobility could be evaluated by FCS in the presence of PARP1 activity-specific 
inhibitors or mutated known PTM sites. In addition, a possibility of homo- or hetero-dimer 
formation of PARP1 can be tested with Fluorescence Cross-Correlation Spectroscopy (FCCS). 
This experiment would evaluate a mobility of two populations of PARP1 or additional candidate 
molecules (e.g. ALC1) labeled with two different fluorescent proteins (e.g. EGFP and mCherry). 
If the two populations diffused together, the cross-correlation of FCCS experiment would be 
positive, thus two tested populations would show identical diffusion times in space and time.    
(iv) PARP1's binding to chromatin is zinc finger-dependent  
An evaluation of dPARP association at the heat-shock loci revealed that dPARP resides at the 
TSS and in the gene body of hsp70 in a PAR modification-independent and -dependent manner, 
respectively (for details see 2.2.4). No importance of zinc fingers for TSS association was 
however tested in these previous studies. My data suggests that zinc fingers are critical in PARP1 
chromatin-association. Lack of functional zinc fingers results in lack of PARP1 binding, even in 
the presence of high amount of DNA breaks (Figure 4.17). It is thus not clear how PARP1 would 
associate with chromatin due to posttranslational modification of histones. Such a mechanism 
was suggested by dPARP association with heat shock loci due to presence of H2A.V histone 
variant and its phosphorylation (for details see 2.2.4; Kotova et al., 2011, Thomas et al., 2014). 
The study of dPARP chromatin association was conducted at hsp70 loci during transcription 
initiation. My study was conducted in the context of PARP1 binding to DNA lesions. Although it 
is not clear that dPARP actually does not become activated at hsp70 promoter due to DNA 
damage (see Outlook, chapter 6) it is possible that PARP1 associates differently at DNA lesion 
sites vs. transcriptional sites. A comprehensive study of PARP1's domain importance for 
mobility and chromatin association in defined transcriptional context would be appreciated.  
(v) Both zinc fingers are essential for PARP1's binding to DNA  
The investigation of the importance of each zinc finger revealed that ZF1 and ZF2 form a 
functional unit, which is essential and sufficient for PARP1's association with chromatin (in 
DBD and full-length contexts). None of the zinc fingers alone was sufficient to even transiently 
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immobilize the PARP1 molecule over the target site. In such a case where both zinc fingers are 
important, the model which disregards zinc finger 2 and importance of the linker contact 
between the zinc fingers may be simply incorrect (see more 2.2.3). Instead, the X-ray structure of 
the full-length PARP1 molecule bound to various DNA structures would be highly appreciated. 
Zinc finger 2 in vitro was shown to have 100-fold higher affinity to DNA than zinc finger 1 (for 
details see 2.2.3). The in vitro differences observed in DNA affinity between ZF1 and ZF2 are 
not visible in vivo. Both zinc fingers in vivo are equally important and most likely bind DNA 
breaks simultaneously. 
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5 Results and Discussion II 
Functions of PARP1 and ALC1 in transcription  
5.1 ALC1 is recruited to DNA damage sites and activated via PAR    
The amplified in liver cancer 1 (ALC1) gene was originally identified as an amplified region of 
chromosome 1 in more than 50 % of hepatocellular carcinomas (HCC). The oncogenic role of 
ALC1 was next confirmed via its ectopic expression in transgenic mice, which developed tumors 
in consequence. In HCC patients, the elevated expression level of ALC1 was correlated with 
shorter disease-free survival time (for details see 2.4). ALC1 is a member of the SNF2 ATPase 
superfamily, some members of which function as chromatin remodelers. ALC1 was found to 
remodel a mono-nucleosome position in vitro (Gottschalk et al., 2009). Thus ALC1's oncogenic 
functions are most likely mediated via its roles in regulation of chromatin structure. However the 
details of this process in vivo are not known. Dynamics of chromatin structure reorganization 
will affect DNA accessibility and all DNA-based processes (Clapier and Cairns, 2009). There are 
two possible models that could explain ALC1 oncogenic functions. The first model describes 
that ALC1's activity regulates DNA repair mechanisms. The second model involves ALC1 roles 
in transcriptional deregulation of other oncogenes.  
ALC1 is recruited to the sites of DNA damage in an exclusively PARP1-dependent manner. The 
recruitment is possible due to ALC1's macrodomain, a globular domain that specifically 
recognizes and binds PAR, which is product of PARP1 enzyme (Karras, et al., 2005, Gottschalk 
et al., 2009). In the transcriptional context, one study has to date reported ALC1 binding to a few 
genome sites that included exons, introns and intergenic regions. A possible DNA sequence 
motif recognized by ALC1 was proposed (Chen et al., 2010). However the validity of these 
findings was not confirmed. Moreover the importance of PAR in ALC1 recruitment to 
transcriptional sites was not tested. A clear understanding of ALC1 recruitment mechanism to 
the genome sites in a transcriptional context matters in order to understand the mechanism of 
ALC1 activation and resulting cellular functions.   
Our current understanding of ALC1 significance in transcription regulation is not clear. To date, 
there are two reports of two individual genes, ARHGEF9 and SPOCK1, whose expression is 
regulated by ALC1. The evidence is based on the fact that changes of ALC1 cellular level, 
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results in changed ARHGEF9 and SPOCK1 expression levels. These findings were followed up 
and ALC1 was found, via ChIP, in the vicinity of transcriptional start sites (TSS) for these genes. 
However, the ChIP results were only qualitative and the authors showed a specific localization 
only for SPOCK1 (for details see 2.4). The authors did not provide a true enrichment (detected 
percentage of input DNA) of ALC1 over the investigated loci. Neither the molecular basis of 
ALC1 recruitment to these sites was investigated and reported. This is important, because ALC1 
as a chromatin remodeler may affect chromatin organization across the genome, which may 
result in deregulation of expression for certain genes. Although these genes not necessarily need 
to be direct targets of ALC1 and the effect does not necessarily need to originate from ALC1's 
transcriptional role, but may instead be a consequence of ALC1 roles in DNA repair. It is widely 
accepted that genome of cancerous cells is unstable. Changes in DNA repair will contribute to 
transcriptional changes and thus deregulation of gene expression, common in carcinogenesis 
(Burgess et al., 2012).  
Therefore, I investigated the properties of ALC1 dependence on PARylation and ALC1 roles in 
transcription. In particular, I aimed to:  
o Identify, if indeed and how ALC1 regulates transcription.  
o Identify the molecular mechanism of ALC1 recruitment and regulation of chromatin 
structure in the context of transcription.   
5.2 PARP1 and ALC1 appear not to function in ER-regulated transcription  
ALC1 via its macrodomain binds in vitro exclusively to chains of PAR, which play a crucial role 
in activation of ALC1's ATPase-dependent remodeling functions (for details see 2.4). Similar to 
the in vitro, thanks to the macrodomain, ALC1 is recruited to the sites of extensive PARylation 
in vivo (laser induced DNA lesions). A functional macrodomain is essential in ALC1 recruitment 
to PARP1 activity sites (Gottschalk et al., 2009). Thus, it appears that ALC1 is highly dependent 
on its macrodomain interactions with PAR for both, the genomic localization and the chromatin 
remodeling function. A dependence of ALC1 on macrodomain and PAR was never tested in the 
context of transcription. Knowing recruitment mechanism of ALC1 to the transcriptional sites 
would facilitate understanding of ALC1's functions as an oncogene.  
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Cellular PAR originates in majority from the activity of PARP1 enzyme (see also 2.3). To date, a 
few transcriptional mechanisms that depend on PARP1 activity and PAR presence were 
reported. For example, PARP1 was found to co-activate transcription together with various 
nuclear receptors (estrogen and progesterone receptors) upon the presence of a respective ligand 
(estrogen or progesterone; Ju et al., 2006, Wright et al., 2012, Zhang et al., 2013a). Therefore I 
used one of the breast cancer cell lines (MDA-MB231-human ERα, see Materials and Methods) 
responsive to estrogen. In this cell line, upon the ligand addition, ERα target genes are 
transcriptionally up-regulated or down-regulated within minutes and hours (depending on the 
gene) following estrogen addition (Ju et al., 2006, Reid et al., 2003, Hah et al., 2012). I 
hypothesized that ALC1 could play a role in estrogen-dependent transcription regulation, if 
ALC1's macrodomain recognizes PAR originating from activated PARP1 in this process. Thus, I 
evaluated up-regulation of mRNA levels (via RT-PCR) for known ERα-regulated genes 
(GREB1, TFF1 and CASP7) in the presence of the ligand across eight different conditions. The 
conditions were the following (for details see Materials and Methods):  
(i) no estrogen treatment (negative control)  
(ii) estrogen treatment (positive control)  
(iii) chemical inhibition of PARP1 activity with 5 µM olaparib and estrogen treatment  
(iv) PARP1 siRNA-mediated knock down (48 hours) and estrogen treatment  
(v) ALC1 siRNA-mediated knock down (48 hours) and estrogen treatment  
(vi) chemical inhibition of PARP1 activity with 15 µM AG14361 and estrogen treatment  
(vii) chemical inhibition of PARP1 activity with 5 µM	  AG14361 and estrogen treatment  
(viii) chemical inhibition of PARP1 activity with 2.5 µM AG14361 and estrogen treatment 
The results of RT-PCR analysis are shown in Figure 5.1. As expected, a chemical inhibition of 
PARP1 activity with the highest concentrations of AG14361 resulted in decreased up-regulation 
of estrogen receptor target genes. Surprisingly, a chemical inhibition of PARP1 activity with 
olaparib or PARP1 down-regulation via siRNA (48 hours) did not interfere with up-regulation of 
the same genes upon estrogen treatment. In addition, siRNA-mediated down-regulation of ALC1 
did also not prevent up-regulation of estrogen receptor target genes. 
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Figure 5.1 Chemical inhibition of PARP1 and siRNA of PARP1 or ALC1 does not interfere 
with up-regulation of estrogen receptor-dependent genes.  Breast cancer cells (MDA-MB231-
human ERα) were treated with chemical inhibitors of PARP1 (olaparib or AG14361) with the 
indicated concentrations (15, 5 or 2.5 µM) for 40 minutes prior to estrogen (E2) treatment, or the 
MDA-MB231-human ERα cells were treated with siRNA (48 hours) to knock-down PARP1or 
ALC1 and then treated with estrogen (E2). Estrogen treatment (100 nM) lasted 3 hours, after 
which total RNA was extracted. Shown on the graph are mRNA levels of the respective genes 
(post estrogen treatment) normalized to the levels prior estrogen addition (indicated as 0 on the 
logarithmic scale, on the Y-axis). PARP1 and ALC1 mRNA levels post-siRNA were normalized 
to mRNA levels of cells treated with non-specific siRNAs (mock control). PARP1 and ALC1 
mRNA levels were not evaluated in cells treated with AG14361 compound. Tested genes were: 
GREB1 - growth regulation by estrogen in breast cancer 1, TFF1 – trefoil factor 1, CASP7 – 
caspase 7 apoptosis-related cysteine peptidase, FAM117 – family with sequence similarity 117, 
GFRA1 – GDNF family receptor alpha 1, PARP1- poly-ADP-ribose polymerase 1, ALC1 – 
amplified in liver cancer 1. Error bars represent Standard Error of Mean from at least 3 
experiments.     
The importance of ALC1 in estrogen receptor-regulated transcription is not known and the main 
goal of this experiment was to test it. However,	  the outcome of the experiment was surprising. I 
expected to see a functional role of PARP1 in deregulation of transcription of estrogen receptor 
responsive genes upon PARP1 chemical inhibition or siRNA knock-down. PARP1's role in this 
process was not observed, unless high concentration of AG14361 (15 µM) were used, suggesting 
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that PARP1 is not important for estrogen receptor transcription control. Thus, my data 
contradicts the previously published results from Ju and co-workers (2006) and Zhang and co-
workers (2013a), where PARP1 and its activity were shown to play a co-activation role in up-
regulation of estrogen receptor dependent genes upon estrogen treatment (see also 2.1.2).  
However, technical differences between my study and the published studies exist. A major 
difference is the choice of PARP1 chemical inhibitors. The Ju and Zhang study deployed the 
early generations of PARP1 chemical inhibitors: 3-aminobenzamide (3AB; Purnell and Whish, 
1980) and PJ-34 (phenanthridinone derivative; Soriano et al., 2001). 3AB is a very weak PARP1 
inhibitor with inhibitory constant (Ki) of 500 nM (Gallmeier et al., 2005), thus the authors used 
high 10 mM concentration of 3AB in the study. The PJ-34 in Zhang study was used at 10 µM 
concentration. Unfortunately, at concentration of 5 µM and higher, PJ-34 was shown to have off 
target proteins, including the PIM family of	   serine/threonine kinases (Antolin et al., 2012). 
Recently, 3AB was additionally judged to be a very poor PARP1 inhibitor thanks to mass 
spectrometry (MS) results (Zhang et al., 2013b). In this study, five different chemical inhibitors 
of PARP1 were compared with respects to their efficiency in inhibition of protein PARylation in 
cells with or without oxidative DNA damage (induced via hydrogen peroxide, H2O2). Use of 
3AB at high concentrations (50 µM) did not prevent PARylation of proteins upon DNA damage, 
and the PAR modified protein profiles between two conditions (no inhibitor or plus inhibitor) in 
cells with or without DNA damage, poorly matched. In contrast, the chemical inhibitors, olaparib 
and AG14361 used at low concentrations (1-3 µM) were found to specifically inhibit PARylation 
of target proteins in relevant conditions. PJ-34 inhibitor was unfortunately not tested in the study 
(Zhang et al., 2013b). Therefore I used recent generation of PARP1 inhibitors: olaparib and 
AG14361 to evaluate PARP1's role in estrogen receptor dependent transcription.  
The use of AG14361 resulted in decreased transcriptional response of ERα target genes, however 
this response was especially present in higher 15 µM and 5 µM AG14361 concentrations. 
Therefore, I conducted siRNA-mediated knock down of PARP1 to re-confirm chemical 
inhibition study. The knock-down efficiency (48 hours) of RNA levels was high, with only 10 % 
PARP1 mRNA remaining. At the protein levels PARP1 was detectable in higher levels than 10 
% of the siRNA mock-treated control (Figure 5.2 A; for details see Materials and Methods). The 
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siRNA-mediated knock down of PARP1 further favored no role of PARP1 in ERα-regulated 
transcription.  
 
   
Figure 5.2 PARP1 and ALC1 are efficiently knocked down in MDA cell lines. Whole-protein 
extracts from MDA-MB231-human ERα cell lines upon transient expression of siRNA specific to 
A) PARP1 or B) ALC1, were analyzed via SDS-PAGE and visualized by western blot with anti-
PARP1, anti-ALC1 and anti-Tubulin (loading control) antibodies. All antibodies detected 
proteins of the expected size: 116 kDa for PARP1, 100 kDa for ALC1 and 55 kDa for Tubulin. 
A) PARP1 – poly-ADP-ribose polymerase 1 and B) ALC1 – amplified in liver cancer 1, are 
significantly depleted in the MDA-MB231-human ERα cell lines (upper panels, respectively). 
Loading of protein extract on SDS-PAGE was similar, as indicated by α-Tubulin levels (lower 
panels, respectively). Marker indicating the size of the protein is indicated on the left in 
kilodaltons (kDa). WT PARP1 and WT ALC1 correspond to cells treated with non-specific 
siRNA (mock control).   
The Ju and Zhang studies deployed siRNA targeting PARP1 to confirm the involvement of 
PARP1 in estrogen receptor-dependent transcription as well. The siRNA used by Ju and co-
workers is no longer in stock (Qiagen). BLAST analysis of this siRNA accuracy showed that this 
siRNA targets other coding regions in addition to PARP1. BLAST analysis of the siRNA used by 
Zhang and co-workers did not yield non-specific coding sequences in addition to PARP1, 
however 3 non-coding regions (each 12 base pair long) were identified. The importance of these 
non-coding sequences is not known.  
Importantly, despite confusing results concerning PARP1 co-activation role, the main goal was 
to evaluate ALC1 importance in estrogen receptor alpha regulated transcription. Upon ALC1 
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  MDA	  cell	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   B	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knock down tested genes responded as genes in wild type cells (control) and no change in 
mRNA levels of ERα regulated genes was observed (Figure 5.1) This result likely diminishes 
ALC1's importance in the studied process. ALC1 was efficiently down-regulated at RNA and 
protein levels (Figure 5.1 and 5.2 B).  
5.3 ERα foci formation is unaffected by interference with PARP1 activity   
According to my data PARP1's activity in not essential for ERα-dependent transcription. This 
result was surprising and opposite to the one expected based on the previously published reports. 
Therefore, I further tested PARP1's importance in estrogen-stimulated transcription from another 
perspective - formation of estrogen receptor alpha (ERα) foci across the genome upon ligand 
addition. Such foci are formed by ERα presumably being bound to estrogen responsive element 
(ERE; Reid et al., 2003, Sharp et al., 2006, Kwon et al., 2007). A rationale for PARP1's possible 
function in the foci formation was based on the fact that PARP1 was shown to PARylate ERα in 
vitro. Also, both PARP1 and ERα were found to co-immunoprecipitate each other (Zhang et al., 
2013a).  
If PARP1 indeed regulated ERα-dependent transcription, I expected changes to ERα foci 
formation upon interference with PARP1 activity. I tested this using live cell imaging of ERα 
labelled with EGFP constructs stably expressed in two estrogen-responsive cell lines: MCF-7-­‐
human-ERα-EGFP and MDA-MB231-human-ERα-EGFP. In addition to estrogen treatment 
(condition i, control), the cells were pretreated with PARP1 chemical inhibitor - olaparib or 
AG14361 (condition ii and iii) or had transiently expressed (24 hours) PARP1 or ALC1 
(condition iv and v, respectively). As expected, the cells expressing ERα-EGFP formed 
significantly distinct foci within 2 minutes of estrogen addition (Figure 5.3 A). Pre-treatment of 
cells with any of the PARP1 inhibitors, olaparib or AG14361, did not prevent foci formation 
(Figure 5.3 B and C). Olaparib was tested at 1 µM and 5 µM and AG14361 at 15 µM 
concentrations. Foci formation was followed for 2 hours since ligand addition. During this time, 
the control (i) and PARP1 chemical inhibition (ii and iii) conditions were indistinguishable in 
terms of foci formation.  
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Figure 5.3 ERα foci form despite chemical inhibition of PARP1 and ERα does not co-
localize with PARP1 or ALC1. MDA-MB231-human ERα-EGFP cells depleted of endogenous 
estrogen receptor (ERα) were stably transfected with human ERα tagged with enhanced Green 
Fluorescent Protein (EGFP) shown as magenta. NT – no E2 treatment (left column) photos prior 
to the ligand addition, the same cells were next treated with 100 nM estrogen (E2; right column) 
and imaged continuously for 2 hours (image frame every 30 seconds). Photos on the right 
represent foci formation or not, upon 15 minutes of the ligand addition. A) ERα forms distinctive 
foci upon E2 treatment (right column). B) ERα foci formation is not affected by presence of 
PARP1 chemical inhibitor - 1 or 5 µM olaparib (right column). C) ERα foci formation is not 
affected by presence of PARP1 chemical inhibitor - 15 µM AG14361 (right column). D) Poly-
ADP-ribose polymerase 1 (PARP1) tagged with mCherry (shown as magenta) does not form foci 
upon E2 treatment (right column). E) Amplified in liver cancer 1 (ALC1) tagged with mCherry 
does not form foci upon E2 treatment (right column). Shown images are representative of results 
acquired from evaluation of at least n = 10 cells for each condition. Foci are visible as circules of 
magenta.   
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In addition, if PARP1 and ERα co-immunoprecipitate (Zhang et al, 2013a), I expected both to 
co-localize in the cells treated with estrogen. However no co-localization between PARP1-
mCherry and ERα-EGFP was observed, neither did PARP1-mCheery form foci at all (Figure 5.3 
D). Similarly to PARP1, ALC1-mCherry did not co-localize or form foci in cells treated with 
estrogen (Figure 5.4 E).  In summary, these results suggest that PARP1 or ALC1 are not 
important for ERα association to genome sites and foci formation.    
5.4 Olaparib and AG14361 lead to different transcriptional outcomes  
Chemical inhibition of PARP1 activity with olaparib or AG14361 did not affect ERα foci 
formation in the presence of estrogen. However, mRNA levels of estrogen responsive genes 
were reduced in presence of AG14361 inhibitor, but not when the olaparib was used. I wanted to 
know why two recent, specific PARP1 inhibitors lead to two different transcription outcomes. 
Therefore, I tested both the PARP1 inhibitors in another transcription-based assay. I used cells in 
which transcription is regulated by another nuclear receptor called retinoic acid receptor (RAR). 
In these cells, transcription activation via a RAR ligand, all-trans retinoic acid (tRA), was shown 
to be negatively regulated by PAR (Le May et al., 2012).       
I evaluated up-regulation of mRNA levels for known tRA regulated genes (TGM2 and PDK4) in 
the presence of the ligand and chemical PARP1 inhibitor, either olaparib or AG14361. 
Pretreatment of HeLa cells, prior the ligand addition, with olaparib (1 or 5 µM) did not lead to 
change of the PAR-independent gene SMAD3 mRNA levels, however did affect as expected one 
of the PAR-dependent genes (PDK4).  In contrast, AG14361 at 15 µM concentration inhibited 
transcription of all the tested genes, PAR-dependent and -independent (Figure 5.4). This result 
suggests that the effect observed at estrogen regulated genes due to high concentration of 
AG14361 may be not specific to PARP1 functions, but simply result from AG14361 off-target 
effects.  
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Figure 5.4 Chemical inhibition of PARP1 with olaparib or AG14361 leads to different 
transcription response. HeLa cells were treated with chemical inhibitors of PARP1 (olaparib or 
AG14361) with the indicated concentrations (5 µM, 1 µM or 15 µM) for 40 minutes prior to all-
trans retinoic acid (tRA) treatment. tRA treatment (10 µM) lasted for 3 hours, after which total 
RNA was extracted. Shown on the graph are mRNA levels of the respective genes (post-tRA 
treatment) normalized to the levels prior to tRA addition (indicated as 0 on the logarithmic scale, 
on the Y-axis). Tested genes were: SMAD3 – SMAD family member 3, TGM2 – 
transglutaminase 2, PDK4 - pyruvate dehydrogenase kinase isoform 4. Error bars represent 
Standard Error of Mean from 4 experiments. 
5.5 Olaparib and AG14361 inhibit PARP1 activity in vivo 
My results suggest that PARP1 activity is not essential for ERα-dependent transcription. In a 
major experimental part that led to me to this conclusion I used chemical inhibitors of PARP1 
whose inhibitory function had to be confirmed. Thus, I used a cellular system in which upon 
induction of oxidative DNA damage with hydrogen peroxide (H2O2), PARP1 undergoes rapid 
activation. Activity of PARP1 can be visualized by direct immunofluorescent staining of the 
PARP1 product, poly-ADP-ribose (PAR). In a positive control, in cells treated with hydrogen 
peroxide, PAR is readily detectable within 10 minutes of the DNA damage induction (Figure 5.5 
B). Presence of any of the PARP1 inhibitors used throughout my work (olaparib or AG14361) 
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abolished PAR, confirming that chemical inhibitors of PARP1 activity are working properly 
(Figure 5.5 C and D).  
 
 
Figure 5.5 Olaparib and AG14361 inhibit PARP1 activity. Progesterone does not lead to 
increased PAR levels. T47D cells were stained for poly-ADP-ribose (PAR) with anti-PAR 
antibody post-treatment: A) no treatment (negative control). B) hydrogen peroxide (H2O2; 1µM) 
treatment for 10 minutes. C) olaparib (5µM or 1µM) treatment for 40 minutes, followed by H2O2 
(as in B). D) AG14361 (15µM/5µM/1µM) treatment for 40 minutes, followed by H2O2 (as in B). 
E) progesterone (R5020) treatment for 20 minutes (10 nM) and 30 minutes (10 nM and 100 nM). 
Nuclei were visualized with Hoechst 33342 (final concentration of 0.1 µg/ml; column on the left).  
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The predominant model of PARP1 activation assumes that PARP1 binds DNA breaks and the 
enzyme becomes subsequently activated. According to the less-established model, PARP1 is 
activated by its post-translational modifications and histone variants. The first model is aligned 
with PARP1 roles in DNA damage. The second model is aligned with PARP1 functions in 
transcription. I wanted to rule out a possibility that perhaps the inhibitors used in transcriptional 
assays do not inactivate PARP1 due to a different mode of enzyme activation. This possibility 
was unlikely when one takes into account that olaparib and AG14361 are NAD+ analogs, 
however I aimed to test PARP1 inhibition in transcription-based assay. Wright and co-workers 
(2012) showed that PAR levels are increased upon progesterone treatment in ductal carcinoma 
(T47D) cells. Progesterone is a ligand of progesterone receptor (nuclear receptor) that leads to 
transcriptional activation of various genes, similarly to ERα. I treated the T47D cells with 
progesterone, however did not observe PAR elevation, thus could not test PARP1 inhibitors 
(Figure 5.5 E). This result was different from the reported one (Wright et al., 2012; see Figure 
2.3).  Importantly, I confirmed that the used cells respond to progesterone treatment based on up-
regulation of PR dependent genes: DUSP1 and EGFR (Figure 5.6).  
 
                       
Figure 5.6 Cells respond to progesterone treatment. T47D cells were treated with 100 nM 
progesterone (R5020) for 3 hours and after the treatment total RNA was extracted.  Each column 
represents a single biological sample (total 3) for each gene. mRNA levels of PR dependent genes 
(DUSP1 and EGFR) and PR independent genes (FAM117) were tested. Shown on the graph are 
mRNA levels of tested genes post-PR treatment normalized to to the mRNA levels prior to PR 
treatment (indicated as 0 on the logarithmic scale, X-axis). DUSP1 - dual specificity phosphatase 
1, EGFR - epidermal growth factor receptor, FAM117 - family with sequence similarity 117. 
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5.6 ALC1 regulates transcription similarly to PARP1  
My initial plan to study ALC1 functions in transcription, via a robust PARP1-dependent 
transcription activation system, had to be discontinued. I could not recapitulate dependence of 
nuclear receptor regulated gene expression on PARP1 activity, as previously reported (Ju et al., 
2006, Wright et al., 2012, Zhang et al., 2013). Lack of robust reproducibility of previously 
published results undermined the validity of use hormone responsive cells as adequate to study 
ALC1 functions. In addition, a direct evaluation of ALC1 importance for ERα-regulated 
transcription and ERα association with chromatin (both upon ligand addition) suggested that 
ALC1 does not play a role in these processes.  
Therefore, I employed a new cellular system to study ALC1 functions in transcription. Again, I 
assumed that PAR is critical in regulating macrodomain-containing ALC1 activity. PARP1 and 
PAR were reported to regulate gene expression at the transcription level in no hormone 
stimulated cells. PARP1 candidate genes were identified via a microarray study of mRNA levels 
in cells with stably knocked-down PARP1. The study identified 115 and 89 genes, which were 
up- or down- regulated in absence of PARP1, when compared to wild-type cells that expressed 
PARP1 (Frizzell et al., 2009). PARP1 was found to reside at the TSS of the candidate genes and 
promote an open chromatin structure via PARylation and subsequent removal of demethylase 5B 
(KDM5B demethylase; Krishnakumar and Kraus, 2008 and 2010, for details see 2.1.2). 
I selected a few extensively studied PARP1 dependent genes (see Figure 2.4) and tested possible 
ALC1 functions in transcription regulation of these genes as well. The candidate genes were the 
following: GDF15 and ITPR1, including a negative control ABDH. I transiently knocked-down 
(48 hours) PARP1 or ALC1 individually and checked the expression level of the candidate target 
genes. As shown on Figure 5.7, knock-down of ALC1 results in similar deregulation of mRNA 
levels of evaluated genes as PARP1 knock-down. ALC1 depletion leads to transcription up-
regulation or down-regulation of the tested genes, whereas mRNA levels of the negative control 
ABDH remained unchanged. Both PARP1 and ALC1 were significatntly down-regulated at the 
RNA and protein levels (Figure 5.7 and 5.8).  
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Figure 5.7 ALC1 knock-down recapitulates an effect of PARP1 knock-down on PARP1 
target genes. Breast cancer cells (MCF-7) were treated with siRNA to knock-down individually 
PARP1 or ALC1. Post-siRNA treatment (48 hours) the cells were collected and total RNA was 
extracted. Shown on the graph are mRNA levels of the respective genes (post-siRNA treatment: 
PARP1 or ALC1) normalized to the mRNA levels of the respective genes from cells treated with 
non-specific siRNA (mock control) (indicated as 0 in the logarithmic scale, on the Y-axis). 
Tested genes were: ABHD2 - abhydrolase domain-containing 2, GDF15 – growth differentiation 
factor 15, ITPR1 – inositol 1,4,5-trisphosphate receptor 1, ALC1 – amplified in liver cancer 1, 
PARP1- poly-ADP-ribose polymerase 1. Error bars represent Standard Error of Mean from 4 
experiments.     
 
The evaluation of mRNA levels for the candidate genes was conducted at 48 hours post-siRNA 
knock-down, of PARP1 or ALC1. At this time point, ALC1 was significantly down-regulated at 
the RNA level, however the protein down-regulation was not as strong as expected based on 
RNA leftover around 10 % (see Figure 5.8). Thus, I tested the efficiency of ALC1 knock-down 
after 72 hours of specific ALC1 siRNA addition (for details see Materials and Methods). As 
shown on Figure 5.9, at the 72 hour time point after siRNA treatment, ALC1 is further down-
regulated at the protein level. I have not tested the mRNA levels of PARP1 target genes upon 72 
hours of ALC1 siRNA.  
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Figure 5.8 PARP1 and ALC1 are efficiently knocked down. Whole-protein extracts from 
MCF-7 cell lines upon transient expression of siRNA specific to PARP1 (A) or ALC1 (B) were 
analyzed via SDS-PAGE and visualized by western blot with anti-PARP1, anti-ALC1 and anti-
Tubulin (loading control) antibodies. All antibodies detected proteins of the expected size: 116 
kDa for PARP1, 100 kDa for ALC1 and 55 kDa for Tubulin. PARP1 (A) and ALC1 (B) are 
significantly depleted in the MCF-7 cell lines (upper panels, respectively). Loading of protein 
extract on SDS-PAGE was similar, as indicated by α-Tubulin levels (lower panels, respectively). 
Markers indicating the size of the protein are indicated on the left in kilodaltons (kDa). WT 
PARP1 and WT ALC1 correspond to cells treated with non-specific siRNA (mock control).  
 
 
                                                     
Figure 5.9 ALC1 is efficiently knocked down at 72 hours after siRNA treatment. Whole- 
protein extracts from MCF-7 cell lines upon transient expression of siRNA specific to ALC1were 
analyzed via SDS-PAGE and visualized by western blot with anti-ALC1 and anti-Tubulin 
(loading control) antibodies. All antibodies detected proteins of the expected size: 100 kDa for 
ALC1 and 55 kDa for Tubulin. ALC1 is significantly depleted in the MCF-7 cell lines (upper 
panels). Loading of protein extract on SDS-PAGE was similar, as indicated by α-Tubulin levels 
(lower panels). Marker indicating the size of the protein is indicated on the left in kilodaltons 
(kDa). WT ALC1 corresponds to cells treated with non-target specific siRNA (mock control).  
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5.7 Generated antibodies anti-ALC1 specifically recognize the target protein 
In order to facilitate studies of the molecular mechanism of ALC1's role in transcription 
regulation, I generated ALC1-specific polyclonal antibodies. Each of the individual ALC1 
domains (macrodomain and ATPase domain) was used as an antigen in rabbit immunization (for 
details see Materials and Methods). The resulting serum from immunized animals was then 
analyzed on the whole-protein extracts from cells: (i) expressing endogenous levels of ALC1, (ii) 
overexpressing ALC1 labelled with YFP, and (iii) cells with siRNA knocked-down ALC1 (72 
hours). As shown on Figure 5.10 both newly generated polyclonal antibodies specifically 
recognize endogenous ALC1 or overexpressed ALC1-YFP and as expected no signal was 
detected in cells depleted of ALC1.   
 
 
                  
Figure 5.10 Generated polyclonal antibodies specifically recognize ALC1. Whole-protein 
extracts from U2OS cell lines: with endogenous ALC1 levels (wild type, WT), overexpressed 
ALC1 tagged with Yellow Fluorescent Protein (YFP), and cells with depleted ALC1 via siRNA 
specific to ALC1 (siRNA; 72 hours) were analyzed via SDS-PAGE and visualized by western 
blot with anti-ALC1 and anti-Tubulin (loading control) antibodies. Used ALC1 antibodies were: 
unpurified serum recognizing ALC1 macrodomain (left) and unpurified serum recognizing ALC1 
ATPase domain (right). All antibodies detected proteins of the expected size: 100 kDa for ALC1 
and 55 kDa for Tubulin. Loading of protein extract on SDS-PAGE was similar, as indicated by α-
Tubulin levels (lower panels). Markers indicating the size of the protein are indicated on the left 
in kilodaltons (kDa). No ALC1-specific signal was detected lanes with knocked down ALC1. 
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5.8 The generated polyclonal antibody immunoprecipitates ALC1  
I planned to use the newly generated antibodies against ALC1 to test ALC1 chromatin 
association, especially at the sites of identified candidate genes (see Figure 5.7). The pattern of 
ALC1 association with these genes, would shed light on the mechanism behind de-regulation of 
GDF15 and ITPR1 expression upon ALC1 knock-down.  
At first, I tested the suitability of ALC1 antibodies to specifically immuno-precipitate (IP) ALC1 
in various conditions, including the typical conditions for chromatin immuno-precipitation 
(ChIP, for details see Materials and Methods). Predominantly I used osteosarcoma cells (U2OS) 
that express ALC1 tagged with YFP. The level of ALC1 in this cell line is a few times higher 
than the endogenous level of ALC1 (see Figure 5.10). A use of cell line that overexpressed 
ALC1 facilitated optimization of IP and ChIP conditions. I optimized the IP conditions in:  
(i) cells that were not treated with formaldehyde  
(ii) cells in which proteins were crosslinked to chromatin via 1 % formaldehyde 
treatment.  
(iii) Cells which underwent formaldehyde treatment as in (ii), plus the cells after 
formaldehyde treatment were sonicated with Covaris in order to shear DNA to 
desirable size (200 bp and 500 bp).  
In order to pull down ALC1, I used antibodies against YFP and directly against ALC1. An 
antibody against YFP was generated with GFP as an antigen (Ladurner laboratory own stock). 
Between YFP and GFP is only one amino acid difference, and the anti-GFP antibody recognizes 
YFP very well. 
In tested conditions, an antibody against GFP readily precipitated ALC1-YFP from cells not 
treated with formaldehyde and the cells treated with formaldehyde (indicated as crosslinked, 
Figure 5.11 A). Once I established good IP conditions with the anti-GFP antibody, I tested the 
suitability of generated ALC1 antibodies on the same cellular material. As shown on Figure 5.11 
B, the generated ALC1 antibody immunoprecipitates ALC1 from cells that underwent 
formaldehyde treatment (crosslinked). Whereas precipitation of ALC1 was straightforward in no 
formaldehyde or with formaldehyde treated cells, the addition of sonication to the crosslinked 
material caused difficulties in ALC1 precipitation.  
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Figure 5.11 Generated ALC1 polyclonal antibody specifically immunoprecipitates ALC1. 
U2OS ALC1 was immunoprecipitated from cells that express ALC1 labelled with yellow 
fluorescent protein (YFP). The following antibodies were used: anti - green fluorescent protein 
(GFP) and anti – amplified in liver cancer 1 (ALC1) generated with ALC1 macrodomain as 
antigen. The cells were: A) not treated (not crosslinked) or treated with 1% formaldehyde for 10 
minutes at RT (crosslinked). IN – input, 30 %. B) cells were treated with 1% formaldehyde for 10 
minutes at RT (crosslinked).  30 % input. C) cells were treated with 1% formaldehyde for 10 
minutes at RT (crosslinked/cross) and Covaris sonicated (son) for indicated time - 12 or 18 
minutes. 7 % input.    
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Eventually, an increase of input material and modification of sonication conditions (time and 
sonication temperature) allowed for ALC1 precipitation (Figure 5.11 C). Afterwards, the same 
conditions were used to pull down DNA fragments that are presumably crosslinked to ALC1. 
qPCR was performed on the pull-down DNA with the primers spanning TSS and up- and down- 
stream regions from the TSS of ALC1 candidate genes. However, the results of ALC1 residence 
at these sites were inconsistent and not robustly reproducible (data not shown).  
5.9 Discussion  
(i) ALC1's transcriptional functions depend on PARP1 activity  
My data suggests that ALC1 plays a role in transcription regulation. The functions of ALC1 
seem to be restricted to certain transcriptional programs, importantly downstream of PARP1 
(Figure 5.7). The previously published reports, which linked ALC1 to transcription, lacked the 
underlying mechanism for ALC1 association with chromatin. As shown in Figure 5.12 ALC1 is 
highly mobile within nucleus (similar to PARP1, FRAP evaluated), thus ALC1 associations with 
chromatin are most likely transient and only prolonged upon specific stimuli. 
 
         
Figure 5.12 ALC1 is a freely diffusive molecule within the nucleus. Amplified in liver cancer 
1 (ALC1) was transiently expressed (24 hours) in breast cancer cells (MCF-7) and FRAP 
measured. Only cells with low fluorescence intensity were chosen for the analysis. Showed FRAP 
curves for each construct are the averaged measurements from at least 10 cells.  
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Knock down of ALC1 results in a similar outcome on the target genes as the knock-down of 
PARP1. This result suggests that prolonged chromatin association of ALC1 will depend on PAR 
signal in the transcriptional context, similarly to DNA damage. However no macrodomain 
mutants of ALC1 (unable to bind PAR) were evaluated in transcription assays.  
(ii) ALC1 acts as co-activator and co-repressor of transcription   
Based on deregulation of target genes (GDF15 and ITPR1) upon ALC1 knock-down, it appears 
that ALC1 can act as a transcription activator or repressor, similarly to PARP1. It will be 
interesting to find out how exactly ALC1, as a chromatin remodeler, achieves its bi-functionality 
at the chromatin structure level. Deciphering a role for ALC1 in nucleosome position, or 
nucleosome composition is of great importance. Mass spectrometry study of ALC1 interactors 
identified H2A and H2B histones as immunoprecipitated with ALC1 (Gottschalk et al., 2009). 
For example, enrichment or depletion of these histones or histone variants could be tested at 
ALC1 target genes upon ALC1 wild type knock-down or overexpression. As well, an evaluation 
of chromatin structure organization, upon presence of non-functional macro and ATPase mutants 
of ALC1, could shed light on the chromatin remodeler functions. It would however be critical in 
these steps first to know the occupancy profiles of ALC1 genome-wide (TSS, gene body, 
enhancers, etc.). A difficulty in this respect may be overcome by further optimizing ChIP 
conditions with alternative fragmentation of DNA e.g. enzymatic or modification of crosslinking 
conditions. Presumably PARP1 is not activated at the target genes as robustly as it is at sites of 
DNA damage. Thus it may be that the number of ALC1 molecules recruited to the sites of 
PARP1 activity at genes is low or even that the function of ALC1 is short lived. This may 
explain difficulties in consistency of ALC1 ChIP at the target genes.      
(iii) Functions of PARP1 and ALC1 in ER-dependent transcription need a re-evaluation  
PAR levels in unstressed cells (no DNA damage, no heat shock) are very low. The use of 
estrogen-inducible transcription system to study PARP1-dependent genes (as reported 
previously) seemed to be desirable to decipher ALC1 functions in transcription. The hormone 
and nuclear receptor-regulated transcription was supposed to rely on high PAR levels, which 
were assumed to promote robust chromatin association of PAR readers, including ALC1.	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Strikingly, my data questions the previously reported essential role of PARP1 in transcriptional 
activation of estrogen receptor-dependent genes (Figure 5.1, 5.3 and 5.5). 
Both chemical inhibitors of PARP1 used in this study effectively prevent activation of PARP1 
(PAR levels are not detectable in vivo). Only AG1436 deregulated expression of ERα-responsive 
genes, however mainly at high concentrations (5	   μM and 15μM). This effect is most likely 
caused by secondary off-target effects of the AG14361 molecules (see Figure 5.4). The possible 
secondary targets of AG14361 are not known. The analysis of commonly used PARP1 inhibitors 
in the field, suggests that most of them are not exclusively PARP1-specific. Often at high 
concentrations, in addition to PARP1, other PARPs or non-PARP family members can be 
targeted (Wahlberg et al., 2012). The off-target effects stem from a fact that used PARP1 
inhibitors are actually NAD+ analogs, thus not specific to PARP1 only. In this study, the most 
recent PARP1 inhibitors were used (olaparib and AG14361) with higher specificity than 3-AB or 
PJ-34 used by authors of previous reports of PARP1 importance in nuclear receptor gene 
expression regulation (see also 5.1).	  
Another explanation may be that PARP1 plays an important role in activation of these genes 
however the PARP1's role is highly resolved in time. It would be important to look at mRNA 
levels of ERα-responsive genes post-estrogen stimulation in time (30 minutes, 45 minutes, 60 
minutes and 90 minutes). However, no changes in ERα chromatin association in early time 
points, upon transcription stimulation with estrogen were, observed suggesting, the changes in 
that mRNA level may not be noticeable either.   
Importantly, the evidence so far rules out the importance of ALC1 in ERα-dependent 
transcription, when ALC1 was evaluated directly (Figure 5.1 and 5.3).   
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6 Outlook  
The significance of PAR metabolism in regulating human health is widely recognized. It even 
seems that it is only a matter of time before we see chemical compounds prescribed by doctors as 
medicines in order to modify cellular PAR signaling in a benefit to the patient. Recent progress 
regarding the mechanisms driving occurrence and degradation of PAR metabolism further 
increases the chances of more adequate diagnosis and treatment in cases of human 
pathophysiology, involving PAR. The recent progress regarding the molecular mechanism of 
PARP1 activation is promising, however some questions are still not answered.  
How does PARP1 associate with transcriptional sites? 
The conclusions of my work suggest that binding of PARP1 to DNA breaks is zinc finger- 
mediated. However the dependence of zinc fingers for PARP1 binding to transcriptional sites is 
not clear and not extensively evaluated in vivo. Thanks to recent work, it is for example known 
that PARP1 needs to be already activated (presumably elsewhere) and PAR modified, in order to 
associate with androgen receptor (AR)-dependent genes (Schiewer et al., 2012) or c-FOS 
promoter (O'Donell et al., 2013). In the presence of chemical inhibitors of PARP1, the 
association of PARP1 is no longer detectable at these genes (Schiewer et al., 2012, O'Donell et 
al., 2013). In contrast, at DNA damage sites, bound PARP1 is stably trapped in the presence of 
chemical inhibitors (Timinszky et al., 2009). An investigation of PARP1 domain importance for 
chromatin association in well defined transcriptional context is necessary.  
How does PARP1 become activated at transcriptional sites? 
It is not clear how PARP1 becomes activated at transcription sites. In recent studies where 
PARP1 is claimed to regulate the co-activation of transcription, PARP1 activation was linked to 
its phosphorylation (Wright et al., 2012, O'Donell et al., 2013). Genome-wide profiling of 
PARP1 and CDK2 kinase reveled only 31 % overlap between the two. CDK2 was suggested to 
play a critical role in PARP1's activation upon progesterone stimuli (Wright et al., 2012). 
However, the knock-down of CDK2 reduced PAR levels in a cell, but did not abolish then 
completely (Wright et al., 2012). These results suggest that indeed phosphorylation of PARP1 
enhances its activity but is not essential for PARP1 activation. In addition, the nearly full-length 
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X-ray structure of PARP1 bound to blunt ended DNA stress the importance of intramolecular 
interactions between the ZF1, ZF3 and WGR for PARP1 catalytic domain activation (Langelier 
et al., 2012). The intramolecular interactions are triggered by PARP1 binding to DNA. Thus 
PARP1 activation exclusively due to posttranslational modification needs further evidence.  
Drosophila melanogaster PARP activation was proposed to depend on	  phosphorylation of the 
H2A.V histone variant (Kotova et al., 2011, Thomas et al., 2014). Presence of H2A.V histone 
variant exposes H4, which supposedly stimulates dPARP in vitro (Pinnola et al., 2007, Thomas 
et al., 2014). This stimulatory effect of H4 on PARP1 activity was however not seen by others	  
(Kim et al., 2004, Clark et al., 2012). Depletion of H2A.V in flies leads to increased association 
of dPARP at hsp70 loci (Kotova et al., 2011). Thus, if activated dPARP was released from 
chromatin due to H2A.V stimulation, indeed it would not be surprising to see increased levels of 
dPARP in the absence of H2A.V. However, upon H2A.V depletion, dPARP would have to 
remain inactive and PAR levels not detectable at hsp70 loci. These assumptions need to be 
tested.  
Does PARP1 regulate transcription due to functions in DNA repair? 
It is not clear that PARP1 does not associate and become activated at some of the transcription 
sites due to the presence of DNA breaks. The comprehensive analysis of hsp70 loci prior to heat 
shock revealed that PARP1 association with hsp70 TSS is PAR activity-independent and PARP1 
is inactive. The importance of zinc fingers for PARP1 association was unfortunately not tested 
(Petesch and Lis, 2012). Upon heat shock, Topoisomerase I (Top I) is recruited to the hsp70 loci 
within seconds post-RNA polymerase II recruitment (Zobeck et al., 2010). It is highly probable 
that Top I is recruited to the heat shock regulated loci in order to release the DNA topological 
stress introduced by transcription. Top I could introduce the DNA break, which has not been 
tested. Thus, it is possible that PARP1 could be activated due to the presence of DNA breaks at 
the highly transcribed hsp70 loci. For example, in differentiating adipocytes, PAR and transcript 
levels of PARP1-dependent genes are reduced upon chemical inhibition of Topoisomerase II 
(Top II) activity (Erener at al., 2012). Unfortunately, an association of PARP1 with PARP1 
target genes upon chemical inhibition of Top II was not tested. In addition, the phosphorylation 
of H2A.V is considered a DNA damage marker in flies, analogous to H2A.X phosphorylation in 
higher eukaryotes (Baldi and Becker, 2013).   
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Heat shock and hormonal treatment are sources of stress for a cell. It is known that excessive 
proliferation upon e.g. estrogen, progesterone or androgen treatment contributes to genome 
instability due to stalled DNA replication forks and their incorrect repair (Halazonetis et al., 
2008, Williamson et al., 2011). The ERα signaling down-regulates the DNA damage response, 
further increasing DNA instability (Caldon, 2014). Importantly, the DNA breaks were detected 
at ERα-regulated pS2 promoter upon estrogen treatment (Ju et al., 2006). The peculiar finding 
only PAR modified PARP1's presence at c-FOS gene and androgen responsive genes suggests 
that DNA lesions could be in the vicinity to these promoters. If so, PARP1 could be activated at 
DNA breaks and spread into the evaluated promoters in a PAR-dependent fashion.  
In summary, it is of high interest to resolve the DNA break presence at and near the transcription 
sites upon rapid transcription induction, in order to re-solve PARP1's binding to transcription 
sites and subsequent activation mechanisms. It is probable that PARP1 initiates DNA repair at 
highly transcribed genome regions. Thus some of the roles of PARP1 in transcription could still 
be PARP1's classic functions in DNA repair.   
PARP1's association with DNA matters  
Understanding PARP1's association with chromatin at DNA damage and transcription sites 
matters. If the mechanisms behind the chromatin association were similar, it would allow for 
universal modification of PARP1 activity via chemical compounds in various physiological 
conditions. If the mechanisms of PARP1 and chromatin interactions are different, then the 
chemical inhibition of PARP1 activity has to be carefully tailored depending on the actual 
molecular mechanism underlying the PAR metabolism malformation. Not tailored interference 
with PARP1 activity may be not beneficial and moreover lead to the off-target side effects. For 
example, where it is known that PARP1 associates with chromatin due to zinc fingers, the use of 
PARP1 inhibitors (NAD+ analogs) results in trapped PARP1 at the DNA breaks, increasing 
toxicity and cancer cell death (Murai et al., 2012 and 2014).  
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Specific PARP1 inhibitors are needed  
PARP1 inhibitors (NAD+ analogs), which are used commonly in basic research laboratories, are 
often not specific to a single target	   (Wahlberg et al., 2012, Antolin et al., 2012,	  Zhang et al., 
2013b). Olaparib, the compound proposed to Food and Drug Administration (FDA) as a 
treatment for a subset of ovarian cancers, was found to target PARP1, PARP2, PARP3, PARP4, 
PARP12, PARP15 and PARP16 (Wahlberg et al., 2012). Whereas in disease treatment non-
specificity of the compound can be beneficial, like it is with kinase inhibitors (Goreschi et al., 
2009), in basic research laboratories the non-specificity of the compound is a major limitation. 
The observed biological phenomena that are attributed exclusively to one of the PARPs may in 
reality be a summary of various unknown off-target effects. The commonly used 3-AB inhibitor 
of PARP1 actually shows low potency and specificity in inhibiting PAR modification of the 
acceptor proteins (Zhang et al., 2013b). Another commonly used PARP1 inhibitor, PJ-34, targets 
other PARPs and PIM kinases (Antolin et al., 2012).  
Luckily a need for specific chemical compounds exclusively modulating PARP1 activity has 
been recognized. A new approach takes advantage of intramolecular domain interactions that are 
specific to PARP1 based on the X-ray structure (Langelier et al., 2012). The authors developed 
the high throughput assay to screen for the compounds that interfere with intramolecular 
interactions of PARP1 domains and thus exclusively inhibit PARP1 (Steffen et al., 2014).   
PARP1 and ALC1 co-regulate each other  
ALC1's chromatin remodeling functions depend on PAR. This dependence is manifested in 
ATPase domain activation, upon macrodomain-mediated PAR binding and possibly ALC1 
protein PAR modification (Gottschalk et al., 2009). Thus, ALC1 functions in transcription and 
DNA repair are coupled to PARP1 roles in transcription and DNA repair. A clarification of 
PARP1 association with, and activation at, chromatin sites will facilitate studies of ALC1 
chromatin remodeling roles in vivo.  
Interestingly, a more detailed investigation of ALC1's dependence on active PARP1 revealed 
that both ALC1 and PARP1 co-operatively bind to DNA or nucleosomes in vitro. This results in 
formation of a stable PARP1-ALC1-DNA/nucleosome complex and prevents release of PARP1 
from the complex (Gottschalk et al., 2012). I tested if ALC1 can modulate PARP1 association  
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Figure 6.1 ALC1 overexpression leads to elevated PAR levels in 5 minutes after DNA 
damage induction. A) Cells expressing endogenous ALC1 levels (no yellow fluorescent protein 
signal – no YFP) were mixed with cells overexpressing ALC1 (YFP signal) and stained for poly-
ADP-ribose (PAR) levels upon DNA damage induction with hydrogen peroxide treatment (1 
μM; 5-30 minutes). Shown on the left are all the cells, which nuclei was stained with Hoechst 
33285 (blue), in the middle are cells that overexpress ALC1 (green), and on the right are cells that 
underwent PARylation upon hydrogen peroxide treatment (red; shown is a 5 minute time point 
during treatment). B) Quantification of PAR levels (0 – 30 minutes) upon DNA damage 
induction. PAR levels were elevated at 5 minute time point in cells that overexpressed ALC1 (* - 
statistically significant; each condition and each cell line n > 100 cells). PAR levels were 
quantified with Cell Profiler software.  
 
and activity at chromatin sites in vivo.  Two cell lines were mixed and cultured together. One that 
expressed endogenous levels of ALC1 and another that had ALC1 levels a few times elevated 
when compared to endogenous ALC1 levels (ALC1-YFP). The cells were distinguishable due to 
YFP tag on ALC1.  The cells were treated with hydrogen peroxide to induce oxidative DNA 
damage, which is known to stimulate PARP1 activity. Next, PARP'1s activity was evaluated via 
PAR staining. The time course of hydrogen peroxide treatment suggested that PAR is elevated 
between 5 and 20 minutes. Interestingly, higher levels of ALC1 lead to increased levels of PAR 
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at 5 minutes after DNA damage induction (Figure 6.1). This result is reproducible and suggests 
that ALC1 can modulate PARP1 activity in vivo. Taking into account that PARP1's activity is 
coupled to DNA break binding, it appears that PARP1 association with chromatin will be 
regulated by ALC1 (data not shown). It remains to be determined if the chromatin remodeling 
function of ALC1 is a main reason behind ALC1 roles in regulation of PARP1 activity.  
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7 Appendix: Additional Figures  
 
 
              
Figure 7.1 Generated polyclonal antibodies specifically recognize PARP1. Whole-cell protein 
extracts from HeLa-Kyoto wild type (WT) cells transiently transfected with PARP1-GFP (first on 
the left), WT cells transiently transfected with PARP1-E998K-GFP (the mutant capable of mono-
ADP-ribosylation, in the middle) and WT (first on the right) were analyzed via SDS-PAGE and 
visualized by Western blot with anti-PARP1 and anti-Tubulin (loading control) antibodies. Used 
antibody against PARP1 was an unpurified serum (fourth bleed) from a rabbit injected with zinc 
finger 1 and zinc finger 2 as antigen. Both antibodies detected proteins of the expected size: 
Above 130 kDa for PARP1-GFP, above 100 kDa for PARP1. Marker indicating the size of the 
protein is indicated on the left in kilodaltons (kDa).  
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Figure 7.2 Diffusion time of the second component of HP1α-full length is reduced due to 
chromatin binding. Mobility of HP1α– heterochromatin protein 1 alpha stably expressed in 
U2OS cells was FCS tested. The box plot is composed of FCS measurements taken in more than 
10 cells. In each cell the measurement was taken in 3 randomly chosen sites in the nucleus 
avoiding nucleoli and nuclear periphery. Only cells with identical fluorescence intensity were 
selected. The horizontal lines (whiskers) represent the maximum and minimum values, the box 
signifies the upper (75th) and lower quartiles (25th), the median is represented by a short line 
within the box and the mean is represented by a square within the box.  
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9 Abbreviations 
Abbreviation  Full name  
A    adenine, a nucleotide 
 aa    amino acid 
Ab    antibody 
3AB    3-aminobenzamide  
ALC1    amplified in liver cancer 1 
APS    ammonium persulfate 
BER    base excision repair  
bp    base pair 
BSA    bovine serum albumin 
C    cytosin, a nucleotide 
CB    Cycle/Burst (count) 
C-terminus   carboxy-terminus of a peptide 
ChIP    chromatin immune-precipitation 
Da    Dalton; atomic mass unit, used here for the mass of peptides and 
proteins; 1 Da = 1.66*10-24 g 
H2O    water 
DF     Duty Factor (%)  
DMEM   Dulbecco’s modified Eagle medium – named after Renato Dulbecco 
DMSO   dimethyl sulfoxide 
DNA    deoxyribonucleic acid 
dNTP    deoxyribonucleotide triphosphate 
EB    elution buffer 
EDTA    ethylenediamine tetraacetic acid 
FRAP    fluorescence recovery after photobleaching 
G guanine,   a purine base 
148	  
	  
G418    geneticin; aminoglycoside antibiotic, resistance through neo gene; 
here used as marker for eukaryotic cell culture selection 
GFP    gfp green fluorescent protein 
Gln    glutamine 
Glu    glutamate, glutamic acid 
GO    GeneOntology 
HeLa    Henriette Lacks; HeLa cells are an immortal human cell line 
derived from cervical cancer of this person 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid 
HR   homologous recombination   
IF    immunofluorescence 
IgG    immunoglobulin G 
IP    immunoprecipitation 
Kan    kanamycin 
KD    knockdown 
NAD+   nicotinamide adenine dinucleotide 
MeOH   methanol 
MS    mass spectrometry 
MW    molecular weight, in Da or kDa 
NER    nucleotide excision repair  
NMR   nuclear magnetic resonance 
NP-40    Nonidet P40 
N-terminus   amino-terminus of a peptide 
o/N    overnight 
OptiMEM   modification of MEM, for reduced serum supplementation 
PAGE    polyacrylamide gel electrophoresis 
PBS-    phosphate buffered saline 
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PFA    para-formaldehyde 
Puromycin aminoglycoside antibiotic; resistance through pac gene; here used as 
selection marker in eukaryotic cell culture 
PJ34  Acetamide, N-(5,6-dihydro-6-oxo-2-phenanthridinyl)-2-(dimethylamino)-, 
hydrochloride (1:1) 
PTM    post-translational modification  
PIP  Peak Incident Power (Watt) 
PVDF    polyvinylidene fluoride; material of WB membranes 
RNA    ribonucleic acid 
ROI    region of interest 
rpm    revolutions per minute 
RT    room temperature 
SDS    sodium dodecyl sulphate 
SEM    standard error of the mean 
siRNA   short interfering RNA 
TE    Tris-EDTA 
TEMED   N,N,N’,N’-Tetramethylethylene-1,2-diamine 
Tris    tris(hydroxymethyl)aminoethane 
TSS   transcription start site 
YFP    yellow fluorescent protein  
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